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“The most beautiful thing we can experienceis the mysterious.It is the source
of all true art and all science”
Albert Einstein
Abstract
Neuropilin-1 (NRP-1) was discovered in the 1990’s as a powerful cellular membrane protein
involved in the control of axon migration and angiogenesis. Owing to its large multidomain
structure, it was thought to interact with multiple molecules present in its environment, and
thus, play an important role as a molecular network hub regulating the local multi-component
signalling flow. While NRP-1 does not possesanyintrinsic tyrosine kinase activity on its own,
it was suggested to act via formation of signalling complexes with other receptors and affect
their signalling properties in response to their soluble ligands. Importantly, as a part of the
extracellular matrix, NRP-1 was also suggested to be further regulated by interaction with cell
surface heparan sulfate.
The doctoral project targeted several principle ideas of the field. First of all, the extensive
analysis of NRP-1’s interaction with the proxy of heparan sulfate, heparin, was undertaken.
The characterisation of NRP-1’s preference for the sulfation pattern and length of oligosac-
charideis the first obtained for the recombinant NRP-1 species. An additional attempt to map
major areas involvedin interaction with heparin within recombinant NRP-1 revealed possible
sites of heparin interaction and intramolecular interactions occurring due to the binding of the
protein to the polysaccharide. Since the study used a dimeric Fc fusion construct, a set of ex-
periments were designedto identify the importance of functional properties that derived from
NRP-1’s dimerisation, the regions that may be importantin driving dimerisation and so explain
the differences observed between monomeric and dimeric NRP-1 species.
Anotherpart of the project was focused onthe functional aspect of the recombinant NRP-
 1 species and demonstrated an exciting new property of the protein, namely that contrary
to the current view that defines NRP-1 as an enhancer of VEGF-Ajg5-driven angiogenesis,
the dimeric NRP-1 independently induced tubular differentiation of endothelial cells. This was
observed even in the presence of a VEGF-A sequestering antibody and was mediated by
direct VEGFR-2activation. This finding undermines the current model of NPR-1’s mechanism
of function and also indicates putative pharmacological applications of recombinant NRP-1.
Finally, the work on the NRP-1 biochemical and functional properties was complemented
by the developmentof a novel method of analysis of interactions of polysaccharides with pro-
teins. The method records the thermostabilisation effect that polysaccharide bestows on an
interacting protein partner and provides numerical values of detected melting temperatures.
Adapted to a multiwell format, the assay allows investigation of the specificity of binding in a
high-throughput manner.
Overall, the thesis provides new insights into NRP-1 structure-function relationship and
advancesseveral aspects of understanding of its nature. The thermostability assay developed
and described alongside goes beyond the NRP-1 field, and permits high quality data to be
obtained for any protein that is stabilised by polysaccharides or other small molecules.
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Chapter1
Introduction
1.1 NRP-1 state of knowledge
In 2006, when the doctoral project was commenced, there were ca 500 publications focused
on Neuropilin-1 (NRP-1), with the first publications appearing in 1990-91 [2, 3], which de-
scribed NRP-1 as the antigen A5. This meansthat during 16 years 462 publications on NRP-1
emerged, while during the length of the subsequent doctoral study, which is 3.5 years, 272
novelfindings were published. This numberreflects the dynamics of the NRP-1 field, and when
compared with the p53 protein, andits total publication record - ca 53000(http://www.ncbi.nim
.nih.gov/sites/entrez), it illustrates the potential capacity for growth. Muchof the data on NRP-1
that has been published up to 2007 wascollated and publishedin the form of a comprehensive
review [4] - Supplemental paper 1. Additionally, each chapterof this thesis commenceswith
a small review of papers that are directly relevant to the focus of the chapter. This Introduc-
tion Chapter provides an overview and,in particular, aims to highlight some of the intriguing
aspects of NRP-1.
Introduction
 
1.2 Things about NRP-1 that we know and we do not know
It is a well known fact that the vascular and nervous systems show high degreeof similarity
at the level of organisation and development[5]. First of all, the general architecture of both
systems is analogous, where nerves are built of neural cells supported by glial cells, while
blood vessels are built of endothelial cells supported by vascular smooth muscle cells and
pericytes. Also the co-patterning across the organism and their coordination in responding
to the same growth factors is a feature that highlights their likeness [5]. NRP-1 is one of
the several molecules, which are expressed by cells in both systems, andis typically listed
among strong candidatesthat indicate the coordination and co-dependenceof these systems.
This feature makes NRP-1 a very interesting target of studies that aim to investigate the more
generic features of the regulation of the neurovascular niche[6], in contrast to the dominating
approachesthat focus on each system separately. Albeit NRP-1 is a powerfullinking argument
for the existence of the neurovascular niche,it is its interacting partner molecules that are
directly involved in mediating specific responses. The partners use NRP-1 as a non-signalling
co-receptor, andit is their presence that allows NRP-1 to be involved in the complex regulation
of their action. This is why NRP-1 for most, but not all of its functions, is described in the
contextofits ligands’ properties and their respective signalling receptors.
The interactions of NRP-1 have been described in several publications [4,6—8], and can oc-
cur between NRP-1 and other membranereceptors (including NRPs), soluble species (includ-
ing growth factors and possibly soluble NRPs), and intracellular proteins (Figure 1.1, Table 1.1).
Importantly, although more data on NRP-1 interactions is possible to retrieve, someofit is
based on techniques such as co-immunoprecipitation and should be treated with caution[9],
as they do not necessarily prove a direct interaction. Similarly, a novel source of information on
proteins’ interactions are multiple online databases, however, they also should be treated cau-
tiously. The main reasonis that as they progress by collecting records of possible interactions
and arrange them in clusters, some of them remain functional clusters although there is no
evidencefor a direct physical interaction (http://genomeknowledge.org and [10]). Still, most of
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the collected researcharticles tackling particular interactions of NRP-1 will present reasonable
biochemical and/ or biophysical data, however, in a few cases a numberof uncertainties arise
anda list of articlesillustrating the argumentis provided. This applies especially in the case of
the interactions of NRP-1 with tyrosine kinase receptors, where a direct interaction and bridg-
ing through a ligand wereinitially two parallel concepts presentin the field, until more data was
provided to support the latter mechanism. Such observations were made for VEGFR-2 and
PDGFR,where the most popular view, namely ligand mediated bridging of the NRP: receptor
complex, is supported by [11-13] and [14], respectively. A related aspect of the NRP-1 func-
tion, although no physical interaction has been confirmed,is the synergism occurring between
pathways where NRP-1 is indicated as a linking component. Such synergism was observed
between FGF-2 and VEGF-A\g¢s5 [15], but is not supported by biophysical evidence of a direct
complex formation between FGF-2 and NRP-1 and VEGFR-2. Thus,alternative mechanisms
are equally likely, involving other pathway(s) of NRP-1 function. Until more data are available
it is impossible to distinguish between the prevalent view and the alternatives.
Importantly, due to its large size and complex multidomain structure, NRP-1 was suggested
to be a hubprotein involved in coordinating of the numerous interactions, and probably, in the
coming future moreproteinswill be identified as its interacting partners. Indeed,in silico analy-
sis by the InterDom server(http://interdom.i2r.a-star.edu.sg/) estimated that the ala2 domains
could interact with 177 other types of domains, the b1b2 domains with 121, and the c domain
with 31 [16]. Additionally, the extracellular domains’ loops and unstructured intracellular do-
main may provide a backbonefor more interactions. This contrasts with the up-to-date state of
knowledge on NRP-1, whichlists ca 30 interacting partners of NRP-1 (Figure 1.1, Table 1.1).
Another group of molecules that interact with NRP-1 are polysaccharides. With regard to
the NRP-1 localisation in the pericellular and extracellular matrix (ECM) compartment, the fact
that polysaccharides may regulate NRP-1 function is not surprising, given the primordial role
of sugars in regulating cell-cell communication [17].
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other soluble species
truncated NRP-1
Galectin-1
other membrane receptors
VEGFR-1
VEGFR-2
C-MET
Integrin-f1
Integrin-a5-f1
Integrin-a5-B3
L1
Plexin A1
Plexin A2  
soluble growth factors
VEGF-A121
VEGF-A165
VEGF-B
VEGF-C
VEGF-D
PIGF-2
SEMA3A
SEMA3F
FGF-2
FGF-4
HGF/SF
TGF-B
PDGF-AA
PDGF-BB
other membrane NRP-1/ NRP-2
©
intracellular proteins
NIP/GLUT1CBP/Synectin
FER
CDK5
TCGAP
Figure 1.1: Postulated Neuropilin-1 extracellular and intracellular interactions.
The molecules that are putative NRP-1 interaction partners were classified into subgroups accordingto their type and
location. Thus in separate groups gathered are soluble growth factors, other soluble proteins, membranereceptors,
intracellular proteins, with indication of possible homophilic interactions with other NRPs.
 
Interacting partner References
VEGF-Aj424
VEGF-At65
VEGF-B
VEGF-C
VEGF-D
PIGF-2
SEMA3A
SEMA3F
FGF-2
FGF-4
HGF/SF
TGF-B
PDGF-AA
PDGF-BB
NRPs
Galectin-1
VEGFR-1
VEGFR-2
C-MET
Integrin-B1
Integrin-a5-B 1
Integrin-a5-B3
uu
Plexin-A1
Plexin-A2
NIP/GLUT1CBP/Synectin
FER
CDK5
TCGAP
[12, 18-20][18, 21-29]
[30][31][31][18, 29, 32][25, 28, 33-35][25][36][36][36,37]
[38][14][14][25, 34, 36, 39, 40]
[41][26][11-13, 18, 24, 28, 42, 43]
[44][45][46][47][48][9, 28, 49, 50]
[50][9, 42, 46,51, 52]
[9][9][9]
 
Table 1.1: An up-to-datelist of proteins that interact with NRP-1 with appropriate references documenting
the discovery and functionality of the interaction.
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Initial studies suggested that interaction of NRP-1 with an exogenously administered drug-
heparin - enhanced VEGF-Ajg¢5 [21,22, 24, 26, 53], PIGF-2 [29, 32], and SEMA3A[53,54] bind-
ing. Moreover, binding of VEGF-C and VEGF-D to NRP-1 seemedto be heparin-dependent
[31]. Interestingly, at the same time, using biophysical methods heparin appeared to have an
antagonistic effect on the interaction of NRP-1 and VEGFR-1 [26]. Together these data sug-
gestthat interactions with polysaccharides can mediate both enhancing andinhibitory effects.
The current mainstream explanation of the function of the NRP1-heparin interaction is thatit
increases the number of VEGF binding sites [21] without changing the overall affinity for VEGF
binding [18,22]. Although these observations were obtained mainly using heparin, there are
studies that indicate that similar processes might take place in the presence of native cell-
surface heparan sulfate (HS) [55]. Recently, more polysaccharide-based compounds were
tested for their impact on NRP-1. Lake and co-workers investigated NRP-1 interaction with
low-molecular weight fucoidan [56] and showedthatit causes, in a similar manner to heparin,
enhanced binding of VEGF-Aig5 to VEGFR-2 and NRP-1 complexes on the endothelialcells.
It is noteworthy, that for technical reasons,it is impossible to differentiate between enhanced
growth factor binding to NRP-1 in the presence of heparin and growth factor binding to the
heparin chain that is already bound to the NRP-1. Thus, none of these mechanisms can be
excluded.
On the other hand, another exogenous compound, a non-sulfated analogue of heparin
- phenylacetate carboxymethyl benzylamine dextran - was observed to convey an exactly
contrary effect and inhibited growth factor binding and signalling [57]. Additionally, sulfated
polysaccharides - fucoidan and dextran - both were shownto enhancethe internalisation of
cell-surface NRP-1 providing a direct tool to control the level of responsivenessof the cells to
the NRP-1 ligands [58]. The latter studies used different polysaccharides to obtain contrast-
ing results, and these results were reflected in the angiogenic properties of the cells and had
clear functional outputs. This meansthat polysaccharides may be a good sourceof regulatory/
therapeutic molecules affecting NRP-1 function.
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Most of the classical NRP-1 studies describe NRP-1 as a derivative of its extracellular
interactions. Nevertheless, some studies indicate that there are functions of NRP-1 that are
independentofits main ligands, VEGF and semaphorins, andrely on otherintrinsic properties
of NRP-1 [59]. It is especially evident in the case of some NRP-1 functions, which appear
to be VEGFR-2 independent[24, 60-62], where the link between NRP-1 andits extracellular
ligands is less obvious. For example, the fact that several cell lines express only NRP-1, but
not any knowntyrosine kinase receptorthat interacts with NRP-1, has been a puzzle for a long
time [24]. A possible explanation is that NRP-1 maintains cell survival and supports VEGF
autocrine function either alone or together with other receptors [60]. On the other hand, no
link with classical NRP-1 co-partners was found in a study that showed direct involvement
of NRP-1 in the adhesion process [61]. The explanation indicated that the intracellular part
of NRP-1 was responsible for such behaviour, which wasin disagreement with the apparent
independence of Plexin-NRP-1 signalling from the cytoplasmic domain of NRP-1 [34, 49]. In
contrast, in a numberof studies the presenceorlack of the intracellular domain of NRP-1 was
a critical factor in driving NRP-1-dependent responses, such as migration and angiogenesis
[52,62]. Thus, in addition to supporting the interaction of NRP-1 and VEGFR-2 [42], it was
suggested that NRP-1 wasinvolved in other mechanisms of control due to the intracellular
interactions it can promote (Figure 1.1, Table 1.1). Additionally, Abcam has developed an
antibody against phosphorylated threonine 916 of NRP-1, which has confirmed the presence
of a substantial pool of intracellularly phosphorylated NRP-1. Again, this suggests further
function of the intracellular domain. Therefore,it is highly plausible that the intracellular part of
NRP-1 will bring a lot more functional discoveryto the field.
Another interesting aspect of the NRP-1 is its c domain, which spans a meprin (MAM)
domain and is considered to be responsible for protein-protein interactions [63, 64]. It was
discovered to be essential for signal transduction of the NRP-1: Plexin-A complex [34, 49, 65],
and this property wasin fact used to raise anti-MAM blocking antibodies and peptidesto inhibit
this pathway [9, 25, 66]. Initially, it was postulated to mediate NRP-1 oligomerisation [26, 34],
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however,later on, it was shownthatit was not absolutely required for such dimerisation [1,25].
At the same time the c domain was shownto benotcritical for the binding of extracellular
ligands, such as SEMA@ZA[25, 34,39, 49], VEGF-Aj65 [25], VEGF-C [31]. Overall, the observed
functions of the c domain remain largely unexplained. The contemporary hypothesisis thatit
contributes to someotherinteractions [34, 65] and helpsin orientating the NRP-1 in relation to
other molecules[67].
The next interesting aspect of NRP-1s are its soluble isoforms. They were described at both
theoretical and experimental levels [4,68], and comprise severaldifferent empirically confirmed
proteins. In humans,the first described isoform was a 90 kDa truncated NRP-1, comprising
the ala2b1b2 domains [27], which was subsequently confirmed in other studies, that also
identified 75 kDa and 120 kDa truncated NRP-1s [68, 69]. While the former is probably the
90 kDavariant with small truncation in the C-terminal part [70], the latter comprises the entire
extracellular part of NRP-1 (a1a2b1b2c domains). Interestingly, while the 90 kDavariantis
producedas a result of alternative splicing, the 120 kDa variant is suggested to be a product
of membrane shedding, and the 75 kDa can be producedeitherby alternative splicing or mem-
brane shedding [68, 71]. Therefore, different mechanisms contribute to the formation of a pool
of molecules that encodethe part of the NRP-1 responsible for its extracellular interactions.
Howthe production of these NRP-1 variants is controlled is not known. Additionally, the fact
that soluble species of the same protein may havedifferent domain compositions implies im-
portant functional differences between them, and highlights howlittle is known ontheroles of
the particular domains. The notion of soluble NRP-1 dimerisation and its subsequenteffect on
ligand binding (growth factors, receptors, glycosaminoglycans) in comparisonto its membrane
counterpart is also largely unknown.
Another complication associated with the soluble isoforms of NRP-1 followed several con-
tradictory studies that identified soluble NRP-1 isoforms as agonists or antagonists of mem-
brane NRP-1. Although most data indicate that exogenously added NRP-1 is an antagonistof
membrane NRP-1 [27, 34,53, 72-78], some studies were able to show the opposite.
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Thus, when NRP-1 wasprovided as a soluble dimer, it could bind to the cell surface and
mediate agonistic responses in the presence of VEGF-Aj65 [11, 73], however, again, not in
all cases [74, 79]. Occasionally, monomeric NRP-1 was also found to mediate agonistic re-
sponses[80]. Importantly, all the tested dimeric forms wereartificial Fc-fusions. Consequently,
the hypothesis was put forward that some of the soluble NRP-1 variants, which have been
identified in silico, might have similar property of dimerisation in vivo [81]. Together with the
suggestion that NRP-1 can act both in cis and in trans [11], this led to a rather unclearpicture
of the physical state of soluble NRP-1 (monomeric or dimeric) and its actual mechanism of
action (soluble antagonist, cell-surface attached agonist) [82].
Another developing aspect of our understanding of the NRP-1 functionis its internalisa-
tion. Several studies indicated that different molecules caused the internalisation of NRP-1,
e.g., VEGF-Aj65 [53,83], SEMA3A[53,84], HGF/ SF [44], NIP [46], sulfated polyoligosaccha-
rides [58]. In fact, a short sequence, R/K/XXR/K, was described as a recognition motif driving
NRP-1-dependentinternalisation, and wasidentified in several known NRP-1 ligands [85]. The
fact that various NRP-1 ligands are causing the internalisation of NRP-1 and therest of the sig-
nalling complexis not surprising, however, the mechanismsunderlying this processare diverse
and have important implications. Thus, NRP-1 can be internalised via a clathrin-dependent
mechanism [13, 46, 84, 86], [46] or clathrin-independent caveolar mechanism initiated in lipid
rafts [13], although the latter was basedsolely on the location of NRP-1 within rafts [87, 88].
The differences between these processes are substantial, as they determine subsequentin-
tracellular signalling, degradation, or translocation to the nucleus, and this potentially provides
another regulatory mechanism of NRP-1 [89].
Another significant feature of NRP-1 that has resulted in substantial confusion is ligand
competition. In the early days of NRP-1 research there were two dominant experimental ap-
proaches,onesolely focused onits function in neural system in association with semaphorins,
and the other focused onits angiogenic function in concert with VEGFs. These approaches
were subsequently combined and the notion of crosstalk betweenthe twosignalling pathways
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wasinvestigated. Initially, the competition between VEGF-Ajg5 and various semaphorins was
consideredrelevant at the molecular and functional level [25, 35, 53, 90]. However, later stud-
ies suggested that no direct competition takes place, and that there are other mechanisms
controlling the selectivity of response, such as downstream signalling, affinity and preferen-
tial binding or internalisation [1, 28, 91,92]. Nonetheless, for some ligands the overlapping
binding sites were documented, and the discussion remains open on the NRP-1-dependent
selectivity of signal transduction. Among those are PIGF-2 and VEGF-Aje¢5 [29], VEGFR-1
and VEGF-Aije¢5 [26], SEMA3F and VEGF-C [31], TGF-8 and VEGF-Ajg¢5 [38]. Interestingly,
these data, although they provide a rather hazy insight into the functions of NRP-1, they have
the potential to become a sourceof predictive data through the use of various mathematical
approachesthat aim to combine in an algorithm-based mannerseveral input parameters in
orderto interpret and estimate further outputs. To date Wu and co-workers have performed
extensive modelling of the angiogenic processes, so far based on various characteristics of
VEGFR-2, VEGFR-1, soluble VEGFR-1 and membrane NRP-1 (see [93]). With regard to the
enormous advancesin the classical and ‘omics data acquisition methods,it is plausible that
this type of analysis will expand quickly, to provide a means of generating novel hypotheses
and so indicate new directions of research.
The description above of NRP-1 providesa lot of information on possible functions and
mechanismsof regulation of NRP-1, however, at the sametime, it opens several discussions
andindicates important questions that need to be answered (Figure 1.2). This thesis attempted
to target some of these questions, and provide further explanations of some of the NRP-1
properties.
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Figure 1.2: Challenging novel aspects of NRP-1 biology.
The figure illustrates phenomena described in the text, that are raising a lot of interest in the field, often remain
not characterised and await clarification. The pool of soluble NRP-1 molecules symbolises multiplicity of such iso-
forms in vivo, which are producedeither via alternative splicing or as a result of the surface shedding. They may
have monomeric or dimeric properties, and no knowledge ontheir exact mechanism of function is available at the
moment. Another aspect of NRP-1 biology is the multitude of its interacting ligands, which mediate variouscellular
responses and might act via NRP-1 either in an agonistic or antagonistic manner, possibly undergoing functional and
structural competition. GAG interactions with NRP-1 might be a means of modulating NRP-1 interactions with the
ligands and cell surface receptors, thus, might be responsible for the regulation of the signalling responses. The c do-
main, transmembraneandintracellular parts remain the least characterised parts of the NRP-1 and are suggested to
bestow importantinteractions and, at the sametime, allow NRP-1 functions that are independentfrom its extracellular-
interactions. Internalisation might be a novel mechanism of regulation of NRP-1 function related to the properties of
the membrane milieu whereit forms signalling complexes. This mechanism would allow anotherlevel of regulation,
responsible for the ligand selectivity and secondary signalling effects occurring after complexinternalisation.
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1.3 Thesis objectives
This study begins with a presentation of a novel method for the measurement of the inter-
actions of proteins and polysaccharides in a high-throughput manner. The methodis briefly
introduced in Chapter 3 and is described in a peer-reviewed publication (Supplemental paper
2).
The NRP-1 part of the study is focused on two important aspects of NRP-1 function, namely
its interactions with the polysaccharide heparin, an experimental proxy for cellular HS andits
pro-angiogenic activity.
Chapter4 aimsto define the interaction of NRP-1 with heparin, as a modelforcellular HS.
In this part of the thesis, the structural requirements for this interaction are established from
both the perspective of the polysaccharide and the protein. In the latter instance, the impact of
NRP-1 dimerisation and of the c domain of NRP-1 onthe interaction is established.
Chapter5 is focused onthe functional aspect of the NRP-1 in the context of a 3-dimensional
angiogenesis assay. Hereit is shown that a dimeric form of NRP-1 elicits a strong proangio-
genic response, independently of VEGF-A, on the endothelial cells. It also provides confir-
mation of the agonistic character of the soluble dimeric form of the protein, and, surprisingly,
possibly also for the truncated monomer.
Overall, the thesis introduces advancesto the methodology of studying protein-polysaccharide
interactions and broadens our contemporary view on NRP-1-polysaccharide interactions and
angiogenic functions.
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Materials and Methods
2.1 Materials
Recombinant rat NRP-1 chimera (Fc rNRP-1), soluble human truncated variant (ShANRP-1),
human Fc and humanIL-2 were purchased from R&D Systems (Abingdon, Oxon, UK), VEGF-
Aji21 was purchased from PeproTech EC Ltd (London, UK). VEGF-Aj¢65 and IL-6 were kindly
provided by NCI-Frederick (Frederick, MD, USA). Humanlactoferrin and BSA were purchased
from Sigma-Aldrich (Gillingham, Kent, UK). S100A4 wasa kind gift from Dr Thamir Ismail. The
same heparin (17 kDa avarage molecular weight) (Celsus Lab, Cincinnati, OH, USA) was used
in the assay andfor the production of modified derivatives, cationic forms and oligosaccharide
fragments. The HDMECsandtissue culture reagents were purchased from Promocell GmbH
(Heidelberg, Germany) and Lonza (Wokingham, Berks, UK). Antibodies against phospho-
VEGFR-2 clone 19A10 (Y1175), VEGFR-2 clone 55B11, phospho-PLCy (Y783), phospho
ERK-1/2 (Y202,204/Y185,187) were purchased from Cell Signaling Technology (NEB,Hitchin,
Herts, UK); against RCAN-1.4 (DSCR-1/ ADAPT78/ Calcipressin-1) and against His-tag from
Sigma-Aldrich; against actin from Santa Cruz Biotechnology(Insight Biotechnology, Wembley,
Middx, UK); against phospho-tyrosine clone 4G10 from Upstate Biotechnology (Buckingham,
Bucks, UK); anti-mouse-HRPand anti-rabbit-HRP antibodies were purchased from GE Health-
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care (Amersham, Bucks, UK); sequestering anti-VEGF and anti-rNRP-1 antibodies were from
R&D Systems. VEGFR-2 kinase inhibitor (ZM323881) [94] was purchased from Tocris Bio-
science (Bristol, Avon, Uk).
2.2 Protein biochemical methods
2.2.1 N-glycanase digest
One yg of Fc rNRP-1, shNRP-1 and Fc werediluted in 50 y»L phosphate-buffered saline
(PBS, 150 mM NaCl, 2.7 mM KCI, 1.5 mM KH,PO,, 10 mM NaHPO, pH 7.4) and incu-
bated overnight at 37°C with or without (mock control) 2.5 mU N-glycanase (Glyko, Prozyme,
Ely, Cambs, UK). One hundred ng samples were subsequently analysed by SDS-PAGE; Fc
rNRP1 and shNRP1 on 8 %(w/v) SDS-PAGE,Fc on 15 %(w/v) SDS-PAGE. Proteins were
visualised by silver staining.
2.2.2 Selective labelling and identification of the heparin-binding pep-
tides derived from Fc rNRP1
Mapping of the heparin-binding site has been performed as described previously [95], with
some modifications. To 20 wL of AF-heparin beads packed in a minitip column and edquili-
brated in buffer A (17.6 mM Na,HPO,, 2.6 mM NaH,PO,, 100 mM NaCl, pH 7.6, 0.02 %
Tween), 4 yg of Fc rNRP-1 was addedin a total volume of 80 pL of buffer A. The loading was
repeated three times. After the minicolumn has been washedwith the buffer A, the lysines not
involved in heparin binding were acetylated by means of 50 mM sulfo-NHS-acetate (Thermo,
Pierce, Perbio Science, Cramlington, Northumberland, UK) (Figure 2.1) in buffer B (18.3 mM
Na,HPO,, 1.7 mM NaH,PO,, pH 7.8) during 5 min incubation. The reaction was stopped by
washing the microcolumn with buffer B. Acetylated proteins bound to the column wereeluted
with buffer C (45.75 mM Na,HPQ,, 4.25 mM NaH,PO,, 2M NaCl pH 7.8). The elution was
buffer exchangedinto buffer D (45.75 mM Na,HPO,, 4.25 mM NaH,PQO,, pH 7.8) using a
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Vivaspin 100 kDa MWCOcentrifugalfilter (Sartorius Stedim, Epsom, Surrey, UK) blocked pre-
viously in BSA to avoid Fc rNRP1 nonspecific binding to the filter. Subsequently, the lysines
that were protected by heparin interaction were biotinylated using a final concentration of 10
mM NHS-biotin in DMSO (Thermo) (Figure 2.1) (added as 7 % v/v) during 30 min incubation at
room temperature. The reaction was quenchedbythe addition of a final concentration of 100
mM Tris pH 6.8 (added as 9 %v/v). Next, the solution was buffer exchangedinto buffer E (4.58
mM Na,HPO,, 0.438 mM NaH,PO,, pH 7.8) using new Vivaspin 100 kDa MWCOcentrifugalfil-
ter also blocked previously in BSA, and the remaining sample wasdried by rotary evaporation.
Afterwards, it was dissolved in buffer F (8 M urea, 400 mM NH,HCO,pH 7.8, 2.5 pL 45 mM
DTT) and incubated for 15 min in 56°C. Next, protein was carbamidomethylated using a final
concentration of 9 mM iodoacetamide (added as 9 %v/v) during 15 min incubation at room
temperature in the dark. After dilution 1: 4 with HPLC grade water, the sample wasdigested
with 1.5 yg of chymotrypsin (Sigma-Aldrich) overnight at 37°C (cuts after T, F, W, L, M, N and
Q). The digest mixture was diluted a further four times with HPLC grade water and applied
to a 40 wL Strep-Tactin® Sepharose® (IBA, Stratech, Newmarket, Suffolk, UK) minitip column
equilibrated previouslyin sixteen times diluted buffer F (500 mM urea, 25 mM NH,HCO,). The
microcolumn was washedwith the same buffer and HPLC grade water and the boundbiotiny-
lated peptides were eluted with buffer G (80 %v/v, acetonitrile, 20 %v/v,trifluoroacetic acid, 5
mM biotin). The elution was dried by rotary evaporation down to 4 pL and topped upwith 50
uL of 0.1 %(v/v) trifluoroacetic acid. Subsequently, the sample was desalted by C18 ZipTip™
(Millipore, Watford, Herts, UK) according to the manufacturer's instruction and the peptides
were eluted with buffer H (60 %v/v, acetonitrile, 0.1 % v/v,trifluoroacetic acid). The sample
wasanalysed by MALDI-Q-TOF Premier mass spectrometer (Waters-Micromass, Manchester,
UK).
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2.2.3 Peptide analysis
Biotinylated peptides obtained from MALDIanalysis were analysed using MassLynx software
(Waters - Micromass, Manchester, UK) and identified with Protein Prospector MS-Tag (UCSF,
San Francisco, CA, USA). The settings included: chymotrypsin digest, nonspecific cleavage on
one peptide termini, a set of variable modificiations, as acetylation and biotinylation of lysines,
carbamidomethylation and carboxymethylation of cysteines (occurring due to iodoacetamide
presencein the procedure), and oxidation of methionines (related to the sample handling).
The analysis was performed for monoisotopic ions with error tolerance of 100 ppm for parental
ions, and 300 ppm for fragmented ions in MALDI-Q-TOFinstrument setting. The peptides
were ascribed to the regions of rat NRP-1 (Uniprot accession number Q9QWJ9) or human
IgG1 (Uniprot accession number P01857) and were presentedin the text.
2.2.4 Binding to heparin affinity minicolumns
Twotypesof heparin resins, Affi-gel heparin (Bio-Rad) and Toyopearl AF-heparin 650M (Tosoh
Bioscience, Redditch, Worcs, UK), were used to analyse Fc rNRP-1 and shNRP-1 binding to
heparin. The minicolumns were assembledin a minitip (0.1-10 yL range)fitted with a filter and
approximately 25 pL of slurry of the respective resins. In order to eliminate the residual con-
tamination with the storage buffer the minicolumns were washedwith 4 column volums (CV) of
water and, subsequently, with 8 CV of PBSTidentical to the buffer used in the Biosensor anal-
ysis. Next, 50 yl of 20 yg/ mL of Fc rNRP-1 and shNRP-1 (1 wg) was applied 3 times on the
minicolumn. The load (LD) and flow through (FT) fractions were collected and 100 ng samples
were resolved on 8 % (w/v) SDS-PAGEandvisualised by silver staining. Concurrently, 100
uL of each resin was washed with excessive amount of water and heparinase digest buffer 5x
(500mM CH;COONa,0.5 mM (CH,;COO),Ca pH 7.0). Subsequently, the resins were resus-
pendedin 800 uL of heparinase digest buffer 1x (100mM CH3;COONa,0.1 mM (CH3;COO),Ca
pH 7.0) supplemented with 2.5 mU heparinasesI/II/III (IBEX Technologies, Montreal, Canada).
The digest samples were incubated on tuberotator at 37°C overnight. Afterwards, the resins
 Doctoral thesis Study of Neuropilin-1 interactions by Katarzyna Adela Uniewicz 15
Materials and Methods
 
were extensively washed and packed into minicolumns of the same volume astheoriginal
onesand,the proteins were analysed for binding to the resins as previously.
2.2.5 Differential Scanning Fluorimetry (DSF)
DSF was performed as described previously (see [96] , Chapter 3 and Supplemental paper
2). Briefly, a final concentration of 0.57 uM (136 yg/ mL) Fc rNRP1 wastested alone or with
1.132 yM (19 yg/ mL) heparin or 11.32 uM (190 pg/ mL) heparin, which gave respectively 1: 2
and 1: 20 ratios of dimeric Fc rNRP1 versus heparin. Similarily, a final concentration of 1.132
uM shNRP1 wastested with 1.132 »M heparin or 11.32 uM heparin, which gave respectively
1: 1 and 1: 10 monomeric truncated shNRP1 versus heparin. The assay was performedin
96-Well Reaction Plate (Applied Biosystems, Warrington, Cheshire, UK). The final volume per
well (25 yL) comprised of the protein dissolved in PBS (20 %v/v), heparin dissolved in HPLC
grade water (10 % v/v), PBS (60 %v/v or 70 % v/v in case of the condition containing no
heparin) and freshly prepared 100x water baseddilution of Sypro® Orange 5000x(Invitrogen)
(10 %v/v), added in the given order. During the preparation, the plate was kept on ice and
immediately afterwards, it was sealed with Optical Adhesive Film (Applied Biosystems) and
directly analysed in a 7500 Fast Real Time PCR System (software version 1.4.0) (Applied
Biosystems) instrument. The heating cycle comprised of a 120 s pre-warming step at 31°C
and a subsequentgradient between 32 and 81°C obtained in 99 steps of 20 s, each of 0.5°C
ramp. Data were collected using the calibration setting for TAMRA™dye detection (Aex 560
nm; Aem 582 nm) installed on the instrument (as compared to Sypro® Orange idealsettings
Aex 492 nm; Aem 610 nm).
2.2.6 DSF data analysis
The data were analysedusing the Plot v. 0.997 software for Mac OSX (http://plot.micw.eu/) by
application of an exponential correlation function approximation ofthe first derivative for each
melting curve.
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2.2.7 Native proteolytic digest
The native proteolytic digest experiments were performedin fresh tubes to obtain the best
efficiency of the digests not affected by the interaction betweenthe protein andtheplastic tube
following freezing. Both digestes were performed in the volume not larger than 30 pL. Ina
digest A 2 yg of Fc rNRP-1 in 0.1 M phosphate buffer pH 7.7, 75 mM NaCl supplemented with
50 ng of trypsin (porcine trypsin sequence grade modified) (Promega, Southampton, Hants,
UK) was incubated in 37°C for 30 min. For a digest B 2 pg of Fc rNRP-1 in 0.5 M NaCl
supplemented with 75 ng of the sametrypsin stock was incubated in 12°C for 90 min. Each
digest was reproducible as confirmed by three independent repeats visualised by SDS-PAGE,
where amounts equivalent to 90 ng of Fc rNRP-1 of each digest were resolved. Prior to Dual
Polarisation Interferometry (DPI) analysis the digest solutions were supplemented with PBSto
the final volume of 600 yL. The final NaCl concentration in the samples used for the binding
experiments was approximately 0.15 M, while the final Fc rNRP-1 concentration was 14 nM.
2.2.8 Crosslinking
Following the digest procedure, each sample wasdiluted either with PBS or phosphate buffer
pH 7.7 to contain a final concentration of 0.14 M NaCl. Subsequently, 6 mM of fresh 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Thermo) and 15 mM of
N-hydroxysuccinimide (NHS) (Thermo) from DMSO-basedstock were added (Figure 2.1). The
mixtures were incubated for 45 min at room temperature and analysed on SDS-PAGE where
amounts equivalent to 90 ng of Fc rNRP-1 of each digest were resolved.
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2.3 Surface-based methods
2.3.1. Heparin surface preparation
Surfaces were preparedin an lasys optical biosensor running |Asys plus software version 3.01
(NeoSensors, Sedgefield, Cleveland, UK). Biotin functionalised surfaces were derivatised with
streptavidin to enable subsequentcapture of internally biotinylated heparin (via internal free
amino groups). The usual volume addedto the cuvette was 50 wL, unless indicated otherwise.
Most of the precedure was performed at 20°C. Briefly, biotin functionalised surface cuvette
(NeoSensors) after regeneration with acidic wash solution A (20 mM HCl) and basic wash
solution B (20 mM NaOH2 M NaCl) was washed with PBST (140 mM NaCl, 5 mM NaH,PO,,
5 mM Na,HPO,, 0.02 %(v/v) Tween, 0.02 % (w/v) sodium azide) and subsequently incubated
for 40 minutes with 20 uL of 2.5 mg/ mL streptavidin (Sigma-Aldrich, Gillingham, Kent, UK) and
10 yL of PBST. After thorough PBST washesthe surface was incubated overnight at 4°C with
20 pL of 10 mg/ mL heparin internally biotinylated on free amines(kind gift from Yassir Ahmed)
protected against evaporation and drying. The resonancescan confirmed that the surface was
modified uniformly.
2.3.2 Binding assays
The binding assays were performed in automated IAsys optical biosensor device controled by
lAsys Auto Plus software version 3.01 applying appropriate scripts for kinetic association and
competition assays. Theinitial binding tests and kinetic dissociation assay was performed in a
manually operated IAsys. The total volume of solution over the surface was constant for each
step of the experiment and equal 50 yL. The temperature of the experiments was 20°C.
For the initial binding tests of Fc rNRP-1, shNRP-1 and Fe, to 45 yL of PBST 5 pL of the
tested protein was added. Thefinal concentration of the proteins in the cuvette was 0.5 g/
mL.
In kinetic association assays the binding solution consisted of 45 wL of PBST and 5 pL of Fe
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rNRP-1 at 10 times final concentration. Fc rNRP-1 final concentration range was 0.25 nM-1.6
nM. The experimental steps consisted of setting a PBST baseline (500s), an association phase
(240s), followed by a dissociation phase (60s). The regeneration of the surface was achieved
by washing with solution B. The needle was washed with wash solution A. The association
experiment was repeated 5 times to provide the ka,, values used for further calculation of Kg.
In dissociation assays, higher concentrations of Fc rNRP-1 were used,1.2 yg/ mL in 50 pL
of PBST,to reduce the probability of re-binding. Following association and washing, dissoci-
ation wasinitiated by the addition of 40 yg/ mL heparin in PBST; the competing heparin also
reduced the probablitly of re-binding. The experiment steps consisted of acquiring a baseline
(60s), an association phase (240s), dissociation with PBST (120s) and dissociation with 1 yL
of 2 mg/ mLporcine heparin (at least 60s). Regeneration was achieved with washsolution B.
The dissociation experiment was repeated 5 times to provide the kovalues used for further
calculation of Kg.
In competition assays the binding solution consisted of 40 yL of PBST, 5 wL of Fc rNRP-1 at
10 times the final concentration, and 5 pL of competing sugarat 10 times the final concentration
added from a 96-well plate where a range of appropriate solutions were prepared. The sugars
used in the competition assay were either modified heparin derivatives (kind gift from Dr Ed
Yates) [97,98] or heparin derived oligosaccharides obtained from partial heparinase | (IBEX
Technologies) digest of porcine heparin (Celsus Lab) performed as described previously [99].
The range of concentration of competing sugars did not exceed 0.01-100 g/ mL. The Fc rNRP-
1 was aliquoted from 10 times concentrated solution (5 yg/ mL). The final concentration of
sugars varied within the experimental range, while the Fc rNRP-1 concentration was constant
(0.5 yg/ mL). The experimental steps consisted of setting a PBST baseline (30s), acquiring a
baseline after sugar addition (150-450s), and the association phase (300s). Regeneration was
achieved with wash solution B and the needle was washed with washsolution A. As Fc rNRP-1
seemed to loose its heparin-binding activity, no more than 25 binding curves were collected
from a single stock tube of the protein. Each set of data for each sugar wascollected at least
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twice.
2.3.3 Biosensor data analysis
The analysis was doneusing FastFit software version 2.03 (NeoSensors). The collected data
were analysed using single-site binding model. For the analysis of the kinetic data the FastFit
software provideddistribution of the data around the one site model and a measure of the
consequentvariation, the slope ofinitial rate, k,, and the extent of binding in a graphical
and numerical output. The FastPlot software version 2.0 juxtaposed the binding curves for
each Fc rNRP-1 concentration. The dissociation data were analysed in FastFit where 60s of
the heparin-dependent dissociation was used for the calculation. Kg calculation was based
on the values of Kass and kgis, obtained in association and dissociation assays, respectively.
Thefinal kinetic values and their respective standard errors (SE) were calculated basing on 5
independentassociation experiments, and 6 independentdissociation experiments.
The competition assay data were normalised by comparison of extent of response of Fc
rNRP-1 binding to the heparin surface versus the extents of Fc rNRP-1 responsein the pres-
enceof sugar. This allowed a comparison to be made betweensets of binding curves compris-
ing of a control Fc rNRP-1 and a range of concentrations of the competitor. The control extent
of binding was defined as 100 %, while the following values of Fc rNRP-1 extent of binding in
the presenceof inhibiting compounds werecalculated as fractions of 100 %. The ICs values
were calculated using Origin 8 (OriginLab Corporation, Northampton, MA, USA) applying a
non-linear curvefit.
2.3.4 Dual polarisation interferometry (DPI)
DPI analysis was performed on an AnaLight® Bio200 System (Farfield Scientific, Crewe, Cheshire,
UK) equipped with a 632.8 nm laser. The experiment was performed as described previ-
ously [100]. Briefly, the thiol chip wasverified for sufficient polarisation pattern characterised by
Te and T,, values over 0.6. Next, the chip was calibrated with 80 % (w/v) ethanol and waterat
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20°C at 50 yL/ min flow. Subsequently, the temperature of the flow cell was set to 30°C and 180
pL of freshly prepared 5 mg/ mL N-(f-maleimidopropionic acid) hydrazide (BMPH) (Thermo)
(Figure 2.1) dissolved in PBS wasapplied at 8 yL/ min to eachflow cell. In this way reactive
thiol groups of the chip reacted with maleimide groups of BMPHto form stable thioether bonds,
and consequently, a new surface with reactive hydrazide groups wasobtained. This step was
followed by extensive PBS washing at 50 »L/ min. Next, the flow cell destined to be modified
with oligosaccharide wasinjected with 180 pL of 2 mg/ mL hexadecasaccharide (dp 16) dis-
solved in PBS pH 5 at 2 wL/ min. Thereupon, aldehyde groups of dp 16 producedbypartial
nitrous acid digest (on reducing end) [99] created stable hydrazone bondswith the hydrazide
groups of immobilised BMPH. Subsequently, both flow cells were modified with aldehyde-
functionalised poly(ethylene glycol) (PEG-CHO) (Rapp Polymere, Tubingen, Germany) used
here as a blocking reagent. PEG-CHO (180 pL of 20 mg/ mL) dissolved in PBS was applied
at 1 ypL/ min and incubated overnight resulting in blocking of the remaining hydrazide groups
of the oligosaccharide flow cell and hydrazide groups of the secondflow cell. The injection
of PEG-CHO wasrepeatedto ensure full modification of the surface. After extensive PBS
washesthe temperature was returned to 20°C and the surface was regenerated with 2 M NaCl
phosphate buffer pH 7.5. The binding assays of each molecule were repeated three times and
each binding was followed by regeneration with 20 mM HCI. The molecules weretested at
3.33 g/ mL, which equals to 14 nM (Fc rNRP-1), 47 nM (hNRP1) and 123 nM (control Fc).
The native digest samples were prepared for analysis as described in the previous section.
2.3.5 DPI data analysis
The surface preparation and binding events were analysed applying Analight Explorer 1.5.2.17946
software version according to the manufacturer's instructions. For the illustrations, the mass
readings of the binding events were normalised to start from 0 value. The thickness and den-
sity readings are presented according to the experimental recordings.
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2.4 Tissue culture methods
2.4.1 BaF3 proliferation assay
The BaF3 assay was performed as described previously [101]. Briefly, the cells were cultured
in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10 %(v/v) fetal calf serum (Gibco,
Invitrogen, Paisley, Scotland, UK), 50 »M L-glutamine (Gibco), 100 U/ mL penicillin G, 50 pg/
mL streptomycin sulfate (Gibco) and 2 ng/ mL murine IL-3 (R&D Systems) at 37°C and 5 %
(v/v) COs.
The assays were performedin 96-well tissue culture plates and consisted of standard con-
trols (negative, positive, FGF-2 alone and FGF-2 in combination with heparin) and a dilution
curve of total 6 points spanning the range of concentrations of the antagonists (Fc rNRP-1,
shNRP-1, Fc) of a step dilution factor of 3. Each variant was prepared in 3 repeats.
The control wells were supplemented with 50 pL of the basic medium withoutIL-3 (negative
control), medium containing 4 ng/ mLIL-3 (final 2 ng/ mL) (positive control), medium containing
2 nM FGF-2 (final 1 nM) and medium containing 2 nM FGF-2 and 20 yg/ mL heparin (final 1
nM FGF-2 and 10 pg/ mL heparin).
The wells prepared for the dilution curve were supplemented with 50 wL of the basic
medium with the addition of appropriate amounts of FGF-2 and heparin in order to obtain
4 variants of final concentrations (0.1 nM FGF-2 and 0.1 g/ mL heparin, 0.1 nM FGF-2 and
1 yg/ mL heparin, 0.3 nM FGF-2 and 0.1 yg/ mL heparin and 0.3 nM FGF-2 and 1 yg/ mL
heparin).
The wells designed to contain the highest concentration of the antagonists (30 nM) were
supplementedwith 75 uL of the medium containing appropriate concentrations of FGF-2, hep-
arin (consistent with the variant) and antagonists (Fc rNRP-1, shNRP-1, Fc). Subsequently,
25 pL of the solution containing the antagonists wastransfered to the next set of wells, and the
operation was repeatedto obtain full set of dilutions.
Finally, to the wells containing 50 wL of the 2 x concentrated IL-3, FGF-2, heparin and
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antagonists, the cells, which were previously washed twice in the basic medium, were added
in 50 pL at 1 x 104 per well in the basic medium.
After 72h of incubation in 37°C 10 pL of MTT solution (5 mg/ mL in PBS) was added to
each well and incubation wascontinuedfor a further 4h. Finally, 100 yL of solubilising solution
(10 % (w/v) SDS, 0.01M HCl) was addedto each well and incubation in 37°C was continued
overnight. The plate was subsequently analysed by reading ODs99 values for each well. The
presented resultis illustrated by the mean values and SD of readings for each variant.
2.4.2 Tissue culture of HDMECs
HDMECswere purchased from Promocell and were cultured with the Endothelial Cell Growth
Medium MV2 Kit (Promocell) consisting of the Endothelial Cell Basal Medium with appropri-
ate supplements provided by the manufacturer (5 %v/v fetal calf serum, 5 ng/ mL human
epidermal growth factor, 10 ng/ mL FGF-2, 20 ng/ mL insulin-like growth factor, 0.5 ng/ mL
VEGF-Ai6s, 1 g/ mL ascorbic acid, 0.2 g/ mL hydrocortisone). Alternatively, the cells were
grown with 0.5 ng/ mL VEGF-Aj;2; instead of VEGF-Aigs5 where indicated. Cells were used
until passage 10. For routine cell maintenance, HDMECs were grown on 1 %(w/v) gelatin-
coated plates at 37°C and 5 %(v/v) CO,. Twenty four hours prior to the experiments, the
cells were serum-starved by replacing the fully supplemented medium with 1 %(v/v)fetal calf
serum Endothelial Cell Basal Medium. For regular maintenance, cells were detached from the
plates using solution of 0.05 % (w/v) trypsin in 0.53 mM EDTA(Invitrogen, Paisley, UK). For
the experiments the cells were detached using Accutase solution (Promocell) to preserve the
extracellular membraneproteins.
2.4.3 Tube formation assay
The tube formation assay was performedas described previously [102]. Collagen type | (Vitro-
gen, Cohesion Technologies, Palo Alto, CA, USA) was mixedat a ratio 8: 1: 1 with 0.1 MNaOH
and 10x concentrated Ham’s F-12 medium (Promocell). The solution was supplemented to
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contain 0.02 M Hepes, 0.1 % (w/v) sodium bicarbonate and 2 mM Glutamax-I (Invitrogen),
and kept onice until placed into the wells. The assay was prepared in 24-well plate format
and the bottom layer of collagen was formed by adding 300 uL of the solution per well and
allowing subsequentgelation at 37°C overnight. Following serum starvation, cells were plated
at 8-9 x 10* in 500 pL per well in 1 %(v/v) fetal calf serum Endothelial Cell Basal Medium.
After 120 min the medium wasaspirated and a secondlayerof collagen (200 yL per well) was
prepared according to the sameprotocol and gently placed on top of the cell layer. After 90
min of incubation at 37°C, the medium wasreturned to the wells. The photos weretaken after
17h to 20h incubation at 37°C from approximately the same coordinates in each well within
the experimentalplate.
Thefinal volume of the assay was 1 mL, comprising of 0.5 mL of the collagen layers and
0.5 mL of medium. Depending ontheligand type, various orders of addition were employed.
The higher molecular weight ligands, such as Fc, shNRP-1 and Fc rNRP-1 were addedto the
cells at the adhesion step (final concentration 5 nM,unless indicated otherwise), while smaller
molecular weight ligands, such as VEGF-Ajg¢s (final concentration 10 ng/ mL) and VEGFR-2
inhibitor ZM323881 (final concentration 3 uM) were added to the medium after formation of the
top layer of collagen. In experiments using sequestering VEGF-A antibody, the antibody (20
ug/ mL) wasincubated with VEGF-Ajg¢5 (10 ng/ mL) for 60 min at room temperature and added
after formation of the top layer of collagen. For experiments with the Fc rNRP-1/ shNRP-1
variants the antibody was addeddirectly to the medium.
2.4.4 Data analysis of the tube formation
Photographs of HDMECsinthe tube formation assays were analysed with Adobe® Photoshop®
CS3 Extended version 10.0 (San Jose, CA, USA). For each experimental condition three
squares of 400 x 400 pixels were selected in the photograph and on each, the area cov-
ered by tubes wascalculated. The output values were usedfor the Student's t test evaluation
of the significant difference between the experiments. To allow comparison between experi-
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ments, the mean value of the tubes’ surface in the control containing no agonist was set as a
reference value 1, and used to normalise all other experimental values.
2.4.5 Signalling assay
Serum-starved cells were plated at 1.8 x 10° cells in 500 wL per well of 12-well plates either
on collagen or a layer of 1 %(w/v) gelatin in 1 %(v/v) fetal calf serum Endothelial Cell Basal
Medium. Two hourslater the medium with appropriate ligands was addedto the wells and the
plate was returned to the incubator. After an appropriate time of incubation (10 min and 180
min), plates were placed onice and the cells were lysed by 3 min incubation with RIPA buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10 %(w/v) glycerol, 1 %(w/v) Triton-X-100,
1 mM sodium vanadate, 10 mg/ mL aprotinin, 10 mg/ mL leupeptin, 1 mM PMSF, 0.1 %(w/v)
SDS, 0.5 %(w/v) sodium deoxycholate). The lysates werecollected, clarified by centrifugation
at 11000 RPM (ca 13000 g) at 4°C for 20 min, boiled with NUPAGE LDS Sample Buffer and
analysed by SDS-PAGE.
2.4.6 Data analysis of the signalling assay
The bandintensities in analysed western blots were estimated using Adobe® Photoshop® CS3
Extended version 10.0 and presented asrelative values comparedto the control. To do so, the
pictures were convertedto their respective negatives, and the samesurface for each condition
was analysedforthe light intensity profile.
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2.5 PAGE,western blot and silver staining
2.5.1 Biochemical analysis
Eight or 15 % (w/v) SDS-PAGEgels were resolved at 200 V constant voltage and wherere-
quired transferred for 2 h at 100 V by wettransfer onto nitrocellulose membranes (GE Health-
care, Amersham, Bucks, UK) using a Bio-Rad Laboratories apparatus (Hemel Hempstead,
Herts, UK). The membranes were blocked for 1 h at room temperature in PBS, 0.1 %(v/v)
Tween, 5 mg/ ml BSA. Subsequently, they were incubated with the primary antibody solution
(PBS 0.1 % (v/v) Tween, 5 mg/ ml BSA,1: 250 anti-rat NRP-1 antibody raised in mouse (R&D
Systems)) for 1 h at room temperature. After washing they were incubated with the secondary
antibody solution (PBS 0.1 %(v/v) Tween, 5 mg/ ml BSA,1: 250 anti-mouse antibodyraised in
goat conjugated with HRP (Pierce)) for 1 h at room temperaure. Afterwards, the membranes
were extensively washed with PBS 0.1 %(v/v) Tween and developed using Super Signal West
Dura Extended Duration Substrate kit (Thermo). Silver staining of recombinant proteins was
performed as described previously [103].
Native PAGE was performed as SDS-PAGEwith the exception of omission of SDS, f-
mercaptoethanol and sample boiling. One yg samples of heparin, dp 24 and dp 26 were
analysed on 33 %(w/v) Tris-acetate gels resolved in Tris-Mes running buffer initially at 200 V
for 4 h, then, overnight at 75 V [104]. The gels were stained for 10 min with 0.08 %(w/v) azure
A, dueto its property to interact with sulfate groups, briefly washed, and photographed.
2.5.2 Gel electrophoresis and western blot of HDMECs samples
For gel electrophoresis the NUPAGE Bis-Tris system was used(Invitrogen). The gradient 4-12
% (w/v polyacrylamide) gels were resolved at 50 mA constant current and transferred onto
nitrocellulose membranes (GE Healthcare) using XCell II™ Blot Module for 120 min at 140
mA(Invitrogen). The membraneswereblocked in 5 % (w/v) BSA,0.1 %(v/v) Tween-20in Tris-
buffered saline (TBS) for 60 min at room temperature and subsequently incubated overnight
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in the cold room with the appropriate antibody solution prepared in 2 % (w/v) BSA, 0.1 %
(v/v) Tween-20 in TBS. After washing, the membranes were incubated with the appropriate
secondary antibodies in 2 % (w/v) BSA in TBS 0.1 %(v/v) Tween-20 for 60 min in the cold
room. The membranes were developed using Super Signal West Dura Extended Duration
Substrate kit (Pierce, Perbio Science, Cramlington, Northumberland, Uk).
2.6 Bioinformatics
2.6.1. General bioinformatics
The preliminary characterisation of the NRP-1 publication record was made using PubMed
(http://www.ncbi.nim.nih.gov/sites/entrez). The putative interaction record was obtained with
the. help of the InterDom server(http://interdom.i2r.a-star.edu.sqg/).
2.6.2 Homology modelling of the c domain
The sequence of the c domain (Uniprot accession number 014786, residues 645-804) was
used to search HHPred algorithm in searchfor the mostsimilar available templates (http://toolkit.
tuebingen.mpg.de/hhpred) [105]. The best templates indicated by the software, 2C9A (2.7
A resolution) [106] and 2V5Y (3.1 A resolution) [107] both contained the immunoglobulin
domain of the Receptor-type tyrosine-protein phosphatase MUthat served for the further
modelling of the c domain. It is noteworthy that the sequence similarity between the c do-
main and both templates within the matching region was low, and with the 2C9A was 24 %
identity and 38.6 % similarity, and with 2V5Y was 24.1 %identity and 38.8 %similarity as
shown by Embosspairwise alignment (http://www.ebi.ac.uk/Tools/emboss/align/index.html).
The consistency of the secondary structures within the templates was verified by Dalilite
(http://www.ebi.ac.uk/Tools/dalilite/index.html) [108]. The alignment of the c domain and the
two structures was performed by Clustal W (http://align.genome.jp/) [109] and its PIR presen-
tation served to prepare the inputfile for Modeller 9v7 (http://www.salilab.org/modeller/) [110].
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Subsequent modelling producedfive initial structures which were verified by DOPE score
in Modeller 9v7, and the lowest score model (most energetically favoured) was further op-
timised. In order to do so, the Ramachandran plot of the chosen model was examined
(http://mordred.bioc.cam.ac.uk/ rapper/rampage.php), and residues in the outlier region were
remodelled to obtain correct biophysical properties. Again, the best model was validated by
the DOPEscore, and additionally inspected by Model Quality AssesmentSuite (http://ika.bwh.
harvard.edu/testmod/Qasmod.html), and compared with the template structural files. This
showed that the obtained model was of medium quality, however, at the sametimeit did not
differ substantially in its properties from the input templates and it had no major structural con-
strains. The final model was used to visualise the peptides identified in the P&L experiment.
2.6.3 Docking analysis of the c domain
The obtained model of the c domain was subsequently analysed by PPI-Pred (http://ombpcu36.
leeds.ac.uk/ppi_pred/index.html [111], meta-PPISP (http://pipe.scs.fsu.edu/meta-ppisp.html)
[112] and WHISCY(http://nmr.chem.uu.nl/Software/whiscy/index.html) [113]. The output resi-
dues were suggested to beinvolvedin protein-protein interactions. The final consensus se-
quence was subsequently used to model a putative dimer of the c domain by HADDOCK
server.
2.6.4 Homology modelling of NRP-1
The sequence of NRP-1 (Uniprot accession number 014786,residues 22-808) was homology-
modelled basing on the 2QQM and 2QQkKstructures, and previously homology-modelled a1
and c domains. The standard procedure as described above wasapplied for a1, c, and the
final NRP-1 modelling.
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2.6.5 Sequence alignments of NRP sequences
Alignments of rat NRP-1 versus human NRP-2 sequence covered by the 2QQLstructure
and human NRP-1 were performed by Clustal W [109] (http://align.genome.jp/) and served
to reflect bestfitting of the identified peptides on the available crystal structure. The level
of identity and similarity of the sequences was calculated using Embosspairwise alignment
(http://www.ebi.ac.uk/Tools/emboss/align/index.html).
2.6.6 Visualisation of the structures
In order to present approximated location of the identified biotinylated peptides of rat NRP-
1, either a human NRP-2 structure covering all ala2b1b2 domains (the 2QQL) [1] or the
homology-modelled c domain or human NRP-1 were used. Subsequently, the Pymol software
(http://pymol.org/) was usedtoillustrate the above regions.
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Figure 2.1: Crosslinking reagents usedin the study.
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Chapter3
Developmentof the differential
scanning fluorimetry method to
probe protein-glycosaminoglycans
interactions
Abstract
This chapter presents a novel methodthat investigates protein-polysaccharide interactionsin
a high-throughput manner. The method provides a direct rapid measurement of the melting
temperature shifts of the studied protein-polysaccharide complexes and allows simultaneous
analysis of up to 96 possible conditions. The method was based on workof Niesenetal., [114],
and was additionally used in Chapter4 to confirm the binding of heparin to recombinant NRP-
1s (see Figure 4.16). The choice of FGFs astest proteins resulted from a relatively solid
knowledge on the chosen - FGF-1, FGF-2, and partially FGF-18 - interaction with various
heparin-derived molecules. This knowledgeallowedthe verification of the method's applicabil-
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ity to screen in a high-throughput mannerstructural requirements of molecules that can bestow
changesin thermostability of their protein partners. The method appeared successful for the
tested proteins, and allowedto follow several aspects of the polysaccharide: FGF interactions.
First of all, the heparin-concentration dependentelevation of stability was observed, secondly,
oligosaccharide size influence on stability, thirdly, sulfation pattern of the polysaccharide re-
quirementto bestowstability. Such a set of data provides information on the thermostabilising
aspectof the given interactions, however, it might be very useful as a partial characterisation
of the binding events.It is importantto note that in orderto obtain a full picture of the functional
aspectof the interaction more assays are indispensable (e.g. structural shift characterisation,
signalling capability correlation).
The publication describing the method is attached as a Supplementalpaper2.
Introduction
The name Differential scanning fluorimetry (DSF) derives from the measurements of small
differences in fluorescence of an analysed sample. When combined with a gradient of tem-
peratureit allows collection of data points in defined temperature and time intervals in order
to build a thermalprofile of an unfolding protein. Although in general, due to the presence
of aromatic amino acids, proteins possessintrinsic fluorescence properties, the application of
the method detecting the intrinsic fluorescenceis limited to proteins containing at least one of
those amino acids. Using an additional dye to detect fluorescence measurementsis therefore
useful due to its independence of amino acid content. Additionally, in case of Sypro® Orange
dye, its high signal-to-noise ratio makes it an excellent probe enhancing the detection of un-
folding [82]. Application of Sypro® Orange dye is also usefulas it allows the experiment to
be run in a standard RT-PCR machines, which usually have a default setting for detection of
similar dyes, thus, does not require a specific calibration, and is available in most molecular
biology laboratories.
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Figure 3.1: Typical recording of fluorescence intensity versus temperature for the unfolding of protein
(citrate synthase) in the presence of Sypro® Orange (adapted from [114]).
The dye is symbolised as a three-ring aromatic molecule. In the presence of a globular protein (spherical shape at the
baseline of the curve) the dye doesnotinteract with the protein and the basic fluorescenceintensity is low. Through
unfolding of the protein, hydrophobic patches(in gray) become exposed,the dye binds to them,and strong fluorescent
light (depicted by orange curved arrows) is emitted by the dye molecules bound to them. Following the peakin the
intensity, a gradual decrease is observed, which is mainly explained by protein being removed from solution owing
to precipitation and aggregation. The lower and upperlevel in the fluorescence intensity are marked LL and UL,
respectively.
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The Sypro® Orangeis a commercial dyeof a classified structure that wasinitially developed
as an SDS-PAGEstain. Its mechanism of interaction with proteins is driven by hydrophobic
forces. Namely, in native conditions when the protein is folded and its hydrophobic residues
are buried inside the structure the dye remains largely free in solution and its fluorescence
is low. However, upon transition of the protein into an unfolded state, as the hydrophobic
residues become exposed, the dye interacts with them, and this causes significant rise in
its fluorescence signal (Figure 3.1). Thus, so that the method was suitable for the protein
analysis, first of all, the dye needs to have no backgroundaffinity for the protein in its native
state, secondly, a more universal requirement for the protein to undergo a state transition
denaturation is fundamental.
In most cases, the shape of the thermal (denaturation) curve recorded by the RT-PCR
machinewill resemble a two-state transition curve (Figure 3.1), and this is a prerequisite for
the further analysis. The inflection point, defined by the maximum ofthefirst derivative of the
thermal curve, is a melting temperature (T,,) of the protein, and is a direct output value allowing
data interpretation.
Several proteins were tested to confirm that the method could be ubiquitously applied
for the protein studies (Figure 3.2). Among proteins belonging to Al/ a protein class were
Interleukin-6 (IL-6), BSA and S100A4 [115-117], in a and B class waslactoferrin [118], and in
All B class were FGFspresented in the Supplementalpaper2. All of them required 5 yM con-
centration to provide detectable signal. IL-6 and lactoferrin underwent denaturation according
to the two-state model. BSA and S100A4 had less evident melting curves, nonetheless, the
estimation of their respective T,, values waspossible. It is important to remember, as in the
latter cases, whenthefirst derivatives were based on shallow thermalprofiles, that the preci-
sion, repeatability, and, consequently, the errors of the measurement can be affected by the
shape of the thermal curves. Overall, the chosen test proteins allowed the determination of
the output T, values, which was a good prognostic for the method.
Next, the obtained T,, values were compared with the literature-derived values. Only for
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lactoferrin and BSA [119] was such comparison possible, and revealed that the method was
providing values in a close range to the published data [119, 120], for lactoferrin 66°C as
compared with the published 72°C, for BSA 61°C as compared with the published 59°C. The
66°C for IL-6 and 52°C for S100A4 are to the author’s knowledgethefirst determinations of
their respective T,, values.
This initial experimental stage led to a further developmentof the application of this method
to studying protein-polysaccharide complexes. Detailed description of this part of the project
is presented in the Supplemental paper2.
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Figure 3.2: Denaturation curvesof the proteins tested by DSF applying Sypro® Orangedye.
Thefigure presents denaturation curves of the chosentestproteins(left panels) and their respective first derivatives
(right panels) calculated as described in the Section 2.2.6. The indicated molar amountsof the proteins were subjected
to the procedure described in the Section 2.2.5. A, B) IL-6. C, D) Lactoferrin. E, F) BSA. G, H) S100A4. The
experiment was performed in 2 repeats for each concentration variant and one representative curve is plotted and
analysedonthefigure.
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Biochemical analysis of the
interaction of Neuropilin-1 with
heparin
Abstract
Neuropilin-1 (NRP-1) is a vertebrate specific molecule recognised for its involvement in the
developmentof vasculature, neural patterning, immunological responses and pathological an-
giogenesis. It is a large multidomain membraneprotein involved in a complex interaction net-
work with other membrane receptors, such as VEGFRs,plexins, c-MET, and their respective
ligands, VEGFs, PIGF-2, SEMA-3A, and HGF/ SF. As a co-receptor, lacking an intracellular
domain with an enzymeactivity or an obvious motif to dock to such an enzyme,its function
is either to allow signal transduction to occur or modulate its strength. Besides membrane
location, NRP-1 exists also as several truncated soluble isoforms, resulting from alternative
splicing, which additionally increase the complexity of possible interactions and mechanismsof
control. This study applied two different commercially available NRP-1 isoforms, and showed
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that, depending on the structure context, distinct NRP-1 isoforms can have altered heparin-
binding properties. The recombinant dimeric Fc fusion of rat NRP-1 bound to heparin with
high affinity (2.5 nM), which permitted thorough characterisation of the interaction, whereas
monomeric human NRP-1 displayed weak binding, detectable only by certain methodologies.
The investigation of the origin of the difference revealed the requirement of the Fc domain, but
not the c domain, to bestow the heparin-binding property. Basing on the findings and contem-
porary views onthe cell surface milieu, a hypothesis defining possible biochemical differences
between populations of NRP-1 molecules presentin the cell environment has been proposed.
Introduction
Neuropilin-1 (NRP-1) was first described in 1987 as antigen A5 [121] expressed by neural
cells of Xenopustadpoles.Its role in the neural system was subsequently confirmed in several
studies where it was defined as a neuronal recognition molecule responsible for, e.g., neural
path finding and cell differentiation [122, 123]. Additionally, it was shownto play an important
role in the vascular system, whereits overexpression resulted in excessive vascularisation in
vivo [124]. Consistently, depletion of NRP-1 impaired the developmentof both neural and vas-
cular systems and had lethal effect on developing embryos [125-127]. Its leading role in an-
giogenesisis considered of high significance, as this allows wound healing [128] and ischemic
revascularisation [129], however, at the same time mobilises tumour angiogenesis (reviewed
in [130]. A consecutive set of NRP-1 functions comprises immunological responses [131],
where NRP-1 was discovered to be a T lymphocyte marker [132], important in the antigen
recognition process [133], and adhesion, duetoits interaction with integrins [45,46]. The latter
interaction is proposed to negatively regulate other NRP-1 functions [47].
As a large multidomain protein with nointrinsic signalling properties, NRP-1 is suggested
to form functional complexes with other molecules in its environment and affect the overall
response[4]. The precise mechanism of NRP-1 functionis thus likely to be highly dependent
on the interaction networks of NRP-1. Briefly, NRP-1 is claimed to regulate several signalling
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pathwaysvia the interactions of its extracellular domain with soluble ligands and membrane
receptors. Thus, amongthe ligands presentin the extracellular environment that can interact
with NRP-1 are VEGF-Ajgs via its exon 7 and exon 8 encoded amino acid sequence [23,
24], VEGF-Aj2; (lacking exon 6 and 7)via its exon exon 8 [12, 19], VEGF-Bi.s7 and VEGF-
Bise [80], via exon 6B andproteolytically processed 6A, respectively, VEGF-C and VEGF-D,
although they require heparin to bind to NRP-1 [31], PIGF-2 via its exon 6 and 7 [32], SEMA-
3A via the SEMA and the c domain [33], FGF-2 and FGF-4 [36], HGF/ SF [36] via its N-
terminus [37], and TGF-f [38]. Importantly, some of the listed interactions remain arguable,
and especially for VEGF-Aj2;, an opinion that it does not bind NRP-1 is widespread [22, 24,
27,134, 135]. Interactions of NRP-1 with cell surface receptors can occur eitherdirectly, or via
ligand bridging, and comprise VEGFR-1 [26], VEGFR-2 [18], PDGFR-a/B [14], c-MET [44],
plexin-A1 [28,49], L1 [136] and the above mentioned integrins. Additionally to these molecules,
NRP-1 can also interact with itself [25,34], and, possibly, its own truncated variants produced,
e.g., by alternative splicing. However, the contribution of these hypothetical interactions to
the function of NRP-1 is not known. Another putative group of NRP-1-interacting partners
are adaptor proteins associating with the intracellular domain of NRP-1, as NRP-1 interacting
protein (NIP) [51], which is crucial for the cell signalling and response to NRP-1 [52]. It is
plausible that more proteins interacting with the intracellular part of NRP-1 will be discovered,
which will expand the range of NRP-1 functions and regulatory mechanismsit can undergo.
This also alters the perception of NRP-1 as acting purely extracellularly.
This study focused on anotherinteracting partner of NRP-1, which is implicated in regu-
lation of its function, heparan sulfate (HS). HS is a heterogenic polysaccharide comprised of
1,4 linked uronic acid (a-L-iduronate or B-D-glucuronate) and a-D-glucosamine with varying
patterns of 2-O-sulfate in the former and 3-O-, 6-O-sulfate and N-sulfate or N-acetyl in the
latter [137]. HS is a component of heparan sulfate proteoglycans (HSPGs) presentin the cel-
lular membranetogether with NRP-1 [138], howeverin research, it is often substituted with
heparin, its more fully sulfated experimental proxy, which is available in large quantities. Up
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to date, there are several putative functions of heparin or other polysaccharides characterised
for NRP-1. Firstly, NRP-1 has been shownto interact with heparin through the b1b2 domain, a
region directly adjacent to the VEGF-Ajg¢5 binding pocket[1,67]. Secondly, NRP-1 is proposed
to dimerise in a heparin dependent manneras a result of heparin and VEGF-Aj¢5 binding [67].
In fact the model of the angiogenic functional complex of NRP-1 comprises of VEGF-Ajgs:
NRP-1: heparin at a ratio 2: 2: 2, and the complex formedin this way would further interact
with VEGFR-2 [67]. In in vitro studies, addition of heparin results in enhancement of VEGF-
Aies (21, 22, 24, 26] and PIGF-2 [29, 32] binding to NRP-1 and is suggested to elevate the
numberof binding sites for VEGF-Ajg5 [21] in a NRP-1 dependent manner, without affecting
the affinity between NRP-1 and VEGF-Ajg¢5 [18, 22]. Moreover, binding of other growth factors,
such as VEGF-C and VEGF-D, to NRP-1 appears to be fully dependent on the presenceof
heparin [31]. An interesting aspect of heparin’s impact on the interaction of NRP-1 and of
VEGFR-1 wasalso described. Namely, as it was observed that heparin enhances VEGF-Aj65
binding to NRP-1 and VEGFR-2, at the sametime it appeared to prevent NRP-1 interaction
with VEGFR-1. Consistent with the fact that VEGFR-1 alone wasinhibiting the interaction of
NPR-1 and VEGF-Ajg5, a mechanism of functional competition was suggested, that favours
the formation of complexes of NRP-1 with VEGFR-1, or NRP-1 with VEGFR-2, VEGF-Ajg5 and
heparin [26]. Additionally, other glycosaminoglycanscan affect NRP-1 functions. Thus, highly
sulfated low molecular weight fucoidan (5 kDa), similarily to heparin, enhanced VEGF-Aj65
binding to NRP-1 [56], while a mimetic of a non sulfated GAG (glycosaminoglycan), phenylac-
etate carboxymethyl benzylamide dextran, inhibited this binding [57].
In order to shed some morelight on the interaction of NRP-1 with HS,two different commer-
cially available NRP-1 isoforms, recombinant dimeric Fc fusion of rat NRP-1 (Fc rNRP-1) and
recombinant monomeric human NRP-1 (ShNRP-1), were used to examine their interactions
with heparin and a series of modified heparins. Fc rNRP-1 bound to heparin with high affinity
(2.5 nM). Fe rNRP-1 interacted in a charge dependent manner, displaying structural selectivity
within a set of tested heparin derivatives. In contrast, monomeric shNRP-1 displayed weak
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binding, detectable only by certain methodologies. The lack of substantial saNRP-1 binding to
heparin was a subject of further analysis.
Results and Discussion
4.1 Structural characterisation of NRP-1 proteins
NRP-1 is a multidomain protein present either as a transmembranecellular receptor or as
a soluble truncated isoform. As often found in other large mammalian complex proteins,it
contains substantial unstructured regions of unidentified function. These stretches, according
to the analysis of disorder (Disembl 1.5, http://dis.embl.de/cgiDict.py), cover significant parts
of NRP-1 (Figure 4.1A) and in this respect resemble FGF-1 (Figure 4.1B), a well-known model
of a molten globule structure [1 39]. According to this analysis, NRP-1 possessesa significant
numberof loop/coil structures, which are the first indication of disorder, because only within
these elements can higher disorder be observed. Additionally, NRP-1 contains high level of
“remark 46” entries, which stand for the missing coordinates in X-ray structures, and also
high motility loops, named “hot loops”, based on Ca temperature factors. The latter two are
considered highly indicative of disorder [140]. Therefore, in silico analysis of the sequence
of NRP-1 complements the knowledge of the domain structure and generatesa picture of a
partially unstructured, dynamic and multifarious protein. Nevertheless, these features, albeit
potentially advantageous for protein function, at the same time are unfavourable for protein
expression, purification and its stability raising numerous technical problems [140].
The commercially available NRP-1s used in this study, Fc rNRP-1 and shNRP-1, are as-
sumed to bypass thesedifficulties due to somestructural amelioration. Thus, to obtain Fc
rNRP-1, small parts of the protein’s amino acid sequence, residues 811-828 and C-terminal
transmembrane/intracellular region, were excluded from the expression construct.
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Figure4.1:
A) The analysis of disorder of full sequence of human NRP-1. B) The analysis of disorderof full sequence of human
FGF-1. Several regions within FGF-1 and NRP-1 sequences exceededthe threshold values for three independent
disorder probability indicators: loop/coil structures (blue), hot loops (red), Remark-454 (green). The thresholds for
disorder prediction provided by the server are marked in respective colours in dashed pattern straight lines (0.43,
0.09, 0.5, respectively). The x axis spans the protein residues, while the y axis showsthe disorder probability.
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Whereasthe deleted 17 internal amino acids might have been a source of somestruc-
tural problems, as indicated by the high probability of encompassing a high motility loop (Fig-
ure 4.1A), the removal of the transmembrane’intracellular region permitted production of the
soluble protein without extra amino acids and membraneinteracting structures. Secondly, the
protein was expressed as a chimeric molecule, where the rat NRP-1 sequence wasfused to
the Xa factor cleavage site followed by the Fc part of human IgG1 sequence, wherethelatter
has the ability to form disulfide bridges between two independent Fes (Figure 4.2B). Con-
sequently, the final protein is a dimer. Such an approach, where proteins are expressed as
dimers, is often chosento raise the stability of the final product. Consequently, excluding the
small deletions, the assayed protein comprises most of the extracellular sequence of NRP-
1 (Figure 4.2A) and is a soluble dimer. Another investigated protein, shNRP-1, covers the
sequenceof a naturally occurring alternatively spliced soluble human isoform (Figure 4.2C).
Contrary to Fc rNRP-1, shNRP-1 is a monomer and its sequence has not beenaltered. Im-
portantly, as the protein consists of 1-644 amino acids, the putatively problematic C-terminal
region is absent. Both proteins were expressed with a C-terminalhistidine tag.
The analysis of protein purity and size by SDS-PAGEin reducing conditions demonstrated
that the Fc rNRP-1, originally estimated 238 kDa, as a dimer and expected 120 kDa as a
monomer, migrated around 150 kDa, while shNRP1, anticipated 71 kDa, migrated around
90 kDa. Both NRP-1s were pure and their migration on SDS-PAGE wasaffected by N-
glycosylation as shownby the treatment of the proteins with N-glycanase (Figure 4.2D). Ad-
ditionally, whereas the band of N-glycanated Fc rNRP-1 was sharp and compact, the band of
N-glycosylated shNRP-1 wasblurred and indicated possible multiple glycan modifications. Im-
portantly, it was verified that also the Fc part of Fc rNRP-1 was the subject of N-glycosylation,
thusit is assumed,that in the same expression system used to produceboth proteins, mouse
myeloma NSOcell line, Fe rNRP-1 is N-glycosylated on its NRP-1 moiety similarly to shaNRP-1,
and additionally on its Fe moiety.
 
Doctoral thesis Study of Neuropilin-1 interactions by Katarzyna Adela Uniewicz 44
Biochemicalanalysis of the interaction of Neuropilin-1 with heparin 
 
 
 
   
 
       
A ANRP-1
N| hNRP-1 1-923 KG
L*|}[eJoeJldilocI me
Fc rNRP-1 dimer
| [| | | | |
N | rNRP-1 1-810 | R| 829-854 IEGRDMD|higG1100-330 | HHHHH Cc
} at} | a2] [bt |] | v2] | ic | jlinker] | Xa | | Fe |
C shNRP-1
N{_ shNRP-1 1-644 [ HHHHHH] C
D Fe Fc rNRP-1 shNRP-1 E—— ee — LS LfS Ca SF. gs & . Ss
&we &ee &ee250kDa _ee 150 kDa a
25 kDa oe OTee|fmm | 100402 =20 kDa 75 kDa _|r
15 kDa 50kDa asi
Silver stain Native PAGE
Figure 4.2: Analysis of recombinant NRP-1 species.
A, B, C) Schematic representations of the respective isoforms of NRP-1. A) Native human NRP-1 (hNRP-1) with
indicated extracellular domains (a1, a2, b1, b2, and c), transmembrane (TM), and intracellular (IC) domains. B)
Recombinant dimeric rat NRP-1 (Fc rNRP-1) with indicated extracellular domains andthelinker sequencederived from
NRP-1 sequence,and additional Xa cleavagesite (Xa), Fc part of human IgG1 (Fc) and the His tag. C) Recombinant
soluble isoform of human NRP-1 (SshNRP-1) with indicated domains and the His tag. D) Silver staining result of N-
glycanase digest, performed as described in the Section 2.2.1, of the reference Fc region, Fc rNRP-1 and shNRP-1,
where control, mock digest and the digest results with indicated marker sizes are shown. E) Silver staining of the
native PAGE of Fc rNRP-1 and shNRP-1 with indicated marker sizes are shown.
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Furthermore, the migration of the proteins studied in native conditions revealed important
differences between them. While the Fc rNRP-1 migrated as a massive aggregate exceeding
the estimatedsize of the intact dimer, the shNRP-1 migrated roughly as the samesize as under
the denaturing conditions (Figure 4.2E). This observation confirmed previously observed Fc
rNRP-1 behaviourin gel filtration [86] and implied an important difference between the two
proteins, as, very possibly, the nature of Fc rNRP-1 is closer to a multi-componentoligomerof
Fe rNRP-1, contrary to the monomeric shNRP-1. Nevertheless,it was not possible to establish
if the oligomerisation occured via the Fc or the NRP-1 part of the dimer, though its previously
observed dependenceonthe concentration of electrolytes [36] suggests that both parts could
be involved, as ionic bonding was observed for both molecules [36, 141].
4.2 Determination of interaction of ShNRP-1 and Fc rNRP-1
with heparin
Oneof the recognised properties of NRP-1 is its interaction with heparin. Studies focused on
functional aspects of this interaction demonstrate that heparin can enhance NRP-1 binding to
VEGF-165 [26] and placenta growth factor 2 (PIGF-2) [29] or be a prerequisite of formation of
multicomponent complexes invoving NRP-1 [32]. The impact of heparin on the properties of
NRP-1 observed was so substantial that, indeed, some biochemical studies of NRP-1 apply
heparin as a fixed constituent in the experiments embodying its presence in overall NRP-
1 function [29]. Despite this, there is not much known regarding how NRP-1 interacts with
heparin.
In this study the two commercially available NRP-1s, shNRP-1 and Fe rNRP-1, were anal-
ysed in an optical biosensor, IAsys, for binding to a heparin derivatised surface. Both con-
structs, although they encompasstheregion identified to contain the heparin-binding site (the
b1 and b2 domains) [29], had markedly different binding ability. Whereas the Fc rNRP-1 bound
well to the surface, the shNRP-1, similarly to control Fc IgG1, showed only the small charac-
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teristic bulk shift associated with the refractive index change of the PBST with protein com-
pared to the PBST, representing no significant binding (Figure 4.3A). In order to examine this
surprising result more thoroughly, a different type of experiment was designed, where a well-
characterised BaF3 cell system was chosenfor a perturbation experiment. In this system the
murine pro-B cells, naturally deficient in cell surface glycosaminoglycans, require exogenous
FGF and heparin to signal through recombinant FGFR-1c receptorin order to survivein IL-3
deficient medium. Therefore, it was hypothesised that the addition of heparin binding, and
potentially sequestering, NRP-1, could affect cell survival. The experiment was designed to
compare four different concentration ratios of FGF-2 versus heparin, to distinguish between
NRP-1s’ effect via sequestration of heparin, or potentially of FGF-2 [36]. Again, both recom-
binant constructs were assayed and comparedwith the Fc IgG1 control. In a similar manner
to the biosensor experiments, only the Fc rNRP-1 appeared to reduce the survival rates of the
pro-B cells, as visualised in colorimetric MTT assay (Figure 4.3B, C, D). The effect of the Fc
rNRP-1 was detectedat its highest employed concentrations (10 and 30 nM), in the conditions
where heparin wasat the lowest, morelimiting, concentration (present at 0.1 yg/ ml, or 6 nM).
To conclude, the scope of recombinant NRP-1s interaction with heparin was tested either
on a heparin-modified surface or in solution. Although for the BaF3 perturbation assay the pos-
sibility that Fc rNRP-1 exerted the observedeffect via interaction with somecellular receptors
cannot befully excluded, due to the convergent result with the optical biosensor experiment,
it seems reasonable to propose that Fc rNRP-1, but not saNRP-1, sequestered heparin and
inhibited the activity of FGF-2. Thus, both approaches demonstrated that Fc rNRP-1, contrary
to shNRP-1, had moreevident heparin-binding property. This leads to conclusion that either
domain composition (the missing in shNRP-1 c domain)orartificial dimerisation (via Fc lgG1)
of the Fc rNRP-1 may berelevantfor protein’s interaction with the sugar.
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Figure 4.3: Characterisation of the interaction of Fc rNRP-1 and shNRP-1 with heparin in an optical
biosensor and a BaF3cell assay.
A) Fe, shNRP-1 and Fe rNRP-1 at final concentration of 0.5 yg/ ml were tested for binding to the heparin surface in
biosensor IAsys. The x axis presents the time scale andthe y axis the extent of binding expressedin [arcs s]. B, C, D)
BaF3 sequestration experiment, where the BaF3 cells were grownin constant concentrations of FGF-2 and heparin,
as described in the Section 2.4.1, with a range of concentrations of B) Fc rNRP-1, C) shaNRP-1 and D) Fe. The graphs
present the ODsgo readings of the MTT assay of the BaF3cells cultured in the tested conditions for 72h. Obtained
values indicate the metabolic activity treated as a proxy for the numberofliving cells. The experiment performed in
triplicate (mean+SD).
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4.3 Characterisation of the Fc rNRP-1 interaction with hep-
arin by optical biosensor
Since measurable binding to a heparin surface was observedonly for Fc rNRP-1, further char-
acterisation of this interaction was carried out with this isoform. The lAsys optical biosensor
allowed two main attributes of binding, kinetics and specificity, to be established. The aim
of the kinetics analysis is to calculate the rate of the association and dissociation reactions,
defined by the association and dissociation rate constants, Kass and kKgiss and the affinity of
the interaction, expressed as the equilibrium dissociation constant (Kg), defined by the ratio of
association and dissociation rate constants (kgiss/ Kags) and denoted in nM. The analysis of ki-
netics of Fc rNRP-1 binding to a heparin surface was performedafterinitial determination of the
concentration range of the Fc rNRP-1 that only yielded monophasic binding kinetics. Heparin
is a polymeric ligand possessing a range of binding sites and immobilisation of the heparin to
the surface through streptavidin may result in steric hindrance of someof these sites. Thus at
higher concentrations of ligate, secondary binding sites can appearin the analysis [142, 143].
As aconsequence,the final concentration range of Fc rNRP-1 spanned 0.25-1.22 nM,as only
within this window, the binding was uniformly presenting a one-site binding model, and at the
sametime was within the detection capacity of the instrument. This meansthat as withall
such analyses,it is the interaction of Fc rNRP-1 with a class of highestaffinity sites within
heparin that is being measured, not the averageof all the potential binding sites in heparin.
Figure 4.4A-H presents analysis of the one outof five independentkinetic experiments. First of
all, increasing concentration of Fc rNRP-1 showedincreasing extents of binding (Figure 4.4A).
Each concentration exhibited a one-site binding model, as confirmed by comparison of the
binding curves versus the mathematical modelof a single site interaction; the data are dis-
tributed randomly around the model(Figure 4.4B-F).
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Figure 4.4: Kinetic analysis of Fc rNRP-1 binding to heparin surface in biosensor lAsys.
Data shownare a representative of a set of five independent experiments described in the Section 2.3.2. A) Extent of
binding of indicated molar amounts of Fc rNRP-1 expressedin [arc s] (y axis). B-F) The distribution of the data points
(jagged line) around a onesite binding model(horizontal line at 0 arc s) is shown for each of the concentrations of Fc
rNRP-1 usedin the binding assay in panel A. B) 0.25 nM. C) 0.33 nM. D) 0.55 nM. E) 0.94 nM.F) 1.22 nM. G) Linear
relationship between the slope ofinitial rate of association and concentration of Fc rNRP-1. H) Linear relationship
between kon, determined from a one-site model, and concentration of Fc rNRP-1.
 
Kass SE pofline Intercept SE  kgiss SE Kg SE
(Ms)! s! nM
9820000 580000 0.95 0.01 0.00 0.02 0.00 2.46 0.00
Table 4.1: Kinetic result of Fc rNRP-1 binding to heparin surface in biosensor lAsys.
The table presents kinetic values characterising the Fc rNRP-1 binding to heparin, where Kass is association rate con-
stant, p value is the correlation coefficient of the linear regression through the kon values, intercept is an approximate
kgisg Value obtained from Kon plot , kgiss is dissociation rate constant obtained in the dissociation experiments, and Kg
is the affinity calculated from the ratio of kgiss/ Kass. The standard errors (SE) were calculated from five independent
association datasets and six independentdissociation datasets.
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The initial rate of binding, defined by the binding of the soluble ligate within thefirst 15s of
the addition of ligate was shownto increasein a linear mannerwith increasing concentration of
Fe rNRP-1 (Figure 4.4G). This illustrated that the binding of Fc rNRP-1 to heparin wasnotlim-
ited by masstransport or by steric hindrance [144]. The calculated on-rate (ko,) was observed
to increaselinearly with the concentration of Fc rNRP-1, which again supports the use of a one
site modelto analyse the data (Figure 4.4H). The linear regression analysis of the ko, valuesal-
lowedthe calculation of kass, defined by the slope ofthe linear interpolation within the collected
dataset. Howeverkgiss, which can be also derived from the graph as a y-axis intercept value,
was nottaken into account, as it is more reliable to measureit directly. Thus, a separate set
of dissociation experiments was performed, where dissociation of Fc rNRP-1 was enhanced
by the addition of competing heparin in solution, to prevent the re-binding of Fc rNRP-1 to the
heparin surface. Values for kgs, were established from 6 independent experiments. The mean
Kass (Supported by high p value indicating variance in the measurementof the gradient of the
plot of Kon against concentration) and kgiss; values allowed the calculation of Kg (formally, the
ratio kKgiss/ Kass), Which was 2.5 nM (Table 4.1). This result was consistent with the only hitherto
published affnity value for NRP-1 binding to heparin, estimated 0.69 nM, which wasobtained
with the same commercial isoform applying surface plasmon resonance [58]. Thus, clearly, Fc
rNRP-1 can be classified among the high affinity interacting partners of heparin, though again
it must be stressed that this is a measurementfor the highestaffinity binding sites in the sugar
and there will be many loweraffinity sites.
After characterisation of the kinetics of the interaction of Fc rNRP-1 with heparin, the next
question was focused onthe structural requirements of heparin that favour this interaction.
Three different parameters were examined, namely, length of the heparin oligosaccharide,
sulfation pattern of the heparin derivative and the cationic form of heparin. While the first one
describes the architectural attribute of the best fitted structure within the binding site of the
Fc rNRP-1, the latter two may provide additional functional information, as different sulfation
patterns and cationic forms of heparin have distinct solution conformations and so functional
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properties [145].
The identification of the binding preferences was established in competition tests, where
Fc rNRP-1 was compelled to select between binding to the heparin immobilised on the sensor
surface and a heparin-derived compound present in solution. In this way, the capacity of
the assayed compounds to compete for Fc rNRP-1 binding to the heparin surface can be
comparedwith the same capacity of heparin addedto solution.
The analysis of the minimal length of oligosaccharide that can be accommodated by Fc
rNRP-1 applied compounds defined by their degree of polymerisation (dp), where dp 2 was
the minimal repeating disaccharide unit of heparin (Figure 4.5A). The range usedin this study
covered dp 2 - dp 26. Oligosaccharides of dp 2 - dp 8 had very weak competing potency,
however, starting from dp 16, a substantial inhibition of binding of the protein to the surface
was observed. However, it is noteworthy that the largest oligosaccharide tested, dp 26, was
still significantly less effective than heparin (Figure 4.7), which correspondedto the difference
in size between dp 26 and heparin (Figure 4.5B). This showed a direct reliance of the tested
oligosaccharide size andits inhibiting property, but also suggested a complex spatial nature
of the interaction between Fc rNRP-1 and heparin, asfull inhibition could only be observed
with native heparin (Figure 4.7). This preference for heparin, which is polydispersein length,
may reflect the recombinant dimeric structure of Fc rNRP-1 in which both NRP-1 moieties are
likely to be involved in heparin binding, or the requirementfor a structure for the highestaffinity
binding that is most commonin the longest chains of heparin.
Next, the potency of variously sulfated heparin derivatives was tested. The compounds
were chemically produced from native heparin and boredifferent substitution patternsof distri-
bution of sulfate groups (Figure 4.6), which allowed an evaluation of the importanceof specific
sulfate groups for Fc rNRP-1 binding.
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Figure 4.5: Additional information on oligosaccharides used in the competition assays.
A) Schemeofapplied classification of oligosaccharide species, where grey large circle is uronic acid, small black circle
is 2-O-sulfate, black rectangle is 2-N-sulfated glucosamine, and small greycircle is 6-O-sulfate. B) PAGE analysis of
1 yg of the largest dps used in the competition assay (dp 24, dp 26) and heparin was performed as described in the
Section 2.5.1.
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Figure 4.6: Schematic presentation of the modified heparin derivatives used in the competition assays.
Label, chemical structure and schematic stick-and-ball image of each derivative is presented, where 6-N-sulfate is
marked yellow, 2-O-sulfate is red, 6-O-sulfate is blue, and two additional 3-O-sulfates of persulfated heparin are
markedorange.
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Figure 4.7: Competition experiments defining length of heparin-derived oligosaccharide requirementthat
enable Fc rNRP-1 binding.
Inhibiting ability of oligosaccharides of selected lengths on Fc rNRP-1 binding to the heparin derivatised surface was
tested as described in the Section 2.3.2. A) The relative binding values at presence of each concentration of added
inhibiting ligand (x axis) were adjusted to 100 % of Fc rNRP-1 binding alone to heparin (measuredat least between
10-40 arc s). The experiment was performed three times independently (mean+SD). B) ICs values were calculated
basing on the non-linear curvefit of single representatives of respective binding curves and are expressedin [ug/ml]
(+SE)for the inhibiting compoundstested in panel A.
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The varied sulfation patterns are consideredlikely to contribute to the specificity of interac-
tion with proteins, either via alteration in conformation/ flexibility of the sugar chain, or merely
the saccharide sequence [145-147], the Fc rNRP-1 did not show anyselective binding prefer-
encefor one sulfate group over anotherin the three monosulfated heparins (Figure 4.8). Hep-
arins desulfated at either N (in this instance re-acetylated), C6 or C2 all showed a substantial
drop in ICso (40- to 77-fold) compared to that of the parental heparin. This suggested that Fc
rNRP-1 requires a combination of all three sulfate groups for effective binding. Nonetheless,
in contrast to these results, Fc rNRP-1 boundalso to a heparin lacking any of these groups,
and for this species the ICsp value was lower than for any of the singly desulfated heparins.
Similarly to the latter compound, heparin desulfated at both N and C2 appeared to be an ef-
fective inhibitor of the Fc rNRP-1 heparin surface binding andits ICs was the closest to the
one of heparin among the desulfated heparin derivatives. Interestingly, the other two doubly
desulfated heparins were very weak competitors (Figure 4.8).
These data indicate that the binding motif of Fc rNRP-1 in heparin is more complex than
one described by a simply linear sequence of sulfated sugar residues. This is in agreement
with the general knowledgethatinteractions of proteins with polysaccharides are driven by var-
ious mechanismsincluding ionic forces, nonionic forces, hydrophobic interactions, hydrogen
bonding and van der Waals packing [148]. In support of this contention, persulfated heparin
was the strongest competitor, but completely desulfated heparin was a stronger competitor
than the singly desulfated polysaccharides. Thus, it would seem that although ionic interac-
tions are important, there are other interactions, which allow a sugar structure to bind to Fc
rNRP-1 quite effectively. Moreover, persulfation places sulfate groups at the C3 position of
glucosamine and it may bethat this is an important requirement for Fc rNRP-1 binding. This
is intriguing, since heparin-like structures are rare in most cellular HS, whereas lower sulfated
structures are relatively common [149].
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Figure 4.8: Competition experiments defining heparin sulfation pattern requirements that enable Fc
rNRP-1 binding.
Inhibiting ability of modified heparin derivatives on Fc rNRP-1 binding to the heparin derivatised surface was tested as
described in the Section 2.3.2. A) The relative binding values at presence of each concentration of addedinhibiting
ligand (x axis) were adjusted to 100 % of Fc rNRP-1 binding alone to heparin (measuredat least between 10-40 arc
s). The experiment was performedthree times independently (mean+SD). B) ICs5o values were calculated basing on
the non-linear curvefit of single representatives of respective binding curves and are expressedin [g/ml] (+SE) for
the inhibiting compoundstested in panel A.
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Thelast investigation of binding preferences of Fc rNRP-1 aimedto resolveif the protein
distinguishes between different cationic forms of native heparin. For this purpose, the test
assayed heparin was saturated with Nat, K*, Ca®+ and Cu?*+ to form species found in vivo
[150]. From the two main models of ion binding the tested heparins, Na*, K* and Ca** forms,
appear to have delocalised counterion mechanism of ion binding, and only for Cu?* form,
it was possible to show site-specific mechanism of interaction [151], however, it cannot be
excludedfor otherion derivatives. All these complexes havedistinct structural properties [145],
and were shownto specifically regulate properties of interacting proteins [152, 153]. For Fc
rNRP-1 all tested compoundshad similar inhibiting property, therefore, they are unlikely to be
distinguished by Fc rNRP-1 (Figure 4.9).
The optical biosensor study of Fc rNRP-1’s interaction with heparin produceda picture of a
protein that has high affinity to heparin and, thoughit is prone to bind to the sulfated sections
of HS, it clearly can also bind to the non-sulfated regions. /n vivo regions of low sulfation
may, therefore play an important role in regulating the function of NRP-1. The issue of how
NRP-1 could bind to such distinct structures remains to be established, and requires thorough
structural characterisation. The minimal size of oligosaccharide required for Fc rNRP-1 binding
to heparin is clearly not yet defined, however, being a complex molecule,it is plausible that the
interaction with heparin involves more than onebinding site, and possibly, is also affected by
the presence of the |gG1 Fc parts. No detectable difference between anyof the cationic forms
of heparin implies no biophysical importance of their binding to NRP-1. However,in the latter
case and similarly in the variously sulfated species, since these polysaccharides are knownto
possessverydistinct structures,it is possible, that the mechanism of their binding to NRP-1
is distinct and the consequent secondary effects on NRP-1 conformation may be important
for the further complex formation and signalling outcome. Additionally, the complex formation
between NRP-1 anddistinct heparin-derived structures may be a selective factor for assembly
of other signalling complex components only on the basis of the sugar moiety preference.
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Figure 4.9: Competition experiments defining heparin cationic forms requirements that enable Fc rNRP-
1 binding.
Inhibiting ability of cationic forms of heparin on Fc rNRP-1 binding to the heparin derivatised surface was tested as
described in the Section 2.3.2. A) The relative binding values at presence of each concentration of added inhibiting
ligand (x axis) were adjusted to 100 %of Fc rNRP-1 binding alone to heparin (measured at least between 10-40 arc
s). The experiment was performed three times independently (mean+SD). B) ICso values were calculated basing on
the non-linear curvefit of single representatives of respective binding curves and are expressedin [g/ml] (+SE) for
the inhibiting compoundstested in panelA.
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4.4 Identification of the protected/ buried regions of Fc rNRP-
1 upon interaction with heparin
After the analysis of the structural features of heparin-derived polysaccharides required for
strongest NRP-1 binding, the analysis of the regions of Fc rNRP-1 that mediate this interaction
was undertaken. The Protect and Label (P&L) strategy [95] was designedto identify regions of
a protein that contain lysines that remain protected by heparin against chemical modification.
To distinguish lysines that are involved in heparin binding from those that are not, a two-step
procedure was developed. Firstly, as a protein is bound to heparin, the exposed lysines are
acetylated (the Protection step), secondly, after elution of the protein from the heparin resin any
remaining lysines that were protected by heparin are biotinylated. Subsequently, the protein
is digested by chymotrypsin and biotinylated peptides are purified and then identified using
MALDI-Q-TOF. This strategy has been applied successfully to identify heparin-binding sites in
small proteins, such as FGF-2,platelet factor 4 (PF-4) and pleiotrophin (PTN) [95]. Here it was
usedfor thefirst time to study a multidomain protein, Fc rNRP-1.
The initial verification of the suitability of the method to study recombinant NRP-1 revealed
that acetylation of Fc rNRP-1 boundto heparin resulted in its release when the experiment was
conducted in PBS (data not shown). This suggested a dynamic interaction between NRP-1 and
heparin, whereby the protein might “rock” on its polysaccharide-binding site. In the presence
of NHS acetate, the acetylating agent, as lysines involved in heparin binding dissociatiated
they would become acetylated and consequently not be able to re-bind. The result would be
that the protein’s interaction with heparin is lost. To overcome such dynamics, less stringent
conditions of binding were used, in which there was no NaClin the acetylation step. Under
such conditions a substantial amount of the Fc rNRP-1 wasretained on heparin during the
acetylation step, which allowed the subsequent generation of peptides for further analysis
(Figure 4.10).
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Figure 4.10: Analysis of protein in the course of the P&L procedure.
Top and bottom panels present samples for Fc rNRP-1 and shNRP-1, respectively. Lane (LD) corresponds to the
sample applied to the heparin column, lane (FT) is the flow through or unbound material after applying the sample
three times to the column, lanes (B1 and B2) are the two acetylation steps, lane (W1) is the post acetylation wash
of the column, elution (E1) is the material eluted from the column with 2M NaCl, lane (E2) is the same material after
biotinylation (E2), and (E3) is the biotinylated material after concentration and buffer exchange. Five %(v/v) of the
total material, when 4 vg of the proteins was used, was analysed on SDS-PAGE andsilver stained.
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Importantly, the same conditions when applied to shNRP-1 did not preventit from eluting
from heparin, indicating that the interactions of Fc rNRP-1 arelikely to be duetoits specific
high affinity binding site, despite the reduced ionic strength of the buffer used in the acetylation
step (Figure 4.10).
The experiment was performed with 25 yg of Fc rNRP-1 and the analysis returned 16
peptides that were assignedto the particular sequences (Table 4.2). Five peptides were not
matchedto any region of the recombinant NRP-1, which might be due to modifications occur-
ing during the experiment, which were not accountedfor. All identified peptides encompassed
onebiotinylated lysine residue, and corresponded to the NRP-1 moiety of the fusion protein
or, the IgG1 Fc moiety (Table 4.2). The peptides identified within NRP-1 moiety were mapped
to the a1, b1, c domainsandto thelinker following the c domain (L2) (Table 4.2). Within the a1
domain two sequenceswereidentified basing on three independent ions, whereas within the
b1 domain onelargely overlapping sequence wasidentified basing on two independentions.
Within the c domain three sequences wereidentified basing on one ion each, while the frag-
ment within the L2 region wasidentified by two independentions (Table 4.2). In the IgG1 Fe
part of the recombinant protein four sequences wereidentified, where two of them based on
two independent ions, two remaining on oneion each. The list of peaks with assigned values
is enclosed as Supplemental data 3.
The interpretation of the obtained result only partially confirmed the previously identified
heparin-binding region of NRP-1, which wasascribed to the b1 and b2 domains (Figure 4.11,
Figure 4.12) and wasfunctionally confirmed to be sufficient to bind to heparin [29]. Moreover,
the identification of regions within the IgG1 Fc part of the recombinant protein wasparticularly
surprising as in optical biosensor experiments the IgG1 Fe did not interact with heparin or
heparin-derived oligosaccharides (Figure 4.3A, Figure 4.18A). Nevertheless, there are several
reasons to suggest the presented results are of significance.
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First of all, the main structural study deciphering the residues involved in heparin interac-
tion was based only on the b1b2 domain construct [67], it could not predict other areas of
interaction. At the same time the loweraffinity binding sites could have been neglected, while
the importance of the given regions overestimated. Overall, the simplified model of the NRP-1
interaction with heparin describes specifically the heparin interaction with the b1b2 domains,
but not the whole protein losing the context of the additional domains present in NRP-1. Addi-
tionally, in this study, the analysed proteinis a radically different construct, not only comprising
of the rat sequence,but also presentin a form of a dimer of unknown overall conformation and
very specific properties. Indeed, it is very probable that these specific properties might result
from the proximity of the two NRP-1 moieties and novel emerging interactions.
In orderto visualise the identified peptides on a 3-D structural model a search for the most
complete available structure was made. Unfortunately, the best available structures of NRP
protein cover only a1a2b1b2 domains of NRP-2 [1]. This part of the protein is followed by long
fragments of unstructured elements, namely L1 and L2linkers, and to date no data are avail-
able on their possible conformation, as such regions are problematic for obtaining structural
data. Similarly, due to the substantial size of these elements no in silico approach is capable
of making a prediction of their conformation. Therefore, in order to visualise the identified pep-
tides, the most complete structure of the NRP protein was selected, 2QQL[1], covering the
ala2b1b2 domains of the human NRP-2, howeverlacking the subsequent c domain. Given
the limited resemblance of the human NRP-2 and rat NRP-1 (53 %identity and 72 %similarity
within the overlapping region), in order to identify the residues correspondingin the structure,
an alignment of the human NRP-2 and rat NRP-1 was made,and appropriate residues were
highlighted within the structure (Figure 4.11). Importantly, the visualised residues should be
considered of approximate localisation as the sequences within 2QQLthat were aligned to the
identified peptide sequences from rat NRP-1 do not presentsignificant similarity, and none of
the biotinylated lysines of rat NRP-1 has an analogouslysine in human NRP-2.
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Figure 4.11: Clustal W alignment of the NRP sequences.
?
FNPHFDLEDR
FNPHFDLEDR
FNPHFEIEKH
a
NYTTPSGVIK
NYTAPTGVIK
NFTSPNGTIE
240
|
QKTPGRIRSS
QKTPGRIRSS
TKTPSELRSS
=P
NY PENGWT PG
NY PENGWTPG
HGDDNGWTPN
“
DVVVAVFPKP
DVVFGVFPKP
EVVLNKLHAP
an
SGWALPPAPH
TGWALPPSPH
SGWF PRI PQA
ad
NNNYDTPELR
NNNYDTPELR
NMHYDTPDIR
80
80
56
159
159
136
239
239216
318
318
296
398
398
376
478
478
456
552
552
536
Clustal W alignmentof the human NRP-2-derived sequencepresentin the QQLstructurefile and analogous rat NRP-
1 and human NRP-1 sequences. The residues are coloured according to their level of conservation, where the rank
of conservation is marked red<black<blue. The three identified peptides covered by the structure are indicated in red
squares. The green squares mark the positive residues previously identified to bind to heparin [67] together with their
respective residues in NRP-2.
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Contrastingly, it is noteworthy that the same lysines identified by the protect and label
methodare fully conserved in the rat and human NRP-1 sequences(Figure 4.11).
Only five of the peptides identified in the Protect and Label experiment could be mapped
on the available structure, and are indicated by 3 regions highlighted in blue. Three of them
mappedto the a1 domain, while other two were foundto bein close proximity of the heparin-
binding site in the b2 domain identified in other experiments, which is shown in magenta [67]
(Figure 4.12). Interestingly, as NRPs are supposed to form dimers,it is noteworthy that the
saddle-shapedinterface between the two molecules is of approximately 60-70 A width, which
could allow for flexible interactions with a chain of HS.It is especially important, if compared
with the size of heparin, which is estimated around 52 in length for dp 12, and thus, shows,
that substantial fragments of the polysaccharide can be accommodatedin the crevice. As
the larger fragment of HS might bear more varied modifications, this can impact the overall
structure andflexibility of the molecule [154], and consequently, complex formation with NRP-
1.
The structures presented here are of the dimer of NRP-2 observed upon crystallisation. In
this model the magenta heparin-binding residues form a channel between molecules where
heparin could be bound. Indeed,two of the peptides locate close to this area, and this would
support a broadersize of the binding site. Interestingly, the identification of the peptides deriv-
ing from the a1 domain coincides with the observation that exactly this part of the NRP-1 might
be involved in mediating dimerisation [1]. Nevertheless, detection of the a1-driven interaction
of the independent NRP-1 molecules was not confirmed by several other methods, except
crystallography, and thus remains a hypothesis requiring further investigation [1]. Additionally,
the identified a1-domain peptides are not located in the exact interface region between the
molecules. Still, it is possible that the a1 domains of NRP-1 mediate dimerisation in a different
mannerthan the presented a1 domains of NRP-2.
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Unfortunately, the remaining five peptides were not covered by the 2QQLstructure, since
they werelocalised in the c domain and L2linker following the c domain. In an attempt to visu-
alise at least some of those, a homology modelling approach wasapplied to obtain a structure
of the c domain alone. The structure was modelled according to the commonly accepted steps
described in the Section 2.6.2, such asidentification of the best structural templates, alignment
optimisation, building of an initial model, optimisation of the initial model and validation of the
model according to its biophysical properties. After selection of the best model, it served to
visualise the three peptides identified in P&L experiment within the c domain (Figure 4.13).
Although, it is difficult to interpret this picture in the context of the remaining majority of the
NRP-1 structure,still, it is apparent that the identified peptides are located on oneinterface
of the protein and show a consistent pattern of location with clearly electropositive charge,
which could be a sign of an interaction site with a negatively charged polysaccharide. This
supports the hypothesis,that the identification of the peptides outside of the b1b2 region leads
either to the possibility of other secondary heparin-binding sites or long-range intramolecular
conformational changes occurring upon heparin binding.
An additional visualisation of the result of the P&L experiment was presented on an ex-
tended model of the NRP-1 obtained in homolgy modelling. Although, contrary to the QQL
structure, it shows the human sequence of NRP-1, not NRP-2, and additionally, it covers the
L1 linker and the c domain, it is important to note, that the unstructured L1 linker region and
substantial loop region of the c domain are not possible to model, and their assignmentin the
modelis randomised by the software. Consequently,it is not known how the c domainin reality
aligns against the remaining domains. Nonetheless, this presentation provides an insightinto
the general distribution of the identified peptides within the structure (Figure 4.14).
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Figure 4.13: Localisation of the identified rat NRP-1 peptides in the human c domain obtainedbyin silico
modelling.
Illustration of the c domain in light grey, where two different perspectives of the c domain are shown. Thethree
identified in P&L strategy peptides are shownin cyan. Onthe right, analogousvisualisation of the c domain coloured
accordingto its potential is presented (blue is electropositive, red is electronegative potential).
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Figure 4.14: Approximate localisation of the identified rat NRP-1 peptides in the human NRP-1 obtained
by in silico modelling.
Illustration of the NRP-1 in light grey, where four different perspectives of the NRP-1 monomer were shown. The
identified peptides within a1, a2, b1, b2 and c domains are shownin cyan. Theliterature-derived residues responsible
for heparin interaction are labelled in magenta. The c domainis indicated by an arrow.
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Surprisingly, six identified peptides were mapped to the IgG1 Fc part of the recombinant
fusion construct. Fc was confirmed to not bind to heparin on its own in PBS (Figure 4.3A,
Figure 4.18A). Therefore, this result may either be the consequenceof Fc binding heparin at
low ionic strength or raises the possibility that this may occur because of its presence as a
fusion partner of NRP-1. If the latter explanation was correct, the identification of the protected
areas would imply possible intramolecular/ intermolecular interactions occurring upon heparin
binding to the NRP-1 moiety, which mayplay part in stabilising of the Fc rNRP-1-heparin
interaction particularly in the absenceof electrolytes.
To summarise, the regions within the recombinant NRP-1 that were protected against
chemical modification in the presence of heparin were mapped to the a1, b1, c domains and
L2 linker of the protein, and following IgG1 Fe part. The approach allowed confirmation of
the region adjacent to the heparin-binding site currently identified in the protein, however,it
did not detect the bindingsite itself, although it does contain several lysines. It also indicated
the importance of the a1 and the c domains. This result might imply other previously not de-
scribed secondary heparin-binding regions, the appearance of the novel binding sites within
the dimeric form of the NRP-1 or a major rearrangementwithin the molecule after heparin
binding resulting in the protecion of lysine residues. Thefirst hypothesis, proposing multiple
heparin-binding site is supported by several examples of other molecules, such as endostatin,
FGF-2, RANTES [155-157], and, considering the size of NRP-1, might be a probable inter-
pretation of the result. Nevertheless, a set of mutagenesis experiments reinforced by more
structural data could verify such an interpretation. Also the second mechanism, suggesting
the crucial role of protein-protein interactions in the final definition of the heparin-binding site
has been observed [158]. Namely, the complex formation between FGF and FGFRaffected
the mechanism ofinteraction with HS as compared with FGF and FGFRinteracting with HS
individually, and although,in this case it mainly caused a shift of hydrogen bonds,it still opens
up a discussion on the impact of the dimeric fusion, proximity of the two NRP-1 moieties, and
possible intramolecularinteractions on final heparin interacting site.
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Finally, it is possible that the lack of NaCl in the acetylation step, when exposedlysines
were supposedto be labelled, was notfully efficient, and some protein parts in such conditions
could be moreproneto interact or have similar to aggregation behaviour. This could lead to
fake positive results in identification of the heparin-binding regions and cannotbe excluded.
4.5 Further verification of SaNRP-1 binding to heparin
Although both tested NRP-1 proteins possess key structural regions that have been associ-
ated previously with heparin binding, the characterisation of this interaction was achievable
exclusively for Fc rNRP-1, as shNRP-1 not only did not bind to the heparin surface, but also
did not sequester heparin in the BaF3 experiment (Figure 4.3). Additional experiments were
performed to explore in more depth the issue of ShNRP-1 binding to heparin. First ofall, affinity
chromatography wasapplied on an analytical scale. The experiment employed twodifferent
heparin affinity resins, which were packedinto minicolumns, and usedfor binding tests of the
two recombinant NRP-1 proteins. The comparisonofthe fraction boundaftertriple application
on the minicolumn revealed that both proteins boundto the two resins (Figure 4.15). In order
to exclude the possibility that the observed binding was dueto nonspecific interaction with the
matrix alone, an attempt to develop a resin with reduced heparin content was undertaken. To
do so, an overnight digest of both resins in appropriate buffer conditions with a mix of hepari-
nases was done, and afterwards, the resins were usedin a binding test as previously. The
analysis showednoticeable reduction of snaNRP-1 and Fc rNRP-1 binding to the resin, which
was especially observed for the Toyopearl resin, as compared with the untreated resins (Fig-
ure 4.15A). However, as the scope for success of the digest was not technically feasible to
establish, the result of the binding test should be considered with a degree of caution. Never-
theless, this opens upthe possibility that snNRP-1 doesindeedinteract with heparin, however,
in orderto do so,it may require specific favouring conditions, as appropriate molecule density,
which can be achieved within the void volumeof the minicolumn andcouldfacilitate behaviour
similar to the dimer, resulting in SaNRP-1 mimicking Fc rNRP-1.
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Figure 4.15: Comparison of Fc rNRP-1 and shNRP-1 binding to two different heparin affinity resins be-
fore and after heparinasesdigestof the resins.
A) Binding of both recombinant NRP-1 proteins to Toyopearl heparin resin. B) Binding of both recombinant NRP-1
proteins to Affigel heparin. The experiment was performed as described in the Section 2.2.4. Load and flowthrough
(FT) samples are indicated together with the presence or absence of heparinasesdigest of the resin and the marker
sizes.
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Such an explanation, although alluring, falls outside the boundaries of the experimental
expertise and remainssolely a concept.
Nevertheless, as shNRP-1 was confirmed to bind to the heparin resin, the attemptto fur-
ther characterise this interaction was undertaken by P&L strategy (Figure 4.10 bottom panel).
Unfortunately, shNRP-1 after the acetylation step appeared to have lost its heparin-binding
property, and consequently was eluted from the column at the washing step, thus, returning
no peptidesin elution for further analysis. This supported the argumentof the weakerinterac-
tion of the shNRP-1 with heparin, whereby continuous roundsof association and dissociation
during the protection step would result in the acetylation of all lysines, including those in the
heparin-binding site. This idea is consistent with the published data on possible effects of
chemical modification of lysines in some proteins, to name structural rearrangement [159],
loss of stability [160] or loss of binding properties [161], as observedin this study. Therefore,
moreprecise characterisation of SaNRP-1 binding to heparin was not accomplished.
Having shownthatin certain circumstances shNRP-1, contrary to the initial observations,
appearsto interact with heparin, one more experiment, this time exploiting the thermostabilis-
ing property of the protein as a consequenceofits interaction with ligand was designed. The
method had the advantage of testing protein and ligand in solution, whereas the previously
described experimental systems, excluding the BaF3 assay, employed immobilised heparin
(Figure 4.3A, Figure 4.18A). To establish comparable conditions for the analysis of recombi-
nant NRP-1s, it was assumed that each NRP-1 moiety had the potential to bind to heparin,
therefore, whereas shNRP-1 was assayed with heparin at 1: 1 and 1: 10 concentrationratios,
Fc rNRP-1 was assayed at 1: 2 and 1: 20.
As in the affinity chromatography experiment, both isoforms displayed higher Tm values
whenanalysedin the presenceof heparin, which supported the capability of saNRP-1 to bind
to heparin (Figure 4.16A,B). In orderto clarify that the heparin effect was not an nonspecific
effect, the Fc part alone was confirmedto notinteract with heparin, and tested in the presence
and absenceof heparin (Figure 4.16C,D).
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Figure 4.16: Sypro stability assay of recombinant NRP-1s in the presence and absence of heparin.
A) Fc rNRP-1, B) shNRP-1 and C) Fe region were subjected to denaturation cycle alone or with indicated amount of
heparin in the presence of Sypro® Orange dye. The melting curves were recorded by RT-PCR machine and analysed
as described in the Section 2.2.6. Thefirst derivatives of the melting curves were plotted. D) Presentation of the
melting temperature (Tm) values equal to the maximaof the derivatives from the panels A, B, C.
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4.6 Investigation of relationship between monomeric/ dimeric
state of NRP-1 and heparin-binding ability
Althoughin the latter experiments shNRP-1 was demonstratedto bind to heparin, the contrast-
ingly different properties of the two NRP-1 proteins in the surface binding study (Figure 4.3)
raised the questions whetherthe dimeric form of Fc rNRP-1 could give a rise to a monomeric
NRP-1, and what would bethe properties of such a protein. According to the disorder analysis
of the NRP-1 sequence (Figure 4.1), there were several dynamic parts of the protein that could
be accessible for a proteolytic digest, therefore, a trypsin digest of the native Fc rNRP-1 was
performedto determineif truncated isoformswith a structure close to that of sSaNRP-1 could be
produced. Manipulation of the conditions of the digest, such as NaCl concentration, tempera-
ture, time (referred to as digest A in the Section 2.2.7), permitted the production of a derivative
of Fc rNRP-1 of exactly same migration pattern as shNRP1 on SDS-PAGE (Figure 4.17A),
thus of comparative size. The newly produced isoform, from now referred to as trNRP-1, was
recognised by N-terminus targeted antibody (Figure 4.17B), but not by anti-His antibodiestar-
geted to the C-terminal His-tag (Figure 4.17A). This indicated that the cleavage occurredin the
C-terminal part of the protein (Figure 4.22). Interestingly, in contrast to Fc rNRP-1, shNRP-1
resisted trypsin digest in the native conditions, as concluded from the retained size and the
presence of the C-terminal His-tag (Figure 4.17C). Hence,it is reasonable to suggestthat the
trNRP-1 was indeed analogous to shNRP-1.
A polysaccharide surface-binding test of ttNRP-1 was performed using a dualpolarisation
interferometer and a dp 16 surface (Figure 4.18A, E). Contrary to the previously applied optical
biosensor, this method allows calculation of the mass, thickness and density of the bound
protein layer, which provides far greater insight into the formed complexes. Alongside the
analysis of ttNRP-1, Fc rNRP-1, shNRP-1 and Fc weretested as characterised reference
samples. The control proteins reproduced the formerly observed binding pattern. The Fc
rNRP-1 showedsubstantial binding to dp 16.
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Figure 4.17: Tryptic digests of recombinant NRP-1s.
A) Tryptic digest of Fc rNRP-1 was performed either with native or denatured protein. Left panel presents result of
silver staining, right panel presents western blot against the C-terminal His-tag of the protein. B) Western blot result
obtained with anti-N-terminal rat NRP-1 sequence of reference Fc rNRP-1 and the native digest sample. C) Tryptic
digest of shNRP-1 wasperformedeither with native or denatured protein. Left panel presents result ofsilver staining,
right panel presents western blot against the C-terminal His-tag of the protein. The digest was repeated three times
producing the sameresult.
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Figure 4.18: Dual polarisation interferometry analysis of binding of recombinant NRP-1 isoforms to dp
16.
Presented results are a representative of a set of three independent experiments described in the Section 2.3.4. A)
Comparison of masseffect of binding of Fc rNRP-1, shNRP-1, reference Fc, and trNRP-1 expressed in [ng/ mm?] in
a function of time. B-E) Thickness and density measurements of binding of each protein in a function of time. B) Fc
rNRP-1. C) ShNRP-1. D) Fc. E) trNRP-1. They1 axis is thickness [nm], the y2 axis is density [g/ cm].
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In contrast, the ttNRP-1 was observed to behave in exactly same manner as shNRP-1, it
failed to bind at detectable levels to dp 16. This indicates that the high affinity of Fc rNRP-1 for
heparinis likely to reflect its dimeric form, and/ or the presenceof the c domain and associated
linkers as these features are absent from the monomeric NRP-1 proteins, and may mediate
dimerisation in an independent manner.
Unfortunately, the full benefit of the instrument, namely the measurementof the thickness
and density of the layer of the bound protein, mainly Fc rNRP-1, could not be obtained, since
the amountof the protein bound to the surface was too far below saturation to extract these
data.
4.7 Investigation of importance of the c domain of NRP-1
and heparin-binding ability
The work described above showed that a truncated variant of Fc rNRP-1, which migrated
around the size of shNRP-1, lost its heparin-binding affinity in surface-based assays. One
interpretation of these data is that the dimeric state of Fc rNRP-1 was the main driver of
the protein-heparin interaction. However, whereas in Fc rNRP-1 it is the IgG1 part that is
responsible for the dimerisation, in native conditions, NRP-1 has its own dimerisation domain,
the c domain [25, 34], which is also present in Fc rNRP-1.
Therefore, as the previous sections (Chapter 4.4, Chapter 4.6) indicated the possible im-
portance of the c domain of NRP-1 in mediating its binding properties, its structure obtained
in homolgy modelling was subjectedto furtherin silico analysis to answerif bioinformatics can
provide more data on its properties. The analysis aimed to define possible sites of protein-
protein interactions, which could be responsible for either the c domain dimerisation or other
heterogenousinteractions. In order to do so, three different interaction interface prediction
servers were employed. PPI-Pred analyses surface patches by assessing their hydrophobic-
ity, electrostatic potential, solvent accessible surface area and surface topographyto indicate
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most probable interaction areas. meta-PPISP combines three independent servers, where
cons-PPISPis analysing the sequenceprofiles and solvent accessibility of each residue on the
protein surface in neural network mode, PINUPis focused on energy and structural constrains
of each residue, and ProMateis calculating geometrical properties of the surface residuesthat
could imply involvementin interaction. WHISCY uses a different approach to analyse protein
structures, which is based on the sequence alignment and identification of highly conserved
hydrophobic patchesonthe surface. The combined results of the analysis performed by these
servers,intriguingly identified a region within the c domain that overlapped with the area previ-
ously identified in the P&L experiment (Table 4.2, Figure 4.19). This openeda possibility that
the short sequence WKEGRVLcould beinvolvedin a protein-protein interaction specifically in
homodimerisation, since the same region was protected within the Fc rNRP-1.
Therefore, subsequently, an attempt to dock two c domainsvia the identified region was
madetoillustrate a possible mechanism of the dimerisation. HADDOCKserver, that predicts
possible conformations of two interacting molecules requiresa list of indicated active and pas-
sive residues involved in the interaction. For the purpose of this analysis the active residues
chosenasaninput for HADDOCKwereofthe peptide identified in P&L experiment comprising
the WKEGRVL sequence and the passive residues were set for the automatic choice of the
server. The best obtained structure according to the HADDOCKevaluation presented both c
domains adjacent to each othervia the indicated region and, interestingly, forming a consistent
interface by the remaining P&L peptides. Thus, this analysis provided a hypothetical structure
of the dimerised c domains, andputatively, it presented a consistent protein surface interface
that might have beeninvolved in heparin interaction (Figure 4.20). However,it is not possible
to predict how such dimerised structure could be aligned with the remaining ala2b1b2 NRP
structure.
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Figure 4.19: Bioinformatics analysis of the potential docking sites for protein interactions within the c
domain.
The visualisations of the homology-modelled c domain with indicated interaction sites obtained by various prediction
servers and compared to the output peptides of the P&L experiment. A) P&L peptides (in blue). B) PPlI-Pred (in
green). C) meta-PPISP (in magenta). D) WHISCY(in orange). E) the consensus WKEGRVL sequence(in yellow).
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Figure 4.20: The cross-eye stereo picture of the c domains dimer according to the HADDOCKprediction.
The c domainsare both presentedin grey, wheretwodifferent perspectives of the c domain are shown. Therespective
interacting sequencesare labelled in pink and cyan. The remaining P&L peptides on each c domain are coloured in
blue and red, respectively. In order to view the 3-D picture apply cross-eye technique (right eye focused onthe left
picture, left eye on the right).
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In order to experimentally validate the bioinformatics data, an attempt to obtain from Fc
rNRP-1 another truncated variant, this time containing all extracellular domains, was made
to confirm or exclude the ability of the c domain to drive dimerisation alone. Conveniently,
manipulation of the temperature and NaCl concentration during digestion (referred to as digest
B in the Section 2.2.7) allowed a slightly larger protein (crNRP-1) to be obtained (Figure 4.21A,
Figure 4.22), whichis likely to have been digested after the c domain, asit lacked the His-tag
(data not shown). At the sametime a crosslinking method based on EDC/ NHSwasapplied to
verify the possibility of the c domains serving as dimerisation platforms between two rNRP-1s.
To do so, after a tryptic digest the proteins were incubated in appropriate conditions with the
crosslinkers. Interestingly, according to the silver staining of the proteins, contrary to Fc rNRP-
1, none of the truncation products was prone to form dimers that could be detected with the
crosslinking method. Regrettably, the western blot of the N-terminal rat NRP-1 sequence did
not provide clear information (Figure 4.21B), as it seems that both operations,tryptic digest
and crosslinking, affected the epitopes recognised by the antibodies. However, the faint band
present in crNRP-1 sample confirmed the identity of the protein by recognising its N-terminus.
First of all, crosslinked Fc rNRP-1 visible on silver stained gel was not detected on western
blot, secondly, the ttNRP-1 was recognised as a very intense band, while crNRP-1 washardly
detectable, being accompanied by much stronger bandof size of ttNRP-1, which wasvirtually
not visible on silver staining. Similarly, the crosslinked samples of trNRP-1 and crNRP-1,
although not producing any defined bands indicating a larger product in silver staining, on
western blot both appeared to have formed somecrosslinked species of intensity proportional
to its starting material. This result, though very enigmatic, does not allow solid conclusions
to be drawn, however, basing on thesilver staining result, it seems that noneof the truncated
NRP-1s formed substantial amount of dimers/multimers susceptible to EDC/ NHScrosslinking,
whereas based onthe western blot result, it is apparent that this method wasnotreliable for
detection of crosslinked molecules.
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Figure 4.21: The analysis of the binding capacities of the two different products of native tryptic digest
of the Fc rNRP-1.
A) Silverstaining ofthe tryptic digests products, labelled as trNRP-1 and crNRP-1, and the control Fe rNRP-1. Addi-
tionally labelled lanes show the migration of the proteins after crosslinking. B) Anti-His tag western blot result of the
analogous samples as presented on the panel A. C) Comparison of binding of Fc rNRP-1, shNRP-1, reference Fc,
trNRP-1 and crNRP-1 to immobilised dp 16 expressed in [ng/mm~]in a function of time as detected by DPI technique.
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Subsequently, the obtained crNRP-1 wastested in a similar manner as trNRP-1 on the dual
polarisation interferometer, where similarly to ttNRP-1, it did not show any binding to the dp16
surface (Figure 4.21C). This observation wasin contrast to the Fc rNRP-1 binding, which con-
firmedthatit is capable of binding to the native functional sulfated stretches of HS, which span
on average dp 6 - dp 16 [162]. This finding, and the previoussilver staining result, confirmed
the proposal that Fc rNRP-1 owesits heparin-binding feature to the dimeric form occuring via
the recombinantFc part, but not the c domain. However, since the docking analysis indicated
a possible area of dimerisation via the c domain and presented a mutual interface that could
be responsible either for heparin or further protein interaction, it is plausible that the interac-
tion with polysaccharides could be substantial for formation of a dimer, however, this was not
possible to confirm in the surface-based studies performed with the tryptic truncated NRP-1
isoform containing the c domain (crNRP-1 ).
To summarise, this study established some new facts about NRP-1. First of all, a major
difference between recombinant dimeric Fc rNRP-1 and shNRP-1 was revealed. The dimeric
species bound strongly to heparin, whereas shNRP-1 had much weaker heparin-binding affin-
ity, detectable only by affinity chromatography or the Sypro® Orangestability test. Contrast-
ingly to the Fe rNRP-1, shNRP-1 did notinteract with heparin immobilised on optical biosensor
surfaces and DPI, nor with heparin in solution in the BaF3 sequestration experiment.
Partially similar behaviour was previously observed for Cyclophilin B (CyPB) [163]. CyPB
wasable to bind to immobilised by reducing-end oligosaccharides and heparin, however, it
could not bind to heparin, which was immobilised to the surface by meansof biotin groups
introducedto its internal free amino groups. This result was confirmed by the competition
experiments where NAcderivative of heparin had very weak capacity to competefor the protein
binding to the heparin. Nonetheless, in case of the shNRP-1, the protein could not bind to
either of the molecules, internally biotinylated and immobilised heparin in optical biosensor,
or reducing-end immobilised dp 16 in DPI. This may reflect a dissociation rate, which would
renderthe interaction difficult to detect by these methods.
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Figure 4.22: Schematic representation of the truncated Fc rNRP-1-derived proteins obtained in trypsin
digests.
A) Recombinantsoluble isoform of human NRP-1 (shNRP-1) with indicated domains and the His tag. B) Recombinant
dimeric rat NRP-1 (Fc rNRP-1) with indicated extracellular domains and the linker sequence derived from NRP-1
sequence,and additional Xa cleavagesite (Xa), Fc part of human IgG1 (Fc) and the His tag. The red arrowsindicate
suggested approximate areas wherethetrypsin could cleave the protein in order to produce trNRP-1 and crNRP-1.
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The characterisation of the structural requirements of polysaccharide binding by the dimeric
Feo rNRP-1 showedthatit interacted with a large oligosaccharide (> dp 26), however, even dp
26 was not as effectively bound by the Fc rNRP-1 as heparin (approximately dp 50). This
implies that Fc rNRP-1 interacts with a chain of a polysaccharide in a complex manner, where
probably large areasof the protein are involved directly in the binding, which was investigated
in detail by the P&L strategy. Further characterisation of the Fc rNRP-1 revealed that among
polysaccharides bearing distinct patterns of sulfation, several different structures could main-
tain interaction with the Fc rNRP-1. The screening experiment revealed that to mediate strong
interaction, the polysaccharide neededeitherall three sulfate groups (at position 2 of iduronic
acid, and at positions 6 and N of glucosamine), or, surprisingly, none. Although thefirst require-
ment indicated dependence on charge, and, was additionally supported by a strong interaction
with persulfated heparin bearing two additional sulfate groups, the latter requirementclearly
showedthat sulfate groups are notcritical, though the carboxyl of the uronic acid may be.
Thus, although the range of the possible structures accommodated by the Fc rNRP-1 did not
follow any straightforward rule, there was clearly someselectivity mechanism that allowed the
differentiation between various structures. This selectivity means that the tested interactions
could be of high regulatory importance. Further assays exploring functionality of the Fc rNRP-
1 interaction with fully sulfated heparin-like stretches, 3-O-sulfated and non-sulfated stretches
of HS, as comparedwith other possible structures, could providefuller insight into the bases
of the discovered selectivity of the Fc rNRP-1 binding. At the sametime, no major differences
were discovered in the Fc rNRP-1 binding to the various cationic forms of heparin, implying
that there is no straightforward biophysical effect of these structures on interaction with NRP-1.
The P&L experiment provided moreinsight into how Fc rNRP-1 could be engagedinthein-
teraction. This approach benefited from the well-knowneffect of heparin of protecting theinter-
acting residues against chemical modification [164]. In this experiment the protected residues
werelysines, which were possible to identify after the chemical biotinylation and subsequent
procedureof the protein digest, purification and mass spectrometry analysis of the obtained
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peptides. This approach revealed that lysines within vast areas of the Fc rNRP-1 werein-
volved in the interaction, which supported previously discovered requirement of large chains
of oligosaccharidesto efficiently bind to the protein. The identified peptides covered fragments
of the NRP-1 a1, b1, c domains, and the L2 linker region, but also fragments within the Fc
part of the protein. This was surprising as the Fc part showed no heparin-binding property
in the other experiments (Figure 4.3A, Figure 4.18A). Overall, the result implies that NRP-1
might interact with heparin via more binding sites than the currently documented b1b2 do-
main, that was only partially confirmed by this method, and that there are other areas within
the multidomain structure of NRP-1 that can mediate this interaction. Additionally, it shows
that recombinant fusion proteins may have altered properties not only dueto the presence in
close proximity of the two NRP-1 moieties, but that the Fc part alone can be importantfor the
binding. It is noteworthy, that in this methodit is not possible to distinguish between the areas
of the Fc rNRP-1 that are directly involved in the interaction, and those whichareindirectly
undergoing the heparin-driven protection resulting from the conformation change within such
a complexprotein.
Additionally, the docking analysis suggested a possible conformation of the two c domains
with respect to each other, and how, possibly they could form an interface by the peptides
identified in the P&L experiment. Overall, this result indicates the basis of a very interesting
mechanism of the interaction and predicts further directions of investigation of the Fc rNRP-1
heparin-binding property.
Since the P&L approach highlighted the importance in the binding to the heparin of the
parts of the Fc rNRP-1 that are not present in the shNRP-1, an approach that would further
investigate the difference between the two species was undertaken. In order to do so, two
native tryptic digests of the Fc rNRP-1 were performed resulting in two distinct Fc rNRP-1-
derived monomeric proteins. Thefirst product, ttNRP-1, was highly likely to contain a similar
set of domains as shNRP-1, as deduced from the pattern of migration on SDS-PAGEand the
lack of the C-terminal His tag, but presence of the N-terminus. Importantly, likewise shNRP-1,
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it did not show any heparin-binding property in the surface-based study (DPI).
The second product, crNRP-1, raised some uncertainties in the western blot based identi-
fication of the possible domain content, however, basing on the pattern of migration on SDS-
PAGE,it wasstill suggested to contain all saNRP-1 domains plus the c domain, considered
crucial for dimerisation. The docking analysis of the c domain supported the possibility of the
dimerisation and allowed a structure of a potential c domain dimerto be built. Unfortunately,
an attempt to assess experimentally the scope of mediated dimerisation between crNRP-1s
in acrosslinking experiment did not identifiy major multiple migrating isoforms on SDS-PAGE,
therefore, indicating rather a lack of detectable homogenic interactions. This NRP-1 also did
not bind to the heparin in the surface-based study.
Unlessthere is a major incompatibility of the surface-based studies and detection of heparin-
binding property of the monomeric NRP-1s, these observations indicate that the Fc-mediated
fusion of the two rNRP-1 moieties results in unique properties of the Fc rNRP-1 protein.
Heparin-binding ability is definitely one of these features.
These findings raise the question if in the physiological conditions NRP-1 may exist in
a structure similar to Fc rNRP-1 dimeric/multimeric complexes and might play its functional
role via interacting with various domains of heparan sulfate proteoglycans (HSPGs) present
on the cell surface. Or contrastingly, both its membrane and soluble fractions may exist as
monomers, and their role is not substantially affected by HSPGs,or at least not at the levelof
its dimeric counterparts. Owingto its native localisation (membrane) and function (co-receptor,
adhesion molecule), it is plausible that native NRP-1 might share some features with other
proteins of similar localisation/ function, as G-proteins coupled receptors [165] or proteins in
adhesion complexes [166], which are well-known to be present on the cells in large homo-
and heteromeric complexes. Nevertheless,it is important to emphasise, that the mechanism
mimicking Fc fusion would needto be different from the c domain-dependent dimerisation, as
accordingto thefindings of this study, the c domainis not sufficient to bestow Fc rNRP-1 prop-
erties, at least in solution. However, the reduced dimensionality of the membrane may promote
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dimers that are not stable in solution. Recently, among the mechanismsaffecting clustering of
the receptors in the membraneare proposedlipid rafts or galectin lattices (reviewed in [167]).
Interestingly, both of them have beenalready proposedto control NRP-1 [41,87]. If this was the
case, the picture of NRP-1 function could be as follows - membrane embeddedoligomerising
NRP-1 is involved in interactions with HS on the cell surface, while the soluble truncated vari-
ants are responsible for sequestration and possibly biotransport of NRP-1 interacting growth
factors, similarly to soluble VEGFR-1 species [93].
Importantly, the discovery of the discrepancy betweenthese two similar proteins provided
new insights into a recently described regulatory mechanism - shedding of the NRP-1 from
the membrane. Recently, two distinct soluble species of NRP-1 containing eitherall extracel-
lular domains (120 kDa) [68, 69] or snNRP-1 set of domains (75 kDa) were discovered [71].
Similar processes were observed for other proteins, endothelial cell protein C receptor (EPCR)
and receptor for advanced glycation products (RAGE) [168, 169], where the soluble and shed-
ded species had similar functions in the environment, largely not overlapping with the mem-
brane species. This reinforces the proposal that the membrane embedded NRP-1 might have
different functional properties than its soluble isoforms, and, as presentedin this study, the
mechanism of regulation might depend onthe isoform of the protein.
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Exogenous recombinant dimeric
Fc rNRP-1 is sufficient to drive
angiogenesis in human dermal
microvascular endothelial cells
Abstract
Neuropilin-1 (NRP-1) is present on the cell surface of endothelial cells, or as a soluble trun-
cated variant. Membrane NRP-1 is thought to enhance angiogenesis by promoting the forma-
tion of a signalling complex between VEGF-Aig5, VEGFR-2 and heparan sulfate. In contrast,
the truncated soluble variant of NRP-1 is postulated to act as an antagonist of signalling com-
plex formation. In this study, the angiogenic potential of two distinct soluble NRP-1 proteins
was analysed: a chimera comprising the entire extracellular NRP-1 region dimerised through
an Fe IgG domain and a soluble truncated NRP-1 variant. Both NRP-1 proteins stimulated
tubular morphogenesis in primary human dermal microvascular endothelial cells (HDMECs).
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Surprisingly, this stimulatory activity was independent of VEGF-Ajg5. This was evidenced by
depleting the cell culture of exogenous VEGF-Aj¢5, replacing VEGF-Aj¢65 used for routine cul-
ture with VEGF-Aj21, which doesnotinteract with NRP-1 [22, 24, 27, 134, 135], and by thein-
ability of VEGF-A sequestering antibodiesto inhibit the angiogenic activity of the NRP proteins.
The NRP proteins’ angiogenic activity was mediated through VEGFR-2, since they inducedits
phosphorylation and the synthesis of a specific, downstream target of VEGFR-2, regulatorof
calcineurin-1 (RCAN-1.4). Moreover, the stimulation of tube formation and of phosphorylation
of VEGFR-2 by the NRPproteins in HDMECswasblocked by ZM323881, a specific inhibitor of
the VEGFR-2 kinase. Thus,it was concluded that soluble NRP-1s are VEGF-Aj65 independent
agonists of VEGFR-2 that stimulate angiogenesis in HDMECs.
Introduction
NRP-1 is a protein knownfor playing important functions in neural and vascular systems(re-
viewedin [4, 7]). Initially, it was described as a regulator of axon collapse and enhancerof
angiogenesis. Subsequently, new functions of NRP-1 were characterised and the expanded
contemporary view of NRP-1 includes amongstits functions antigen recognition [133], adhe-
sion via interaction with y integrins [45,46], activation of latent forms of cytokines [38], control
of stem cell differentiation [14, 122, 170] and viral infection [171].
Many studies characterising NRP-1 focus onits ability to enhance angiogenesis and cover
experiments in cell biology, animal models and patients. Thus, NRP-1 was shownto be abun-
dantly expressed in human, mouse, and chick with highest expression in the vascular endothe-
lium, heart and placenta [24, 124, 172]. Moreover, it was shown that a homozygousdeletion of
the Nrp7 gene in mice causes embryoniclethality, due to defects in the vessels and general
vascularisation [126], while exogenously overexpressed NRP-1 led to formation of excess cap-
illaries and haemorrhages[124]. Importantly, overexpression of NRP-1 has been observedin
the tumour microenvironment, where apart from endothelial cells, the tumour cells themselves
were shownto express NRP-1 [173,174]. Current knowledge of NRP-1 places it among the key
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drivers of angiogenesis [130], however, it must be emphasised that the exact mechanism ofits
action is not clear. It has been proposed that NRP-1 forms signalling complexes, where, as a
co-receptorwith no intrinsic kinase activity, it associates with other tyrosine kinase receptors,
their ligands and heparan sulfate moieties of heparan sulfate proteoglycans[4]. The formation
of such complexesis regulated by the availability of NRP-1 in the cell membrane, dependent
on its down-regulation by ligand-mediated internalisation. Thus, several studies have shown
that molecules interacting with NRP-1 causeits disappearance from the cell surface and this
mechanism togetherwith ligand binding preference might provide a mechanism for NRP-1 sig-
nalling selectivity [44,46,53,58,84]. The hypothesis that the internalisation process might be a
meansof selecting signalling pathways is supported by observations that VEGF-Aj65 induces
NRP-1 internalisation at a much higherlevel than SEMA-3A, whereas VEGF-Aj2;, which does
not bind NRP-1, fails to affect the internalisation of NRP-1 [53]. Another mechanism controlling
the angiogenic activity of NRP-1 is the secretion of soluble truncated isoformsof the receptors,
which bind the same ligands as membrane NRP-1. For example, in the presence of soluble
NRP-1 species, which sequester VEGF-Aje5, membrane NRP-1 cannot enhance VEGFsig-
nalling nor be internalised, which may lead to an increased probability of NRP-1 interacting
with the antagonising SEMA-3A[53].
Dueto its crucial role in angiogenesis, NRP-1 is currently the target of various prospec-
tive anti-cancer therapies. The most common approaches aim to inhibit NRP-1 function, and,
consequently, block such phenotypes as pathological angiogenesis, and consequently tumor
growth [175]. Among these are antagonistic soluble NRP-1 [75,76], VEGF-A¢5-derived block-
ing peptides [75, 176,177], siRNA against NRP-1 [75], anti-NRP-1 antibodies [178] and re-
cently developed synthetic small molecule inhibitors [179]. Other approaches use NRP-1 to
allow drug delivery inside the cells [85, 180-182], thus providing a route for selective drug
delivery into the cells expressing NRP-1.
In this study it was hypothesised that dimeric NRP-1, a proxy for oligomerised membrane
NRP-1, could be a potential proangiogenic agent mimicking in trans anintercellular activity of
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NRP-1 [11]. Consequently, the molecular components required for NRP-1 to exert an angio-
genic effect in human dermal microvascular endothelial cells (HDMEC) were examined. Two
recombinant NRP-1 proteins were usedin this study. The recombinant dimeric rat NRP-1 (Fe
rNRP-1), which can be considered as a proxy for native oligomerised NRP-1 species embed-
ded onthe cell surface and a soluble human NRP-1 isoform, comprising the a and b, but not
the c domains. Fc rNRP-1 contains all the main extracellular domains from a to c that are
considered essential for ligand/receptor interactions and also for NRP-1 oligomerisation [4].
Surprisingly, the obtained results demonstrated that both forms of NRP-1 can causetubefor-
mation independently of VEGF-Aligand in a collagen-based angiogenesis assay of HDMECs.
The mechanism of Fc rNRP-1 action is VEGFR-2 dependent, as shownbythe stimulation of
VEGFR-2 phosphorylation, RCAN-1.4 induction and blockage by a VEGFR-2 kinaseinhibitor.
The soluble human NRP-1 isoform wassimilarly shown to cause tube formation, though less
effectively. Thus, NRP-1 behaves as a VEGFR-2 agonist and does not require partner growth
factors to exert its angiogenic activity.
Results and Discussion
5.1 Characterisation of recombinant soluble NRP-1s
The NRP-1 proteins used in this study are commercially available recombinant proteins (Fig-
ure 4.2) that were described in the previous chapter. Theydiffer from the membranelocalised
NRP-1 in several aspects (Figure 4.2A). Recombinant rat NRP-1 chimera (Fc rNRP-1) has the
rat sequence of NRP-1, which showshigh similarity (approximately 93 % identity within the
overlapping regions) to the human sequence (Figure 4.2B, Figure 5.1A). It covers all extra-
cellular domains (a1, a2, b1, b2 and c) of the membrane NRP-1 and also fragments of the
linker region that follows the c domain (where amino acids 811-828 are substituted by arginine
residues, but subsequent sequence 829-854is present). This sequenceis fused to the Fc part
of human IgG1 and histidine tag.
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Figure 5.1: Sequence analysis of recombinant NRP-1 proteins and humanwild-type NRP-1.
A) Alignmentoffull-length human NRP-1 and the corresponding rat sequence covered in Fc rNRP-1. B) Alignmentof
full-length human NRP-1 and the NRP-1 sequence covered by shNRP-1 and the rat sequence covered by Fc rNRP-1.
Thediffering amino acids are markedin red.
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Consequently, the protein is expressed as a dimerdueto the formation of disulfide bridges
between the Fc domainsofthe two identical recombinant constructs. Upon SDS-PAGE inre-
ducing conditions it migrates as a monomeraround 150 kDa (Figure 4.2D). Soluble truncated
human NRP-1 (shNRP-1) encodes the human amino acid sequenceof the native soluble iso-
form fused to a histidine tag (Figure 4.2). It differs from Fc rNRP-1 by the absence of the c
domain and minor sequencevariation due to alternative splicing (1) (Figure 4.2C). shNRP-
1 migrates around 90 kDa upon SDS-PAGEin reducing conditions, and both proteins were
confirmed to be pure asjudgedbysilver staining (Figure 4.2D).
5.2 Induction of tube formation by Fc rNRP-1 and shNRP-1
via VEGFR-2 activation
Human Dermal Microvascular Endothelial Cells (HDMECs) were used, which are of simi-
lar characteristics to Human Umbilical Vein Endothelial Cells (HUVECs) [183]. However, in
contrast to the latter, they are of micro-, not macrovascular origin. This makes them more
appropriate subject of angiogenic studies, as angiogenesis is their direct physiological func-
tion [184, 185].
The tubular morphogenesis assay measurestheability of cells to form capillary-like struc-
tures in a 3-D collagen type | gel in response to growth factors and represents an in vitro
angiogenesis assay [102, 186]. This assay confirmed the ability of VEGF-Aig5 to induce an-
giogenesisin vitro. It also demonstrated that both recombinant NRP-1 proteins induced tube
formation (Figure 5.2). Fc rNRP-1 (5 nM) had the highest proangiogenic activity and appeared
to be a more potentstimulator of angiogenesis than VEGF-Aj65 (10 ng/ ml; 224 pM). The Fc
region (5 nM) of Fc rNRP-1 had no stimulatory effect on tube formation, demonstrating that
the effects observed with the Fc rNRP-1 chimeric protein were entirely due to the NRP-1 part.
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Figure 5.2: Recombinant NRP-1 proteins stimulate tube formation in HDMECs.
A, B) The influence of addition of VEGF-Ajg¢5 (10 ng/ mL), reference Fc, shNRP-1 and Fe rNRP-1 (5 nM or 10 nM)
on HDMECstubeformation on collagen substratum. The tubes were photographed and analysed as describedin the
Section 2.4.4. Significant differences betweenthe tested agonists and the control were determined by Student's test.
Asterisks (*) indicate that the P values are <0.001 for comparisonto control.
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The monomeric shNRP-1 (5 nM) induced tube formation to a lesser extent than Fc rNRP-1.
However, as NRP-1s were added at equimolar concentrations, the dimeric form of Fc rNRP-1
had double the content of NRP-1 moieties. Therefore, saNRP-1 wasalso tested at 10 nM,but
this did not increaseits ability to induce the formation of tubes (Figure 5.2), indicating that the
dimerisation of Fc rNRP-1 and/ or the presence of the c domain is the mostlikely reason for
the increased potencyofthe latter in this assay.
To identify the potential molecular partners of NRP-1 in the stimulation of in vitro angio-
genesis, the activation of VEGFR-2 and induction of a downstream VEGF-responsive pro-
tein, RCAN-1.4/ DSCR-1 [187] (Uniprot accession number P53805-2) [188], were analysed by
western blotting. Surprisingly, Fc rNRP-1 in the absence of exogenous VEGF-Ajg5 was able
to stimulate the phosphorylation of VEGFR-2 in the cells plated on collagen (Figure 5.3) and
gelatin (Figure 5.4). Moreover, after 3 hours, the level of RCAN-1.4 was higher, supporting a
VEGFR-2 dependent mechanism of activation of its synthesis [189]. The same molar amount
of shNRP-1, however, did not have any detectable effect on the signalling proteins tested,
which is in accordance with its weaker angiogenic activity, and explained by the similar, but
much weakerresponseit can induce. Indeed, when the amountof shNRP-1 is doubled a very
weakactivation of VEGFR-2 and ERK-1/2 is observed (Figure 5.7), which supports the notion
that the effects of saNRP-1 are the same,but less potent than those of Fc rNRP-1. As NRP-1
is also a putative co-receptor of c-MET and FGF receptors, phosphorylation of total tyrosines
in the lysate samples was investigated to identify whether other pathways were strongly ac-
tivated. However, no significant target phosphorylation candidate was observed other than
VEGFR-2 (Figure 5.5). Consequently, these data indicate that exogenously added recombi-
nant Fc rNRP-1 and shNRP-1arelikely to elicit their proangiogenic response in a VEGFR-2
dependent manner.
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Figure 5.3: Western blot result of experiment with HDMECscultured on a layer of collagen.
The phosphorylation of VEGFR-2 and the levels of RCAN-1 following stimulation with VEGF-Ajg5 or recombinant
NRP-1s are shown. The bandintensities were analysed as described in the Section 2.4.6.
 
Doctoral thesis Study of Neuropilin-1 interactions by Katarzyna Adela Uniewicz 98
Exogenous recombinant dimeric Fc rNRP-1 is sufficient to drive angiogenesis in human
dermal microvascular endothelial cells
 
 
 
10 min 3h
E E
oD) od)
= Oo Cc e Oo ¢f
a 8 ~ = 2 8 = =r =_a#y F 2a iyoe fF ce og ££ FS Ce azo fe 28 26228O w O wOo Ss cc se 6 Se ELE FS
WB:P-VEGFR2, =   
10 45 10 56 1.2 10 10 10 1.0 1.WB:VEGFR2 -=~== snoee
WB:RCAN1_————
10 09 09WB:actin————Sanna
10 #12 09 1.0 0.9 10 10 1.0 1.0 1.1
Oo  
  
Figure 5.4: Western blot result of experiment with HDMECscultured on a layerof gelatin.
The phosphorylation of VEGFR-2 and the levels of RCAN-1 following stimulation with VEGF-A;g5 or recombinant
NRP-1s are shown. The bandintensities were analysed as described in the Section 2.4.6.
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Figure 5.5: Western blot for phosphotyrosine-containing proteins in the HDMECslysates.
The phosphorylation levels after stimulation with VEGF-A;g5 and recombinant NRP-1s are shown. Cells grown on
collagen and gelatin were stimulated with VEGF-A;g5 and recombinant NRP-1 proteins for 10 min and 3h. Asterisk
indicates a band corresponding to the molecular weight of VEGFR-2 which is phosphorylated.
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5.3. Feo rNRP-1 responseis blocked by a VEGFR-2 specific
inhibitor ZM323881
To formally establish that the activation of the VEGFR-2 pathway by Fc rNRP-1 was the cause
of the stimulation of tube formation, the cells were treated with ZM323881, a potent cell-
permeableinhibitor of the VEGFR-2 tyrosine kinase [94] (Figure 5.6). Under these conditions,
Fc rNRP-1 stimulation of tube formation in HDMECswasfully blocked (Figure 5.6). The effi-
ciency of the inhibitor was confirmed by western blot, where it was able to abolish detectable
phosphorylation of VEGFR-2 and downstream responses induced either by VEGF-Aj¢s5 or the
recombinant NRP-1 proteins, both on collagen and gelatin substrata (Figure 5.7, Figure 5.8).
These data demonstrate that NRP-1 stimulates angiogenesis solely through VEGFR-2.
5.4 Fe rNRP-1-driven tube formation occurs in VEGF-Aj¢5
depleted cells
The recombinant NRP-1 proteins were shownto induce angiogenesis in an exclusively VEGFR-
2 dependent manner and aninhibitor of the VEGFR-2 tyrosine kinase could block this re-
sponse. However, most of the published data have been interpreted to suggest that NRP-1
exerts its angiogenic effects by potentiating the effects of VEGF-A165, as generally these exper-
iments were performed in the presence of VEGF-Ajg¢5 [11,73, 74]. In contrast, the experimental
design of the present study implied lack of involvement of endogenous VEGF-Aj¢s, due to the
24h incubation of the HDMECsin low-serum in the absence of VEGF-Aj¢5, prior to the ad-
dition of NRP-1 proteins [190-193]. To rigorously exclude the presence of small amounts of
VEGF-Aj65 carried over from the culture medium or bound to extracellular matrix, the cells
were grownfor at least 7 days in medium containing 0.5 ng/ mL VEGF-Aj2; isoform, instead
of VEGF-A6s.
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Figure 5.6: The effect of the VEGFR-2 kinase inhibitor (ZM323881) on tube formation.
Thestimulation of tube formation by Fc rNRP-1 depends on VEGFR-2 kinaseactivity but not on VEGF-A in HDMECs.
The experiment was performed as described in the Section 2.4.3. The tube formation observed in the presence of
VEGF-Ajgs and recombinant NRP-1 proteins was blocked by the VEGFR-2 kinaseinhibitor (ZM323881).
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Figure 5.7: Western blot result of the effect of addition of VEGFR-2 inhibitor to the HDMECscultured on
collagen.
 
A) The effect of stimulation with VEGF-A;g5 and recombinant NRP-1 proteins on cells grown 7 daysprior to serum
starvation in medium supplemented with VEGF-A;2;._ B) An analogous experiment with cells grown in standard
conditions in medium supplemented with VEGF-Aj¢5 prior to serum starvation. Both panels showtheeffect of the
inhibitor of the VEGFR-2 tyrosine kinase (ZM323881). The band intensities were analysed as described in the Section
2.4.6.
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A) The effect of stimulation with VEGF-A;g5 and recombinant NRP-1 proteins on cells grown 7 days prior to serum
starvation in medium supplemented with VEGF-A;2;. B) An analogous experiment with cells grown in standard
conditions in medium supplemented with VEGF-Aj¢s5 prior to serum starvation. Both panels show theeffect of the
inhibitor of the VEGFR-2 tyrosine kinase (ZM323881). The band intensities were analysed as described in the Section
2.4.6.
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Cells grown in such conditions are most unlikely to contain any residual VEGF-Ajes and
the response observed is expected to be VEGF-Ajg¢5 independent. In parallel, another batch
of cells was grownin the standard conditions containing VEGF-Aj¢s5 for the purpose of com-
parison. Cells grown in both conditions appeared to be similarly sensitive to Fc rNRP-1 (Fig-
ure 5.9). Additionally, they showed exactly the sameprofile of signalling activation, where
VEGF-Aje5, Fc rNRP-1 and to lesser extent saNRP-1 (whose amount was doubled to 20 nM,
whereas Fc rNRP-1 was at 10 nM), caused immediate phosphorylation of VEGFR-2 and ac-
tivation of PLCy-1 and ERK-1/2 on collagen (Figure 5.7) and gelatin substrata (Figure 5.8).
This showsthat cells devoid of VEGF-Aig5 by extended medium depletion are also induced by
NRP-1s to undergo a proangiogenic response.
5.5 Sequestration of VEGFs with anti-VEGF-A antibody does
not block tube formation
To further eliminate the possibility of endogenous VEGF-Aj;65 production contributing to the
angiogenic activity of the NRP-1 proteins, a sequestering antibody that targets the N-terminal
region of human VEGF-A wasintroduced into the tube formation assay. The antibody suc-
cessfully blocked the tube formation of exogenously administered VEGF-Aj¢5, however, the
stimulation of the formation of tubes by recombinant NRP-1 proteins was completely unaf-
fected by the VEGF-A sequestering antibody (Figure 5.10).
To summarise, the addition of Fc rNRP-1/ shNRP-1 triggered tubular morphogenesis in
HDMECs.This early in vitro angiogenic response was a consequenceofthe activation of the
VEGFR-2 receptor and wasinhibited by a specific inhibitor of the VEGFR-2 tyrosine kinase.
At the sametime, cells depleted of VEGF-Ajg5 or incubated with a sequestering antibody to
VEGF-A couldstill be induced by the NRP-1 proteins to form tubes.
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Figure 5.9: The tube formation induced by Fc rNRP-1 depends on VEGFR-2 kinaseactivity but not on
isoform of the VEGF-A in HDMECs.
The angiogenic effect of Fc rNRP-1 on HDMECsgrown7 days prior to serum starvation in medium supplemented
with either VEGF-Ajg5 or VEGF-Aj;2;. The experiment was performedas described in the Section 2.4.3.
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Figure 5.10: Effect of a sequestering antibody to VEGF-A ontube formation by HDMECs.
Top panels presentcontrol variants, while the bottom panels present the same conditions but with the addition of the
VEGF-A sequestering antibody according to the procedure described in the Section 2.4.3.
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Therefore, this study showed that Fc rNRP-1, and to a lesser extent shNRP-1, can be-
have as a VEGFR-2 agonist, possessing a weaker (ShNRP-1) or stronger (Fc rNRP-1) pro-
angiogenesis activity in HDMECs. Thus, the present results extend considerably the regulatory
potential of NRP-1.
The few studies that have focused on the angiogenic activity of recombinant NRP-1, as op-
posedto its activity in the presence of VEGF-Aj¢s, have provided contradictory views. A study
employing monomericfull-length NRP-1 suggested that it inhibited angiogenesis and caused
necrosis in chloromasolid tumor in SCID mice. Moreover, localised expression of this dimeric
form was able to block tumour progression [74]. However, the inhibitory effect of NRP-1 in
these experiments may be due to the NRP-1 sequestering VEGF-Aj65 from the immediate en-
vironment of the endothelial cells. A similar effect was observed in another study, conducted
in explants of para-aortic splanchnopleural mesoderm cells, where monomeric NRP-1 was
found to have an inhibitory effect on vasculogenesis [73]. Further studies of dimeric NRP-1
provide more contradictory data, perhapsrelated to different experimental systems. According
to one study, a chimeric construct similar to the one used here was shownto bind to endothe-
lial cells expressing VEGFR-2 only in the presence of VEGF-Ajgs5 [11], whereas another study
showedthat the dimeric form of the protein induced angiogenesis in the presence of VEGF-
Aies and alone, however even 50 yg/ mL of the dimeric NRP-1 alone had not comparable
activity to VEGF-Aj¢5 [73]. In the presented results the pro-angiogenic activity of Fc rNRP-1
was strongerthan in the case of the shNRP-1 protein, which may be explained by the dimer-
ization of the protein by the Fc fusion [74, 194]. Alternatively, the c domain which is known to
cause dimerisation of native NRP-1 [25,34] and may have otherfunctions, may becritical for
NRP-1’s angiogenic activity.
Overall, the present findings suggest that the dimerisation of NRP-1 by the Fc domain
and/ or the presence of the c domain results in a strong VEGFR-2 agonist. Thus, Fc rNRP-1
may be a good candidate for therapeutic angiogenesis in conditions requiring revascularisation
such as ischemia [195]. It elicits a strong proangiogenic response and could be an additional/
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complementary contribution in the well-studied VEGF-Aj¢5 based therapies [196]. To become
clinically relevant, Fc rNRP-1 would need to undergo two major adaptations: humanisation
and reduction of Fc function [197], which are both currently attainable and allow reduction of
undesirable immunological response without affecting the benefits of the fusion nature [197].
The practical significance is that the half-life of VEGF-A;¢5, does not exceed one hour [198],
limiting the amount of administered agonist, while the modified Fc rNRP-1 may have a con-
siderably longer half-life, as has been found with analogousfusion proteins, which have been
already shown successful in preclinical and clinical studies [199], such as etanercept (Fc-
p75 TNF receptor) [200], alefacept (Fc-LFA-3) [201], and abatacept (Fc-CTLA-4) [202], Fc-
endostatin [203] and VEGF-TRAP(selected VEGFR-1/2 domains trapping VEGF-A indepen-
dently and Fc) [204]. Thus the discovery that Fc rNRP-1 is a potent VEGFR-2 agonist opens
new possibilities for the development of proangiogenic therapies using a powerful approach
that so far has been scarcely employed in proangiogenicfield [205].
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Chapter 6
General Discussion
This study was focused on the molecular mechanism of action and functional characterisation
of NRP-1. It used two commercial recombinant NRP-1 proteins, a dimeric rat Fc rNRP-1 and
monomeric human shNRP-1. The human and rat NRP-1 sequencesare highly conserved,
therefore, the main difference betweenthe two proteins was the monomeric and dimeric form,
and lack of the c domain in the monomeric human NRP-1. Since several biochemical studies
observed dimerisation of NRP-1, it is generally regarded as highly probable that in vivo such
species are formed. Moreover,it is predicted to especially take place in the membranelocation
in lipid rafts or via galectin lattices (reviewed in [167] and [41,87]). Also, formation of dimers by
soluble species was suggested [82], supported by recently discovered soluble species of NRP-
1 containing all extracellular domains including the c domain (120 kDa) [68,69]. Therefore, the
Fc rNRP-1 is used mainly as a proxy for the membrane embedded NRP-1 and possibly some
fraction of soluble native dimers, while shNRP-1 is one of the soluble monomeric isoforms
producedin physiological conditions.
NRP-1, as a membrane receptor, is a componentof the pericellular matrix, which is con-
tinuous with the ECM. Together with other proteins and proteoglycans, which either share
similar membranelocalisation (NRP-1, CD44, syndecans), or are membrane attached by a
glycosylphosphatidylinositol (GPI) anchor(netrins, glypicans) [206] or just associated to the
110
General Discussion
 
cell surface (several growth factors, truncated receptors, perlecan), they create an extremely
complex network of the matrix with unique properties, often characteristic for a tissue/ or-
gan [207,208]. NRP-1, in that respect, is a well-known componentof the endothelial ECM of
cardiovascular and neuraltissues [124], regulatory T lymphocytes [132] and stem cells [122].
NRP-1 is directly involved in protein and polysaccharide interaction networks. On the pro-
tein side, not only doesit interact with specific function-assigned molecules described in Chap-
ter 1, but also with several extracellular scaffold proteins, such as integrins [45-47]. Addition-
ally, it indirectly controls integrin internalisation and fibronectin function [46]. These results
indicate a role for NRP-1 in promoting cell adhesion. In respect to this function, NRP-1 was
suggested to dimerise, both in cis and in trans, and this property, supposedly important for
adhesion, wasoneof the subjects ofthis thesis.
Unfortunately, although the in silico analysis seemed to support dimerisation occuring via
the c domains of NRP-1, the crosslinking method applied to the Fc rNRP-1-derived construct
containing the c domain, but not the Fc part (crNRP-1), did not show formation of di/ multi-
merised species. Additionally, the same construct did not have oligosaccharide binding prop-
erty similar to the Fc rNRP-1. The explanation of this result must take into consideration two
possibilities. First of all, the EDC/ NHS method of crosslinking requires in close proximity a
carboxyl and an amino group, which might not be present in the c domain interaction inter-
face. In this case the dimerisation might have occurred, but was not detectable by the method.
However, such an option would indicate that the actual NRP-1 dimerisation would not result
in molecular properties similar to the ones of the Fc rNRP-1. Secondly,it is plausible that the
mechanism of dimerisation needs someotherstructural elements, e.g., within the L2, whose
presence in the crNRP-1 wasnotpossible to verify. Such a possibility would be confirmed by
the lack of oligosaccharide binding by crNRP-1 in the binding study.
Although the dimerisation of NRP-1 was not successfully confirmed in this study, it is
an important issue, since the recombinant dimeric NRP-1, Fc rNRP-1, had very contrasting
properties compared to those of the monomeric shNRP-1. Interestingly, applying surface-
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based methodsit was observed that only Fc rNRP-1 could efficiently bind to heparin, an HS
proxy. sShnNRP-1 andtryptic digests of Fc rNRP-1 comprising either the same set of domains
as shNRP-1 or a truncated variant additionally containing the c domain, did not bind to the
polysaccharide surfaces. Since shNRP-1 seemed to bind to heparin in solution (detected
in the stability test) and to heparin immobilised on a column, either surface-based methods
were unsuitable to detect shNRP-1 binding to heparin due to conformational or accessibility
difficulties or a dissociation rate of the complex resulted in too weak binding to be detected
directly on a sensor surface. This suggests that the two proteins had very different mecha-
nisms of interacting with heparin. This has important implications for the putative regulation of
NRP-1 function. Namely, the dimerised NRP-1, contrary to its monomer, might be differently
affected by the interaction with polysaccharides. Thesedifferent properties of the two NRP-1s
werealso seenin in vitro studies in endothelial cells. Similarly to the distinct behaviour of the
two proteins in the biochemical studies, in early angiogenesis assays, they elicited proangio-
genic effects of varied potency, namely, Fc rNRP-1’s was morepotent than that of shnNRP-1.
Nonetheless,it is not possible to assessif this property of Fc rNRP-1 could bedirectly related
to its higheraffinity for polysaccharide binding.
This observation is important, as heparin is knownto be crucial for NRP-1 regulation, al-
though it is not yet clear how the interaction with polysaccharides affects NRP-1 function.
Someobservations following the presentation of NRP-1 to heparin have been made. It was
observed that heparin enhanced VEGF-Ajg¢s5 [21, 22, 24, 26, 53], PIGF-2 [29, 32], and SEMA3A
[53,54], and allowed VEGF-C and VEGF-D [81], binding to NRP-1. On the other hand, NRP-1
is knownto be a target of glyco-modification itself, which may result in decreased VEGF-Aj¢5
binding [209], or contrastingly, enhanced VEGF-Ajg¢5 binding to NRP-1 [210]. These discrep-
ancies opena possibility of a tissue specific regulation of NRP-1 function and emphasise the
importance of the glycobiological aspect of the regulation of NRP-1 function. Thus, the present
study supports the importance of polysaccharides in the regulation of NRP-1 function, and
showsthat it might be a reason of the major difference between the monomeric and dimeric
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NRP-1 species.
However, there could be also another explanation of the varied responseof the endothelial
cells to the two proteins. Given that NRP-1 wasfoundtointeract with galectins (animal lectins)
presentin the extracellular milieu [167,211], it is tempting to propose that it might be partici-
pating in the formation of glycoprotein lattices [41]. Such advancedstructures, where galectins
crosslink the N-glycans,is postulated to consolidate signalling for more consistent responses
acrossthe integrin network, where some form of coordination is proposed to occur amongall
the crosslinked constituents.
In this respect, the difference between the Fc rNRP-1 and shNRP-1in exerting their proan-
giogenic effect could be directly related to their varied scope for engagementin such extracel-
lular structures involved in the global signalling cascade. Fc rNRP-1, as a larger molecule of
potentially higher avidity for cell surface epitopes, could be subjected to slowerinternalisation
and at the same time evoke a more potentcellular response, dueto its wider and more stable
interactions. The comparison of the cell surface interaction and internalisation processof the
two proteins could shed somelight on the differences between them.
Someof the newly described features of NRP-1 may beinvolved in the dynamic adaptation
of the ECM to the environmental conditions. First of all, as it was shownto interact with a de-
gree of selectivity with variously sulfated heparin derivatives, this selectivity might be a detector
of changing populations of the synthesised or enzymatically modified extracellular pools of HS.
In this study Fc rNRP-1 was characterised by very high affinity (2.5 nM) for heparin, however,
at the same time it bound well both persulfated heparin and triply desulfated heparin, which
indicated, that it was not the presence of charge, but more complex conformational output
which was a decisive factor for the binding. Although the functional aspectof this selectivity is
not known, it seems a probable biophysical mechanism of regulation. An attractive hypothesis
explaining the obtained result could be that NRP-1, when boundto the non-sulfated region of
HS, is somewhat “blocked” and cannot form a signalling complex with other proteins having
a preference for sulfate groups on HS. Consequently, signalling complex can be formed only
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after a highly sulfated stretch of HS competesoff its non-sulfated counterpart.
Additionally, it is known that NRP-1 is subjected to the enzymatic shedding machinery
[68, 69, 71] that produces togetherwith alternative splicing several shorter isoforms of NRP-
1. Since according to this study shorter isoforms of NRP-1 were shown to havedifferent
heparin-binding properties from the dimerised variant, it is plausible, that alternative splicing
and shedding could produceisoforms, which might drive distinct output responsesofthe cells.
Another novelty identified by this study is the topographical aspect of the heparin-binding
site of the Fc rNRP-1. The characterisation of the protein side of the heparin interaction was
performed using a P&L methodology. This approach revealed that lysines within large areas
of the Fc rNRP-1 wereinvolvedin the interaction, which supported previously discovered re-
quirementfor large chains of oligosaccharidesto efficiently bind to the protein (at least dp 26).
The identified peptides covered fragments of the NRP-1 a1, b1, c domains, and the L2 linker
region, but also fragments within the Fc part of the protein. The result implied that NRP-1
might interact with heparin via more binding sites than the hitherto identified one in the b1b2
domain, which wasonly partially confirmed in the P&L experiments, and that there are other
areas within the multidomain structure of NRP-1 that can mediate this interaction. Still, it was
surprising that both Fc part and the c domain wereidentified as heparin-binding sites, since
neither were expected to interact with the polysaccharide. However, since the method does
not distinguish betweenthe areas of the Fc rNRP-1 that are directly involved in the interaction,
and those which are indirectly undergoing a heparin-driven protection as a consequenceof
conformation changeelicited by binding of the sugar, an analysis of the interaction surface
of the c domain was made. By means of homology modelling and docking analysis, it was
discovered that one of the P&L identified peptides washighly likely to be actually involved in a
protein-protein interaction. Basing on this discovery, a modelof the dimerised c domain was
presented with the remaining P&L peptides creating a consistent surface interface that could
be further involved in heparin interaction. Therefore, it was tempting to suggest that the P&L
approach madeit possible to indicate crucial regions of the Fc rNRP-1 involved in direct and
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indirect interaction of heparin binding. Unfortunately, an attempt to experimentally validate the
proposed modelof a dimerof the c domains wasnot successful. Therefore, unless the method
wasnotsuitable for the confirmation of interaction for this particular protein, the in silico predic-
tion remains a hypothesis, which will require an additional experimental approach to validate
it.
The work on endothelial cells identified a novel function of NRP-1. As described before,
both Fc rNRP-1 and shNRP-1 were able to drive proangiogenic responsesin primary en-
dothelial cells. A fascinating aspect of this finding is that the data indicated that this response
is driven solely by the NRP-1 proteins through VEGFR-2, without requirement for VEGF-A,the
growth factor that NRP-1 is believed to enhancethe responseto. In this study the recombinant
NRP-1 proteins, activated VEGFR-2 and downstream signalling on their own. This discovery
is important as it opens another modeof action of NRP-1 and adds one more mechanism
responsible for driving the angiogenic responsesin cells.
Future directions
Altogether, the data include novel observations andit will be important to follow the suggested
hypothesis. In particular, the issue of the diversity of the soluble isoforms should be addressed
to verify if any species of properties similar to Fc rNRP-1 are present in vivo. Secondly, the
similarity of the Fc rNRP-1 and membrane oligomerised NRP-1 needsto be confirmed.
Next issue to investigate is the ability of the membrane and soluble NRP-1 isoforms to
dimerise. This would shed somelight on the membraneandsoluble pools of NRP-1, and would
facilitate design and interpretation of the research projects applying recombinantproxies of the
particular isoforms. Additionally, it could confirm the predicted functional variability among the
distinct isoforms, pronouncedin this study by different heparin-binding properties. Possible
functional differences between isoforms could also help analyse the dynamics of the changing
pools of NRP-1 in responseto certain stimuli.
Next, the experiments in cells that could clarify if the biophysical data on NRP-1 require-
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ments of polysaccharide binding have implications on the functional regulation of NRP-1. This
would require designing challenging cell biology experiments where the effect of particular
heparan-sulfate mimetic structures on signalling/ responses could be investigated indepen-
dently of each other.
Anotherissue, this time derived from the endothelial cells study, is the surprising proan-
giogenic effect of the shNRP-1. As currently, both anti- or proangigenic properties of solu-
ble NRP-1 are documented,a localised context-dependent activity of the soluble NRP-1s is
tempting to propose and should be tested. The issue of the shNRP-1 biotransport and in vivo
interaction with polysaccharides could additionally help to create a model on its mechanism of
function and possible modulation ofactivity.
Also, the fact that dimerised NRP-1 can mediate angiogenesis alone without VEGF ligands
needs to be further explored, and, the final outputs should be included in the mathematical
models of angiogenesis [93]. This could uncover more comprehensivepicture of the dynamics
of the angiogenesis.
Finally, several structural aspects of NRP-1, while being indicated and discussed in the
study,still require further research. First of all, the c domain with the adjacent importantlinkers
awaits crystallisation and presentation of its most complete structure. In a larger scale, an
assembly of the full set of the domains into a comprehensive structure needs to be done. As
a consequence,the interpretation of the P&L experiment and design of the validating exper-
iments would becomeeasier. At the same time, general understanding howlarge proteins,
such as NRP-1, may interact with polysaccharides would bebetter.
Hopefully, elucidation of some of these mysterious aspects of NRP-1 biology will be achieved
and soon, the picture of NRP-1 will bring some orderinto the more chaos-driven NRP-1 field
at the moment.
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1. ABSTRACT
Neuropilins are a vertebrate-specific family of
membrane multidomain proteins. They are crucial for the
embryonic development of neural and vascular systems,
whereas in the adult organism they are implicated in many
processes, such as angiogenesis and the immune response.
Additionally, it has been shownthat they are overexpressed
in numerous types of tumours, which results in higher
microvessel density and correlates with poor prognosis.
Their functions have been linked to their binding partners:
semaphorins/collapsins, vascular endothelial growth factors
(VEGFs), fibroblast growth factors (FGFs), hepatocyte
growth factor/scatter factor and heparin/heparan sulfate
(HS). Multiplicity of ligands alongside complex formation
with several membrane receptors makes neuropilins
potential ‘hub’ proteins, which act as a scaffold for
multimeric associations. This review focuses on the
structural features of neuropilins that underpin their
multiple molecular interactions and hencetheir functions.
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2. INTRODUCTION
Neuropilin 1 (NRP-1) was first identified as
antigen A5, which was proposed to be a recognition
molecule in the visual centre’s neural cells (1) and a
promoter of neural overgrowth (2). Subsequently, it was
found to be a_ receptor for a family of
semaphorins/collapsins responsible mainly for
chemorepulsive neuronal responses, causing the collapse of
the growth cone in nervous system development (2-4),
however, a mediation of chemoattractive stimuli was
also suggested (5). Additionally, the interaction of
semaphorins with neuropilin-1 was linked to conveying
an apoptotic response in neurons (6), which was
dependent on the presence of neuropilin-l. A
homologoue to the  neuropilin-1 receptor for
semaphorins was identified and named neuropilin-2
(NRP-2) (7-9). Similarly to neuropilin-1, neuropilin-2
was identified as playing a part in nervous system
development(10).
Neuropilins
2.1. Neuropilins’ splice variants
In humansthe gene encoding neuropilin-1 maps
to chromosome 10 and that encoding neuropilin-2 to
chromosome 2 (11). Both proteins are around 140 kDa and
can be glycosylated. The two neuropilins, although
encoded bydistinct genes, arose from gene duplication and
are structurally related, and consist of the same set of
domains, the al, a2, bl, b2 and c extracellular domains, a
transmembrane domain and a short intracellular domain
(12), where the al and a2 domains belong to the CUB (for
complement Clr/Cls, Uegf, Bmp1) family, the b1 and b2
domains belong to the FAS8C (for coagulation factor 5/8
C-terminal domain) family and the c domain belongsto the
MAM(for meprin/A5-protein/PTPmu)family.
As a result of alternative splicing, there are
several splice variants of both neuropilins (7, 11, 13, 14).
Human neuropilin-1 has six splice variants, where four of
them are soluble forms (Figure 1), while neuropilin-2 has
five splice variants, but only one encodes a soluble form
(Figure 2) (11, 15, 16). The highest diversity in sequence is
observed in the C-terminal part of the proteins (starting
where the b2 domain ends), which results in soluble forms
that lack fragments of sequence or possess different
sequence as a consequenceofalternative splicing or the use
of different open reading frames. In the case of neuropilin-
1, all isoforms share the al, a2 and b1 domains. The longest
one (923 amino acids, isoform a) has also the b2 and c
domains. Similar to isoform a is neuropilin-1 (906 amino
acids, delta exon 16), which lacks small fragment between
the c and the transmembrane domains. Amongthe soluble
isoforms, there are two truncated neuropilin-1 proteins,
lacking the C-terminus, including the c domain. These are
sineuropilin-l (644 amino acids, isoform b) and
sivneuropilin-1 (609 amino acids, isoform c), where the
latter also lacks a small fragment within the b-c linker, but
they both contain intron 12 derived C-terminal 3 amino
acid sequence (GIK). The other two soluble neuropilin-1s
differ substantially in C-terminal sequences with respect to
the other isoforms. The ,;,;neuropilin-1 isoform shares with
other neuropilin-1 isoforms a fragment in the b-c linker,
while further sequenceis intron 11 derived, althoughit still
shows some sequencesimilarity to the linker and c domain.
The last soluble form (551 aa, ,,meuropilin-1) is the only
one lacking part of the b2 domain and the rest of the C-
terminal sequence, and it uses a different reading frame in
exon 12, which results some sequence similarity with the
b2 domain.
Among the neuropilin-2 isoforms it is interesting
that all but one share all 5 domains (al, a2, b1, b2, c). The
shortest isoform (555 aminoacids, s9, isoform 6)is soluble,
lacks part of b2 domain together with the rest of the C-
terminus and similarly to ,;;neuropilin-1, it has an intron 9
derived C-terminus, which showssimilarity with the b-c
linker. The longest isoform (931 amino acids, 2a22,
isoform 1) has the full set of domains with transmembrane
and intracellular domains. The 926 amino acids isoform
(2a17, isoform 2) is missing 5 amino acids between the c
domain and the transmembrane domain. The remaining two
isoforms (grouped as isoforms b in contrast to the
previously described two full-length isoforms a) have a
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distinct C-terminus, which is a result ofalternative splicing
and is suggested to encode a functional transmembrane and
intracellular domain. The difference in length is due to a
short fragment after the c domain that the longer isoform
encodes (906 amino acids, 2b5, isoform 4), but not this
shorter isoform (901 amino acids, 2b0, isoform 5).
Analysis of mRNA expression patterns of
variants has revealed that the isoforms are not equally
expressed in human tissues. The tissue specific expression
pattern of neuropilin-1 isoforms seems to be largely
overlapping (brain, heart, kidney, liver, lung, pancreas,
placenta, trachea), however, the mRNAlevel of isoforms
IIIs and IVs of neuropilin-1 is 3 and 10 times less abundant,
respectively (11, 15). Contrary to neuropilin-1, the isoforms
of neuropilin-2 seem to have a more diversified pattern of
expression. While isoforms a of  neuropilin-2 are
dominating in liver, small intestine and placenta, the
isoforms b dominate in heart, skeletal muscles and lung.
Interestingly, difference in expression levels between the
two known isoforms a (2a22 and 2a17) was also observed
with significant predominance of 2al7 isoform and 2a22
isoform expressed in smaller amounts in lung, placenta and
trachea (11). The mechanism of the control of the
expression ofspecific isoforms is not known.
The protein sequence differences between
neuropilins indicate putative modes ofaction. Firstly, the
multiplicity of truncated/soluble isoforms suggests
competition and titration mechanisms, where soluble
isoforms would be responsible for binding of potential
ligands and, therefore, would diminish the local
concentration of the ligand available to form signalling
complexes with membrane-boundneuropilins. The ligands
of neuropilins titrated out by competing soluble isoforms
are not known. However, this has been questioned, as the
level of these isoforms may not always be physiologically
significant (15). Nevertheless, a competition related
antitumour property was confirmed in vivo with a
signeuropilin-1 overexpression system. In addition, the
difference between transmembrane and cytoplasmic fragments
gives rise to a potentially greater multiplicity of interacting
partners. The various short length insertions could possibly
disrupt domain structure and consequently structure-dependent
interactions, e.g., dimerisation. However, in several studies, no
difference in binding features between the short and full length
isoforms was detected. Thus, gistv/si2neuropilin-1s interaction
with VEGF165 and SEMA3A was confirmed in binding
assays (15), independently interaction of VEGF165 with
sizneuropilin-1 in crosslinking experiments was demonstrated
(16) and neuropilin-1(deltaexon16) VEGF 165 interaction was
confirmed as well (13).
Together with the varied expression pattern, these
features expandthe possibilities of the mechanism ofaction
of these related proteins. Moreover, it seems that a similar
set of functional domains is not only characteristic of
neuropilins. One other protein was discovered in human
coronary arterial cells, ESDN (endothelial and smooth
muscle cell-derived neuropilin-like molecule), which
contains CUB and FAS8C domainsand it was suggested to
play a variety of roles akin to those of neuropilins (17).
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Figure 1. Humanneuropilin-1 isoforms analysis; a) schematic representation of multiple alignment, the names of isoforms and
domainsare indicated, alternative sequencesare labelled in green; b) detailed multiple alignment in ClustalW color mode, the
sizes of isoformsare indicated together with their symbols and the domains are marked above the sequence.
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Figure 2. Human neuropilin-2 isoforms analysis; a) schematic representation of multiple alignment, the names ofisoforms and
domainsare indicated, alternative sequences are labelled in green; b) detailed multiple alignment in ClustalW color mode, the
sizes of isoformsare indicated together with their symbols, and the domains are marked above the sequence.
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2.2. Neuropilins’ expression and function
Genetic studies aiming to elucidate functions of
neuropilins have been carried out. In mice, deletion of
neuropilin-1 is embryonically lethal in E12.5, and causes
defective neural patterning and vascular regression (2, 18).
Interestingly, the neural phenotype resembled the knockout
of Sema3A, while the vascular phenotype in comparison to
VEGFR2 knockout suggested a requirement for neuropilin-
1 in late embryonic vasculogenesis and the early
development of the cardiovascular system. Neuropilin-1
overexpression also has severe consequences, namely heart
and blood-vessel formation abnormalities such as excess
capilaries and vessels and hemorrhaging and malformation
of heart, as well as defects in the nervous system and limbs
(19). Significantly, it was shown that neuropilin-1 and
neuropilin-2 knockouts do not have the same phenotypes.
Neuropilin-2 knockouts have a 40% death rate occurring
close to birth and survivors, apart from being smaller in
size, have reduction of lymphatic vessels and capillaries or
their missposition and neuronal defects (10, 20, 21). In
these mutants no change in the blood vessel system was
observed. Interestingly, it was shown that both knockouts,
neuropilin-1_ and neuropilin-2, became unresponsive
towards their semaphorin ligands, Sema3A and Sema3F,
respectively (2, 10). Simultaneous knockouts of both genes
causes E8.5 embryoniclethality (22).
Although these most severe defects after
interference with native levels of neuropilins affect mainly
blood-vessel and neural systems, neuropilins have been
confirmed to be expressed in manyothertissues, often in a
specific manner. Generally, both neuropilins have been
shown to be expressed by several types of organs and
tissues, which makes them a wide ranging interacting
partner, however, their mRNAexpression patterns are often
not overlapping (7, 23). This emphasizes the issue of the
likelihood of neuropilin-1 and neuropilin-2 possessing
distinct functions. In the case of endothelial cells it has
even been suggested that, while arterial areas express
neuropilin-1, veins produce mainly neuropilin-2, and that
this pattern of expression might affect tissue identity (24).
A hormone driven interplay between neuropilin-1 and
neuropilin-2 in human endometrium was also observed.
Underthe natural menstuation cycle an estradiol-dependent
upregulation of neuropilin-1 in the proliferation phase was
followed by neuropilin-2 upregulation in the secretion
phase, whichis also indicative of distinct functions for the
two proteins (25).
Information about the function of neuropilins can
be also deduced from data on the regulation of the
expression of their mRNAs. There have been several
transcription and growth factors identified that influence
their expression (reviewed in (23)). Ets-1 (26), dHAND
(27), SP1 (28) and API (28) increase expression of
neuropilin-1 mRNA. Ets-1 and dHAND upregulation of
neuropilin mRNA is generally linked to vascularisation
processes, whereas the upregulatory effects of SP1 and
API have been obtained from promoter sequence analysis
in cell culture. Growth factors identified that upregulate
neuropilin-| mRNA include TNFq@(29), VEGF, EGF (30-
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32) and IL-6 (33). TNFa has angiogenic properties in vivo,
and at the molecularlevel it has been shownto upregulate
both VEGFR2 and neuropilin-1, which has been suggested
as the mechanism whereby it potentiates VEGF action
though, in another study this effect was not observed (30).
Upregulation of neuropilin-1 has also been observed to be
associated with VEGF and EGF presenceof these growth
factors in tissue is associated with increases in the amount
of mRNAencoding neuropilin-1. In pancreatic cancer cells
IL-6 has been found to upregulate neuropilin-l mRNA. An
orphan receptor, Nurrl, was shownto upregulate the levels
of neuropilin-1, in the course of the formation of dopamine
neurons in midbrain (34). Cyclophilin A, a protein known
to be involved in the regulation of vascularisation and cell
growth, was shown to upregulate neuropilin-l| mRNA
levels in aorta smooth muscle cells (35). Among the
transcription factors responsible for downregulation of
mRNAencoding neuropilin-1 are COUP-TFII (36), Prox-1
(37), HEX (38) and NRSF/REST (39). NRSF/REST was
found to suppress the expression of neuropilin-1 mRNA in
keratinocytes. COUP-TFII, by suppressing neuropilin-1
mRNAexpression within the vasculature, permits arterial-
venial differentiation. In this process, COUP-TFII
dependent downregulation of neuropilin-1 mRNA in
_ presumptive veins enables them to acquire the
characteristics of vein. Prox! controls an analogous switch
in differentiation of blood and lymphatic endothelium.
Here, the downregulation of neuropilin-1 is a characteristic
of developing lymphatic vasculature from classical blood
vessels. Altogether, these results indicate that the expression of
mRNAencoding neuropilin-1 is subjected to a variety of
regulatory inputs, though a regulatory signalling network
responsible for the control of the levels of neuropilin mRNA
has yet to emerge. The extent to which these changes in
expression of mRNA encoding neuropilin-1 may be affected
by neuropilin-2 is not known. Moreover, in the event of co-
expression of the two neuropilins changes in their relative
expression may also affect the cellular response, though this
has yet to be documented directly.
Much less is known about mRNAs encoding
neuropilin-2. High levels of neuropilin-2 mRNA were
suggested to be major drive of axonal regeneration.
Consistently, neuropilin-2 blocking antibodies prevented
first step of regeneration, which is axonal aggregation.
Moreover, forskolin, the axon aggregation mimetic, was
able to downregulate neuropilin-2 mRNA and thus,
confirmits role in regeneration process (40).
It is worth noting that expression of neuropilinsis
also dependent on the cell microenvironment. Hypoxia,
which results in acidic pH has been found to upregulate
neuropilin mRNA.This is important, as hypoxia is a major
driver of angiogenesis and commonly occurs upon tumour
development, when a shortage of oxygen results in the
accumulation of lactate and CO, in the extracellular
compartmentand causes pH valuesto be as low as 5.5 (41,
42). Hypoxic conditions upregulate several mRNAs of
angiogenesis-related proteins, including neuropilin-1 and
neuropilin-2, which lead to enhanced vascularisation (21,
43-45). However, it is noteworthy that so far a direct link
Neuropilins
between the expression of the neuropilins‘mRNA and HIF
(hypoxia-inducible factor), a key molecular regulator ofthe
hypoxic response,has not been confirmed.
Initial studies aiming to characterise mouse gene
expression during embryonic and early postnatal
development show that neuropilin-1 mRNA is expressed in
the cardiovascular system, nervous system and
mesenchymaltissues surrounding them (19, 46). A general
pattern is that rather than being generally expressed in these
tissues, neuropilin-1 expressionis instead focused to certain
types of cells and this localised expression is often
temporally regulated. Interestingly, initial observations
suggested that neuropilin-1 might be an auto-recognition
molecule, as it was abundantin actively growing axons and
the target of these axons also expressed neuropilin-1.
Subsequently, interactions with other molecules were
identified. Consequently, another function postulated for
neuropilin was neuronal circuit formation (46). In the
cardiovascular system highlevels of neuropilin-1 are found in
vessel system epithelium and also in the surrounding blood
vessel mesenchymalcells. Additionally, expression is detected
in endocardial cells in developing heart. Interestingly, in adult
mouse the expression drops and is mainly localised to heart
atria. Neuropilin-l expression is also pivotal in limb
development, where initial high levels in mesenchymal cells
are replaced by only connective tissue expression (19). In
human adult tissues neuropilin-1 is highly expressed in heart
and placenta and at lower levels in lung, skeletal muscles,
kidney and pancreas (14). Mouse neuropilin-2 expression is
also dynamically regulated and is largely separable from that
of neuropilin-1 in the nervous system. Additional locations of
neuropilin-2 expression are limb bud muscle masses, bones,
smooth muscle of the gut, intestinal epithelium, kidney, lung,
inner ear, submandibular glands and whisker follicles of the
snout(7).
Neuropilin mRNAs share a feature of being
overexpressed in a numberofcancers, although usually not
in a redundant manner (reviewed in (23, 47, 48)). High
levels of neuropilin-1 or neuropilin-2 often correlate with
increased tumour size, neovascularisation, decreased
tumour apoptosis, tumour cell migration and clinically is
often associated with poor prognosis (49, 50). However, the
association betweenthe levels of expression of neuropilin-1
and patient prognosis is somewhat contradictory. Thus, in
colon cancer one study that measured the level of
expression ofmRNAencoding both soluble and membrane
bound neuropilin-1 suggested that neuropilin-1 expression
correlated with a better patient prognosis (51), whereas
another study that used immunocytochemistry and
presumably was biased towards the detection of cell-
associated neuropilin-! protein suggested that neuropilin-1!
wasassociated with a poor disease outcome(52).
3. SEQUENCE ANALYSIS
3.1. Origins of the domainsof neuropilins
Both neuropilins are comprised of the same set of
domains, al, a2, bl, b2 and c, where al and a2 belong to
the CUB (for complement Cl1/Cls, uEGF, BMP1) family
(53), bl and b2 belong to the FA58C (coagulation factor
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5/8 C-terminal domain) family (54) and the c domain
belongs to the MAM (for meprin/A5-protein/PTPmu)
family. CUB domains have been for some time recognised
as important elements of developmentally significant
proteins, e.g., bone morphogenic protein (BMP1), sea
urchin endothelial growth factor (uEGF) and
subcomponents of complement (ClIr/Cls), spermadhesins,
some vertebrate proteases and mammalian hyaluronate-
binding protein TSG-6. The function of CUBisrelated to
binding sugars, dimerisation (55) and_ protein-protein
interactions (56). The FAS8C domainsare characteristic of
coagulation factors and of discoidin proteins. They are
found in milk fat globule membrane proteins, receptor
tyrosine kinases and contactin-associated proteins. The
function suggested for these domains is binding of anionic
phospholipids on the surface of cells, and a consequent role
in adhesion and cell-cell recognition. The MAM domain
was found in a surface glycoprotein called meprin and a
receptor-like tyrosine protein phosphatase (RPTP mu).
MAM domains have been suggested to play a role in
protein dimerisation (57) and cell-cell adhesion (58).
Importantly, none of the neuropilins has an intracellular
domain with clear interactionor signalling motif.
According to the Blast search engine the
organisation the domains found in neuropilins evolved
relatively late and is not present in any group of organisms
other than vertebrates. However, the individual domain
families are commonly represented in many systematic
groups. CUB-like domains are found in viruses, bacteria,
euglenozoa and across metazoa; FAS8C is found in wide
range of bacteria, archea, metazoa, mycetozoa, fungi,
parabasalidea, viridiplantae, haptophyceae; MAM domain
is not found in viruses, but is present in many groups of
bacteria, in alveolata and metazoa. Therefore, neuropilins
arose from old evolutionary motifs that in this particular
juxtaposition formed a protein of new functions related to
vertebrate-specificity.
3.2. Neuropilins’ in silico sequence analysis
Although neuropilins show domain structure
similarity, comparison of the amino acid sequence between
human neuropilin-la (923 amino acids, Fig.1) and
neuropilin-2 (2a17, isoform 2, Fig.2) reveals 44% identity
(Figure 3). Moreover, the level of conservation is not
uniform throughout the sequence. The highest similarity is
observed in the transmembrane region, whereas the lowest
is in the c domain andits flanking regions that link it to
adjacent domains.In fact, analysis of the C-terminalpart of
the sequence (the transmembrane and intracellular
domains) reveals that neuropilin-2a isoforms show more
sequence similarity with neuropilin-1 than neuropilin-2b
isoforms (11). Interestingly, analysis of charged residues in
sequences of both human neuropilins shows,that although
someofthe charged residues are similar in the alignment,
there are a good numberofresidues of opposite charges in
the two proteins, which may be associated with important
differences in function (Figure 4). Comparison of human,
mouse, rat and zebrafish sequences of most similar length
gives interesting insights into evolutionary conservation.
The zebrafish sequences of both neuropilins vary
substantially from the others, which is apparent in the
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Figure 3. Comparison of most similar human isoforms of neuropilin-1 (isoform a) and neuropilin-2 (isoform 2); the sizes of
isoforms are indicated together with their symbols, the domains are marked above the sequence, the residues marked in blue are
identical.
number of mismatches, insertions and deletions,
especially in the neuropilin-2 b-c linker and c domain and
to lesser extent in the same region in neuropilin-1.
However, another isoform of zebrafish neuropilin-1,
isoform b, has severallarger insertions, e.g., 23 amino acids
in the b-c linker and 19 amino acids in the c domain (not
shown). Overall, the transmembrane and cytoplasmic
fragments seem to be most conserved between species,
which suggests that the intracellular part of neuropilins may
interact with intracellular signalling cascade proteins (59),
despite this region having no obvious signalling motifs.
Whenthe number of mismatches is considered, the a and b
domains are more conserved in  neuropilin-2 (21
mismatches versus 55 in the a and b domainsin neuropilin-
1), while in neuropilin-1 it is c domain that has the lowest
number of substitutions (8 mismatches versus 20 in the
same region in neuropilin-2) (Figure 5, 6). To summarise,
sequence analysis shows that the sequence of zebrafish
variants of neuropilins differ to some extent from those of
other organisms. Comparison between human, mouse and
rat sequences and also between human neuropilin-1 and
neuropilin-2 show distinct conservation patterns in different
parts of the protein, which is a good indication of putative
diverse functions.
Interestingly, the in silico analysis of neuropilin
sequences in search of putative N-glycosylation and O-
glycosylation sites reveals one possible important feature of
the multiple splice variants (Figure 7, 8) (60, 61). Most N-
glycosylation sites are located in the regions shared by all
neuropilin-1 and neuropilin-2 isoforms. Thus, among
neuropilin-1 isoforms, four out of six N-glycosylation sites
are shared, whereas the sites in the flanking regions of
transmembrane domain are shared only by the two longest
variants of neuropilin-1. In neuropilin-2 isoforms, two out
of four sites are common, one site is absent only in the
mosttruncated isoform 6, and another is only present in the
two longest variants of neuropilin-2. Analysis of potential
O-glycosylation sites reveals that there are two suchsites in
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both proteins and they localise in both cases to the b-c
linker, the least conserved part of the sequence. In
neuropilin-2 both predicted sites are shared by all isoforms
except for isoform 6. In neuropilin-1 there are also two
potential O-glycosylation sites and the shortest isoform sIII
lacks both, while the s11 and sIV isoforms have just one,
but each of them has a different one. Isoforms a, b (s12)
and delta exon 16 share both putative sites. Serine 612 of
neuropilin-1 isoform a, which has been suggested to be
facultatively glycanated by the glycosaminoglycans
heparan sulfate and chondroitin sulfate (62), is located very
closely to the region containing the predicted O-
glycosylation sites. It is important to note that the
interdomain linkers in both neuropilins have no recognised
structure. These are likely to be important in mediating
domain orientation, interactions with other proteins and
contain posttranslational modification sites (63). Thus,
these putative posttranslational modification sites could be
a part ofthe regulation of the function of neuropilins.
4. NEUROPILINS’ INTERACTOME
The number of different molecular interactions
that neuropilins make describe an ever-increasing catalogue
of partners. These interactions are, where it is known,
associated with particular domains of neuropilin. Alongside
the large number of normal and pathological events where
neuropilins have been suggested to play important
regulatory functions, this suggests that the domains of
neuropilins may provide a set of modules involved in
multiple molecular interactions. Thus, one view of
neuropilins is as a scaffold for cell-cell and cell guidance
signalling.
Initially, molecules related to the function of
neuropilins were discovered in the neural system, e.g.,
plexins, semaphorins (firstly SEMA3A) (64).
Subsequently, more interacting partners were discovered,
like L1-CAM, which is an adhesion molecule that can
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(isoform 2); the sizes of
isoforms are indicated together with their symbols, the domains are marked above the sequence, the basic and acidic residues are
marked blue and red, respectively.
modify the SEMA3repulsive signals (65). The next group
of partners of neuropilins were the glycosaminoglycans
heparan sulfate, the dominant scaffold and long-range
integrator of extracellular signals (66) and members ofthe
VEGFfamily that bind to heparan sulfate (67). The latest
group of partners of neuropilins are prion protein, several
members of the FGF family (fibroblast growth factor) and
HGF/SF (hepatocyte growth factor/scatter factor) and
receptors such as FGF receptor | (68), VEGF receptors
(69-71) and integrins (72). These proteins are structurally
unrelated and apart from integrins they possess in common
only one feature: binding to sulfated glycosaminoglycans
such as heparan sulfate. Not typical was the discovery of
NIP (neuropilin-1 interacting protein), a protein
containing the common protein interaction motif PDZ
that binds the intracellular part of neuropilin-1 (59).
Adding to this complexity are dimerisation and possibly
higher order oligomers of neuropilins that have been
observed (9, 68, 73, 74). Interaction with heparan
sulfate may modify binding affinities and is likely to
bring neuropilin into proximity with many complexes
involved in cell adhesion and cell-cell communication.
In some cases the protein-protein interactions were
suggested to occur upon heparin binding, e.g. interaction
of neuropilin-1 with VEGFR2 (75) or neuropilin-1/2
with VEGFD (76). Additionally, it has been
hypothesised that heparin/heparan sulfate might cause
multimerisation of neuropilin-! (69), however, a
mechanism whereby heparin/heparan sulfate serves as a
docking molecule for multivalent interactions with
neuropilin-1 has also been suggested (77).
4.1. Structural features of neuropilin interactions
The structure of neuropilins suggests they might
be a scaffold for protein-protein interactions. This idea is
supported by an increasing body of evidence from studies
using a variety of approaches such as deletion analysis,
mutagenesis, crystallography and biophysics.
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Investigation of semaphorin binding until
recently had no underpinning from structural biology.
Thus, what wasinitially suggested from deletion studies
wasthat the sema domain of semaphorins bound the ala2
domains and that these interactions defined the specificity
of binding, whilst basic C-terminal region of semaphorins
binds to ala2 and blb2 (4, 78, 79). In another study the
semaphorin specificity was attributed to both regions of
ala2 and blb2 domains (9). In parallel, it was shown for
neuropilin-2 that binding SEMA3Frequired both ala2 and
blb2 domains (80). Subsequent work refined the
identification of potential semaphorin binding sites by
mutational analysis. Basing on structural alignment of the
neuropilin-| al domain and bovine spermadhesin CUB
domain, residues likely to be exposed to solvent in the al
predicted loop regions were identified and mutated into
residues of opposite charge (residues 46, 47, 51, 52, 53, 79,
80, 128, 129, 130). The introduced mutations inhibited
binding of semaphorin, but not that of VEGF. Importantly,
these mutations had inhibited the binding of both SEMA3C
and F, indicating that the discrimination between these two
semaphorins was lost. Also, no effect of these mutations
was observed on the interactions with plexin and VEGFR2
(79). Recently, this body of data could be compared to a
crystallographic model of neuropilin-2 domains al to b2 in
complex with a semaphorin-specific blocking antibody
(77). The region where the antibody is binding neuropilin-2
is in al (residues 39, 45-47, 72-77, 107, 138) and is highly
conserved in the neuropilin-1 al domain. The antibody
binding area appears to be adjacent to the region
characterised by Guet al. as a semaphorin binding region,
therefore, together these data span the semaphorin binding
site on a larger interface of the al domain. Moreover, as a
putative calcium binding motif was discovered in crystal
models of the al domain in close approximity to the
characterised semaphorin binding site, it was shown that
the interaction with semaphorins is indeed calcium
dependent(77).
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Comparison of most similar human (isoform a), mouse, rat, zebrafish (isoform a) neuropilin-! sequence; the sizes of
isoforms are indicated together with their symbols, the domains are marked above the sequence, the residues marked in blue are
identical.
By and large the analysis of VEGF165 binding
structures in neuropilins has been supported by subsequent
crystallographic models, initially of the human b1 domain
and then of rat blb2 domains (81, 82). Similarly to
semaphorins, it was shown by deletion analysis that the
blb2 domain is crucial for the binding of VEGF165 to
neuropilin and that the additional presence of the ala2
domain enhancedthe binding (79, 83). Similar results were
obtained for the interaction of VEGF165 and neuropilin-2
(80). On the other hand the related PIGF was suggested to
bind to only the blb2 domain of neuropilin-1 and its
binding sites in the b domains was thought to overlap with
that of VEGF165 (83). Mutational analysis of neuropilin-2,
based on sequence similarity with the known neuropilin-1
b1 domain crystal structure, indicated the electronegative
loop in the bl domain as the putative binding site of
VEGF165 (residues 284, 287, 290, 291). As the interaction
between neuropilin-1 and VEGF165 was suggested to
occurvia the positively charged heparin binding domain of
VEGF (68), the mutation of electronegative residues
reduced the binding of VEGF165, whilst mutations
introducing more electronegative residues enhanced
binding of the growth factor. No change in the Kd for
SEMA3Fbinding was observed as a consequence of these
mutations (80). The crystal of the b1b2 domain with tuftsin,
a peptide analogue of the basic heparin binding domain in
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the C-terminus of VEGF, suggests a binding site for this
domain of VEGF 165 in a part of bl (residues 297, 301,
320, 353, 346, 349) adjacent to the area mutated in
neuropilin-2 (80). Interestingly, the binding pocket
identified in the crystallographic model fits the basic tail
that of VEGF 165, tuftsin and SEMA3A,however,the latter
lacks the C-terminal arginine, which seemsto be crucial for
the binding. Consequently, it has been suggested that
several modes of ligand binding are possible (82). This
binding site was further confirmed in a study where a
crystal of neuropilin-1 b1 domain with VEGF165 blocking
antibody was obtained, however, a broader interface
between these molecules was suggested, spanning the b1b2
domain of neuropilin-1 towards putative heparin binding
site (77).
The physical and functional relationship of the
binding sites semaphorins and VEGF in neuropilin is
contentious. A competition effect of SEMA3A and
VEGF165 was observed in cell migration and growth cone
collapse assays (84). Functionally, in lung cancer VEGF
was suggested to promote tumour development while
semaphorins were suggested to act as inhibitors of this
process (85). Additionally, mechanism of VEGF dependent
neuropilin-1 internalisation was observed and explained as
a support of preferential VEGF signalling inhibiting
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neuropilin-semaphorin interactions (86). Interestingly,
competition with semaphorins was not observed for
VEGF121, VEGFB and FGF2 (86). Similarily, it was
shown that neuropilin-2 complexed with VEGFR2/3
promotes cell survival by interaction with VEGFA/C,
which is functionally inhibited by interaction of neuropilin
with SEMA3F (87). This idea was supported by a
crystallographic study of the bl domain of neuropilin-1,
and it was suggested that a pocket binding C-terminal
arginine of VEGFanalogtuftsin can possibly accommodate
also basic tail of semaphorins (82). Nevertheless, recent
studies argue against a physical overlap of the VEGF and
semaophorin bidning sites. Firstly, mutation and deletion
studies aimed at characterising the VEGF and the
semaphorin binding sites indicate that these are locateD
within different domains of neuropilin, i.e. while VEGF
binds mainly b1b2 domains, the semaphorins interact with
ala2 domains (79, 80). Secondly, the ability of semaphorin
binding to the same pocket as VEGF was excluded because
of a lack of the highly conserved arginine as the very C-
terminal residue, which is crucial for interaction with the
VEGFanalog tuftsin (77). Thirdly, crystal structure study
depicting binding sites for both ligands by analysis of
structures of neuropilin domains with ligand binding
blocking antibodies suggests that the biding sites are
separated by 65 Angstrom. This independenceof bindingis
also supported by optical biosensor experiments in which
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footprinting of SEMA3A and VEGF165 binding sites in
neuropilin was attempted and interpreted as independent
event (77). Finally, functional independence is indicated
by experiments in mouse develoopment. A study in
branchiomotor neurons expressing neuropilin-1 showed
that the axon and somata have distinct affinities for
VEGF165 and semaphorins and it was suggested that the
somata is controlled by VEGF165, while the axon by
semaphorins in a neuropilin-1 dependent manner without
competition between tehse ligands (88). In other mouse
developmental studies only selective preference for distinct
ligands was observed during development of vascular and
neural systems without direct competition (89). Taken
together, it seems as if physical competition for binding to
neuropilin may not occur, but that it is possible to engineer
a situation where instances functional competition does
take place. A comprehensive and quantitative analysis of
the interactions of neuropilin with these and other ligands
would certainly help to determine the circumstances
necessary for competition (functional or otherwise)
between VEGFand semaphorins to occur.
Qualitative binding studies have suggested that
a tetradecasaccharide is the minimal structure able to bind
the blb2 domain of neuropilin-1. It has been further
suggested that a mechanim of dimerisation of neuropilin is
mediated by heparin at a 2:2 ratio of heparin:neuropilin.
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Figure 7. /n silico analysis of human isoformsof neuropilin-1; the sizes of isoformsare indicated together with their symbols, the
domains are marked above the sequence, sequencesin black frame are putative N-glycosylation sites, sequences in red frame are
putative O-glysylation sites, sequence in green frame is transmembraneregion.
However, giventhat there is no direct evidence for
an interaction between neuropilin molecules in such
polysaccharide-protein complexes, it remains to be seen
whether heparin does in fact cause neuropilin dimerisation or
whether, by virtue of this polysaccharide possessing multiple
overlapping bindingsites it simply “bridges” neuropilins. The
residues involved in heparin interaction based on the crystal
structure are 359, 373, 513, 514, 516 and locate on the surface
of blb2 adjacent to tuftsin binding pocket, therefore, such
proximity may support a mechanim ofincreased affinity for
VEGF165 mediated by neuropilin-1 (77, 82).
Dimerisation of neuropilins has been also
suggested to occur through the c domain. However,
4349
mutants without c domains still show a degree of
dimerisation and, therefore, another domain may also
mediate neuropilin homophilic interactions (4). Moreover, it
has been shownthat interactions between neuropilins are likely
to be driven by ionic bonding (68). In crystallographic studies
an additional dimerisation role was ascribed to the al domain,
due to its conservedputative interface and flexible character. A
model where dimerisation via the al and c domains together
with heparin interaction take place was suggested. Consistent
with this model is enhanced VEGFbinding and independent
location of semaphorin binding site in such a dimer (77).
As neuropilins mediate cellular responses,
requirements for signal transduction were studied. It was
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Figure 8. /n silico analysis of human isoformsof neuropilin-2; the sizes of isoformsare indicated together with their symbols, the
domains are marked above the sequence, sequences in black frame are putative N-glycosylation sites, sequences in red frame are
putative O-glysylation sites, sequence in green frame is transmembraneregion.
shownin chick neural growth cone assay that the elicited
responseis strongly dependentfirstly on the presence ofthe
ala2 semaphorin binding domain, secondly on the c
domain, and to lesser extent it was observed that full
potency of signal requires the blb2 domain.
Interestingly, it was also shown that transmembrane and
intracellular parts of neuropilins, even upon deletion,
were completely irrelevant for signal transduction in this
model(3, 4).
An important feature of neuropilin-1 is its so-
called adhesive function (90, 91), which structural
requirements were also studied (78). This has been mapped
by deletion experiments and synthetic peptide binding
assays. The adhesion region was found within the b1b2
domain (residues 347-364 in bl and 504-521 in b2) andits
function was neither enhanced nor competed by VEGF 165,
SEMA3Aand plexins. Intriguingly, this suggested region
responsible for the adhesion function of neuropilin-1
overlaps with the putative heparin binding site of the
protein (82), suggesting that neuropilin interactions with
4350
proteoglycans may be responsible for at least part of the
neuropilin’s adhesion function.
4.2. Functional aspect of neuropilin interactions
The main functions of neuropilins that have been
identified with certainty are associated with vessel and
neural systems. In mouse development, both neuropilins
are essential in embryonic angiogenesis (18, 22) and
similarly for neural system development (92, 93). Also,
both of them were confirmed to be important for neural
migration (93-95) and they are involved in endothelial cell
migration (87, 96), cell survival (87, 97) and vascular
permeability (25, 98). Endothelial neuropilin-1 in adult
organisms is also involved in wound angiogenesis (99).
Related to neuropilins’ endothelial localisation is a
developmental role in kidney morphogenesis, where they
seem to provide a morphogenetic guide plan (100). Similar
developmental roles of neuropilin-1 were observed in
salivary gland formation and lung development (101, 102).
This shows that neuropilins have pivotal functions in
development. Anotherfield where neuropilins seem to play
Neuropilins
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an importantrole is the immune system (103). Neuropilin-1
was shownto be involved in the primary immune response
(104) and the migration of thymocytes (105). The presence
of neuropilin-1 in basophils is interpreted as a possible
means whereby basophils regulate angiogenesis (106).
Other studies suggest that neuropilin-1 is involved in the
regulation of hematopoiesis (107). A tissue/organ specific
summary table presents neuropilin expression data (Table
1). Despite such widespread expression and a wealth of
data suggesting that neuropilins play important roles in
vertebrate development and homeostasis, the mechanisms
whereby neuropilins exert these functions are not well
defined. What is known is largely focused around the
molecular partners of neuropilins and the association of
theseinteractions of neuropilins with biological activities.
The original partners of neuropilins, the class
III semaphorins, require neuropilin co-receptors such as
plexins or LI subfamily molecules to transduce
intracellular signals (65, 108). Semaphorins are a
versatile group of membrane-associated or soluble
proteins classified into eight families, where class 3 in
humans consists of 7 members, named A to G. It is
noteworthy that neuropilins do not interact with all
isoforms equally and within those that interact, the
affinities have different values. Thus, the main ligand
for neuropilin-1 is SEMA3A,while for neuropilin-2 it is
SEMA3F (109). Additionally, proteolytic modifications
may influence the binding properties of semaphorins
(110). The expression pattern, interactions and
signalling mechanism of semaphorins has been
thoroughly studied (reviewed in (111)). The interaction
with neuropilins seems to be crucial for neural
development by causing a chemorepulsive signal in
axon guidance (reviewed in (64)) and the expression of
semaphorins and neuropilins in neural systems reveals
high level of complementarity, which suggests
semaphorin function in defining repulsive regions (8, 9).
Importantly, it is suggested in different subpopulations
of cells at different stages of embryonic and postnatal
development the same semaphorins (SEMA3A/E/F)
could have either repulsive or no effect on axonal
response due to differential expression of partners such
as neuropilins (112). 4351
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In the neural system several functions of class III
semaphorins were observed. The main function related to
neuropilins acting as receptors for semaphorins is to
generate a repulsive signal for growing axons, whichis best
studied for SEMA3A (3, 74, 113). Also for SEMA3E/F
mediation of a repulsive function was suggested though no
direct link with neuropilins was identified for this activity
(113, 114). Semaphorins have diverse functions and in fact
they are able to antagonise each other, e.g., SEMA3A
inhibits neural overgrowth via neuropilin-1, whereas other
semaphorins, such as SEMA3C and B, cannot induce such
a response and may even block it. Interestingly, while
SEMA3B/C act as antagonists of neuropilin-1, they are
agonists of neuropilin-2 and via this molecule they can
induce growth cone collapse (74, 115). It is noteworthy in
the latter respect that only SEMA3A does not interact with
neuropilin-2 (7). Similarly, it was shown in zebrafish that
SEMA3D elicits both repulsive or attractive signals,
depending on subset of neuropilins expressed in cells (116).
Other important developmental roles have been observed
for SEMA3B,which together with neuropilin-2 is involvedin
positioning the anterior/posterior orientation of the anterior
commissure, a major brain commissural projection (71). Non
neural developmental function is ascribed to SEMA3A/C and
SEMA3C/F, where they are involved in regulating the
processes of salivary gland formation and lung branching,
respectively (101, 102). Also SEMA3G in zebrafish was
shown to have a function in heart formation (117).
Additionally, SEMA3C has been observedto elicit prosurvival
responses in neurons, which correlates with the presence of
neuropilins (118). SEMA3F, the main interacting ligand of
neuropilin-2, was shown in rat cerebellar cone cells, which
only express neuropilin-2, to elicit a chemoattractive rather
than a repulsive signal (119). SEMA3F wasalso shown to
be important for axonal wiring in guanylate cyclase-D
expressing olfactory neurons together with neuropilin-2
(120). SEMA3Fis also suggested to control neural crest
cells migration together with neuropilin-2 (93). Therefore, a
set of functions of semaphorinsrelatedto their interaction with
neuropilins emerges, as they can elicit not only
antagonising guidance signals, but direct also important
developmental functions. The complexity of the signalling
network, which is a result of multiple members of
semaphorin family, permits a very
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160
160 
fine mechanism of control and, thus, implicates an
importantrole for neuropilins.
As neuropilins are implicated in the formation
and progression of tumours, the impact of semaphorins in
these processes has been studied. In human pancreatic
cancer, high levels of SEMA3A were suggested to be
associated with an increase in the malignancy of the
tumours and also correlated with higher levels of
expression of neuropilin-1 (121). In contrast, in endothelial
cells SEMA3A wassuggested to decrease cell proliferation
in a neuropilin-dependent manner and the inhibition of
expression of both neuropilins resulted in the cells losing
their sensitivity to pro-apoptotic signals caused by Sema3A
(122). SEMA3F expression has been linked to reduced
tumorigenicity and tumour formation, which wasattributed
to its interaction with neuropilin-2 and the inhibition of the
activities of VEGF165 and FGF-2 (123-125). Another
semaphorin, SEMA3B, was shown to enhance apoptosis
and reduce mitosis in a neuropilin dependent way in lung
and breast cancercells (126). This finding is important, as
it relates neuropilins to the cancer field where sets of
proteins of given properties can drive pathological process,
and therefore expands the potential complexity of the
molecular networks that drive tumour progression and
metastasis.
Another large group of neuropilin interacting
ligands are members of the VEGF family. This family
consists of five members in mammals, VEGFA, B, C, D
and PIGF (reviewed in (127)). The functional importance
of the interaction of neuropilins and VEGFsis related to
angiogenesis (128-130) and neural development (131).
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Several mechanisms such as alternative splicing and
proteolytic processing (by matrix metalloproteinases or
plasmin) diversify the number of bioavailable VEGF
isoforms (132-134). Interactions with neuropilins involve a
specific subset of these variants (Table 2), while signal
transduction is thought to occur via the canonical VEGF
receptor tyrosine kinases (127). It is noteworthy that much
less is known about neuropilin-2 function and VEGF
family members than about neuropilin-1. The feature that
seemsto be required for VEGFto bind to both neuropilins
are exons 7-8, where exon 7 encodes the heparin binding
site in VEGF. Thus, the VEGF121 isoform that lacks the
ability to bind heparin does not interact with neuropilins
(14, 135). An absence of interaction with neuropilin-1 was
also shown for isoforms lacking only exon 8, such as
VEGF165b and VEGF159 (136). Another unusual isoform
is VEGF145,which also lacks exon 7, however,it can bind
heparin and is able to interact with neuropilin-2, but not
neuropilin-1 (137). In one study VEGF121 was found to
interact with neuropilin-1 with an affinity similar to that of
VEGF165, which was explained by the fact that
commercial VEGF121 lacks the C-terminus, which is
crucial for the interaction with neuropilin-1 (138).
However, not all studies with VEGF1I21 have used C-
terminally truncated protein, for example, full-length
VEGF121 produced in baculovirus also fails to bind to
neuropilins (70). Nevertheless, in two independent studies
similar concentration of VEGF121 was observed to elicit
either similar effect as VEGF165 or much weaker (138-
140).
Next, neuropilins can bind to VEGF receptors
and it was shown that neuropilin-1 can interact with
VEGFR2 (141) and VEGFR1 (69), while neuropilin-2 can
interact with VEGFRI, VEGFR2 and VEGFR3 (76, 87,
142). Apart from VEGFs which can bind both VEGFRI1/2,
neuropilin-1 can also bind VEGFRI specific PIGF and
VEGFB, and VEGFR2 specific viral VEGFE (143-145).
The interesting feature of neuropilins is that they may
participate in the formation of signalling complexes not
only in cis, but also in trans, between twocells (75). The
formation of complexes between neuropilins and ligands
and receptors for VEGF has been suggested to have several
effects. Thus, it was shown that VEGF165 may possess a
higher signalling potency, compared to that of VEGF121
although they both bind VEGFR2 with similar affinity, due
to interaction with neuropilin-1 and formation a ternary
complex neuropilin-1-VEGF165-VEGFR2 (141).
Moreover, it was shown that mutagenesis of VEGF165,
which blocked its binding to VEGFR2, but not to
neuropilin-1, resulted in the phosphorylation of VEGFR2
(70). Interaction of neuropilin-1 with VEGFR2 was
suggested to result in an enhancement of signalling
potency, however two possible mechanismsexplaining this
were proposed. In one this enhancement was thought to be
due to the formation of a complex without affecting the
complex affinity for ligand (14, 141). Whereas in a
different study, a mechanism whereby neuropilin enhanced
ligand affinity was proposed (69). Interestingly, in case of
neuropilin-1_ and VEGFRI complex no influence on
VEGF165 complex affinity was observed (69).
Importantly, the formation of complexes between
Neuropilins
neuropilin-1_ and WVEGFR2 was questioned and a
VEGF165-dependent, but not VEGF121, mechanism was
suggested (75).
The formation of complexes between neuropilins,
VEGFligand and receptor is complicated by the fact that
all three types of proteins also interact with heparan
sulfate/heparin. Some work has focused on identifying the
relationship between these four partners. In one study it
was suggested that neuropilin-1-VEGFbinding is strongly
enhancedbythe addition of heparin, in a manner dependent
on the size of the heparin oligosaccharides. This was
explained by longer fragments of heparin affecting the
avidity of the complex (69, 135). Heparin may also be
important for the interaction of neuropilin-2 and VEGF165
(76). It is also suggested to inhibit binding of neuropilin-1
and VEGFRI, which is consistent as the
VEGFRI:neuropilin-1 binding site overlaps with the
heparin binding site. Interestingly, an interplay between
VEGF165 and VEGFRI to bind neuropilin-1 was shown,
which implicates overlapping binding sites for these two
targets in neuropilin. Consequently heparin was suggested
to have negative regulating effect as it interferes with
VEGFRI binding but enhances VEGF165 binding (69). A
related study demonstrated that glycanylated neuropilin-1
may increase VEGF165 binding and signalling, thus
showing the importance of the sugar-modified isoforms in
the mechanism of signalling control (62). Another heparin
function is possibily to mediate neuropilin-1
multimerisation (69).
Other VEGFs were also shown to be important
interacting partners of neuropilins. VEGFB similarly to
VEGFApossesses a heparin bindingsite and via this region
it interacts with neuropilin-1 (144). VEGFC and VEGFD
bind both neuropilins, however, only interaction of VEGFC
with neuropilin-2 occures in the absence of heparin, while
the others require heparin. Importantly, VEGFC/D do not
contain typical VEGFA heparin binding sites, which is
thought to mediate interaction with neuropilins. Indeed, it
was shown that VEGFC uses its N-terminal to bind
neuropilins. On the other hand, in order to bind VEGFC
neuropilin-1 requires the bl1b2 domain and heparin, while
neuropilin-2 requires the b1b2 domain and either heparin or
ala2, which may make the ala2 domain functional
eqivalent to heparin in this respect (76).
The role of neuropilins’ interactions with other
growth factors is much less understood. PIGF-2 is
suggested to potentiate VEGF signalling (146) and
increased motility (143). FGF2 together with neuropilin-1
has stimulating effect on endothelial cells (68). Another
neuropilin interacting partner, HGF/SF, is suggested to
promote cancer progression in two independent studies
(147, 148). It was shown that neuropilin-1 is essential for
successful signalling and response in both cases and thus,
enhancescell survival and invasion throughactivation of c-
METpathway through direct c-METinteraction.
Collectively, the structural data reviewed here
together with a set of interactions and associated functions
enriched by genetic studies enable this initial compilation
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of facts about neuropilins that present contemporary
knowledge about this family of proteins. According to the
historical profile of neuropilins the first publication
concerning neuropilin-1 (1) was in 1991, and at the
moment there are around 700 available publications.
However, the complexity of the action of neuropilins seem
to grow proportionally to the numberof studies devoted to
these proteins. Therefore, the current approaches for
elucidating the function of neuropilins needs to be replaced
by novel approaches to characterise protein functions
which would accommodate the flexible and
multifunctionality of proteins such as neuropilins.
4.3. Functional significance of neuropilins‘ interactions
Neuropilins have established cellular functions
such as cell guidance, angiogenesis and cell adhesion. In
the simplified models the cell guiding function is ascribed
to the interaction of neuropilin with semaphorins and
angiogenic function to the interaction with VEGF. The
basis of the adhesive property of neuropilin are still not
known. Contemporary knowledge of neuropilins permits
their schematised characterisation, however, there arestill
many missing elements in the puzzle.
A first key elementstill not fully understood is
the issue of neuropilin oligo/multimerisation. The question
of its functional importance and a putative switch between
the action of monomeric and oligo/multimeric forms could
play a significantrole in the regulation of responseselicited
via neuropilins. Moreover, this mechanism could be allied
to the hypothesised competition between soluble and
membrane bound neuropilins. Evidently, such a switch
would be dependent on protein interactions that involve
neuropilin and, therefore, could determine their ability to
form homophilic associations.
Another mystery is the influence of heparin on
neuropilin function. Interactions with glycosaminoglycans
(heparin being a common experimental proxy) is a
hallmark of many extracellular regulatory molecules, yet
the diversity of data presented so far on neuropilin is
substantial and leaves open any discussion ofthe functional
signalificance of the interaction of neuropilin with the
polysaccharide. Firstly, the issue of the structural role of
heparin as a molecule involved in the formation of
signalling complexes in which neuropilin is involved needs
resolution. Secondly, the question of heparin-dependent
signal transduction and modulation of signalling requires
clarification. Many of the partners of neuropilins bind
heparin/heparan sulfate and the polysaccharide is an
integral part of their ligand-receptor complex. How
neuropilin fits into such complexes and the role ofits
interaction with the polysaccharide is not known. Thirdly,
as a holistic functional consequence in vivo, the relation
between neuropilin dependent responses and_ the
differential expression of specific protein-binding
structures by heparan sulfate observed in tissues may
provide a meansto speficify particular signalling outcomes
and the selection of partners by neuropilin.
Next, the membranelocalisation of neuropilins
indicates that they possess interactions in three different
Neuropilins
compartments, namely the extracellular, intracellular and
transmembrane environments. Therefore, neuropilin is a
target of extracellular signalling molecules, an integral part
of the signalling complexes that are formed at the cell
surface and a molecule that triggeris directly inracellular
signalling cascades.
Last but not least is the involvement of neuropilin
in cell-cell contact. Since it is confirmed that neuropilins
can act in trans between distinct cells, another field of
neuropilin function emerges, which ascribes to neuropilins
the important function of maintaining the physical and
functional connectivity of tissue. Therefore, neuropilins
apart from bridging cells may also play a part in
communication between them.
5. PERSPECTIVES: IN
MOLECULAR NETWORKS
NEUROPILINS
Neuropilins have a large numberofstructurally
unrelated molecular partners, though the biological
functions of a number of these interactions remain to be
elucidated. Neuropilins should thus perhaps be considered
as multifunctional proteins. The functions of neuropilins
at any given time will depend on the localisation of the
neuropilins in plasma membrane domains, and their
association with membrane bound and_pericellular
proteins and glycosaminoglycans or glycans, thus their
functions depend ultimately on the cellular proteome
and glycome. However, individual neuropilin molecules
are likely to partition between different partners or
groups of partners. Thus, on a single cell, not all
neuropilin molecules may be engaged in the same
functionality. This complexity is founded on a protein
structure, which seems able to accommodate multiple
partners. Different parts of the neuropilin protein
interact with members of VEGF family, semaphorins,
signalling receptors and heparin. Neuropilins possess
considerable unstructured regions in the interdomain
linkers and loops joining secondary structural elements.
Such unstructured regions are a hallmark of sites of
interaction, which often become structured in the
molecular complex. The discovery of the the first
partner of the intracellular domain of neuropilin-1, the
PDZ motif containing NIP, suggests that, like other
transmembrane proteins with small cytoplasmic stubs,
such as syndecans, neuropilins may possess a reasonably
complex intracellular interactome. However, a complete
description of the partners of the intracellular domain
remains to be established. The picture of neuropilin
function is perhaps somewhat confounding, which is a
consequence of its multifunctionality and complexity.
Thus, it is expressed by manycell types; as a co-receptor of
several other receptors it modifies their signalling potency;
it interacts with and is probably regulated by heparan
sulfate; its developmental role is clearly significant, but
there is no obvious single molecular mechanism that can
explain, for example, the phenotypes of neuropilins
knockout mice. Collectively, these data suggest that a
simple “A interacts with B, causing signals X, Y and Z”
does not explain the biological functions we can observe.
This problem requires a modification of our models of
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molecular function that incorporate the idea of a protein
interactome. Thus, instead of focusing on one protein, a
model where sets of proteins cooperating in the same
moment and in the same place determine the
functionality of the components of the complexes may
provide a more adequate explanation of molecular
function. Therefore, the overall cell response is a result
of the cooperation of multiple molecules working in
concerted networksto generate intracellular signals.
A major challenge for this field, as for much of
postgenome biology, is to define molecular function.
However, molecules such as neuropilins, which seem to
represent complex regulatory nodes in molecular
networks pose major analytical problems. Thus, the
challenge is one of resolving complexity in the context
of different individual neuropilin molecules performing
different functions at the same time in a single cell.
Current approaches will simply average the functions
across the population of neuropilins. It seems likely that
an individual molecule approach may be required to
resolve the intricacies of the functions of neuropilins.
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Differential Scanning Fluorimetry Measurementof
Protein Stability Changes upon Binding to
Glycosaminoglycans: A Screening Test for Binding
Specificity
Katarzyna A. Uniewicz, Alessandro Ori, Ruoyan Xu, Yassir Ahmed, Mark C. Wilkinson,
David G. Fernig, and Edwin A. Yates*
Schoolof Biological Sciences, University of Liverpool, Liverpool, L69 7ZB, United Kingdom
Theinteraction between glycosaminoglycans (GAGs) and
proteins is important for the regulation of protein trans-
port and activity. Here we presenta novel methodfor the
measurement of protein—GAGinteractions suitable for
high-throughputscreening, able to discriminate between
the interactions of a protein with GAGs of different
structures. Binding of proteins to the GAG heparin, a
proxy for sulfated regionsofextracellular heparan sulfate,
wasfoundto enhancethestability of three test proteins,
fibroblast growth factors (FGFs)-1, -2, and -18. Chemi-
cally modified heparins and heparin oligosaccharides of
different lengths stabilized the three FGFs to different
extents, depending on the pattern of sugar binding speci-
ficity. The method is based on a differential scanning
fluorescence approach.It uses a Sypro Orange dye, which
bindsto exposed core residues ofa denatured protein and
results in an increased fluorescencesignal. It is convenient,
requiring low micromolar amounts of protein and ligand
compared to other interaction assays, employingonly a real-
time polymerase chain reaction (PCR) instrument.
Heparan sulfate (HS) is a memberof the glycosaminoglycan
(GAG) family of highly anionic linear polysaccharides. It is
synthesized as a homogeneous polymerof glucuronicacid linked
to N-acetyl glucosamine ((-4)D-GlcA /(1-4)p-GleNAc @.(1-)), which
is then modified by a series of sulfation and epimerization
reactions. N-Deacetylation and N-sulfation of glucosamine residues
indicates regions for further modifications, which include epimer-
ization of D-glucuronate to L-iduronate and 2-O-sulfation of iduronic
acid, 6-O-sulfation, and morerarely, 3-O-sulfation of glucosamine.'
The resulting HS polymeris of high sequencevariability compris-
ing subunits bearing distinct sulfation patterns.' Heparin can be
considered a specialized form of HS and consists predominantly
of highly modified, sulfated stretches.
HS functionsas an extracellular mechanical support molecule*~
but is also a regulator of the functions of a vast array of proteins,
ranging from thefibroblast growth factors (FGFs),°~’ f-amyloid
cleavage enzyme-1 (BACE-1),* antithrombin,’ and neuropilin-1
4
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(NRP-1).'° The interaction of HS with its protein partners alter
their activity and often serves as a meansof assembling functional
complexes.'!! One of the plausible explanations of the function
of HS within complexesis to enhancethestability of the proteins
with which it is involved.'* The functional importance of protein
interactions with HS and the potential consequences for glyco-
therapies!®has led to the development of many assay systems.!*
These include surface-based methods!’ (enzyme-linked immun-
osorbent assay (ELISA), surface plasmon resonance (SPR)),
calorimetric (isothermaltitration calorimetry (ITC),'° differential
scanning calorimetry (DSC)!*!’), and spectroscopic approaches
such as NMR,'* circular dichroism (CD),!*° and Fourier transform-
infrared (FT-IR).'!° However, these approaches do not lend
themselves to a comprehensive high-throughput screen of sugar
structures involved in the interactions, may suffer from surface
based artifacts,” or may require large amounts of sample and
complex instrumentation.
 
3 Florian, J. A.; Kosky, J. R.; Ainslie, K.; Pang, Z.; Dull, R. O.; Tarbell, J. M.
Circ. Res. 2003, 93, €136—142.
(4) Rodgers, K. D.; San Antonio, J. D.; Jacenko, O. Dev. Dyn. 2008, 237, 2622-
2642.
(5) Pye, D. A; Vives, R. R.; Turnbull, J. E.; Hyde, P.; Gallagher, J. T. J. Biol.
Chem. 1998, 273, 22936-22942.
(6) Sugaya, N.; Habuchi, H.; Nagai, N.; Ashikari-Hada, S.; Kimata, K. J. Biol.
Chem. 2008, 283, 10366-10376.
Guimond, S.; Maccarana, M.; Olwin, B. B.; Lindahl, U.; Rapraeger, A. C.
J. Biol. Chem. 1993, 268, 23906-23914.
(8) Patey, S. J.; Edwards, E. A.; Yates, E. A.; Turnbull, J. E. J. Med. Chem.
2006, 49, 6129-6132.
(9) Hovingh, P.; Piepkorn, M.; Linker, A. Biochem. J. 1986, 237, 573-581.
(10) Uniewicz, K. A.; Fernig, D. G. Front. Biosci. 2008, 13, 4339-4360.
(11) Gallagher, J. T. Biochem. Soc. Trans. 2006, 34, 438-441.
(12) Roy, S.; Fortin, M.; Gagnon,J.; Ghinet, M. G.; Lehoux, J. G.; Dupuis, G.;
Brzezinski, R. Biochim. Biophys. Acta 2007, 1774, 975-984.
(13) Patey, S. J.; Edwards, E. A.; Yates, E. A.; Turnbull, J. E. Neurodegener. Dis.
2008, 5, 197-199.
(14) Hamel, D. J.; Sielaff, I; Proudfoot, A. E.; Handel, T. M. Methods Enzymol.
2009, 461, 71-102.
(15) Delehedde, M.; Lyon, M.; Gallagher, J. T.; Rudland, P. S.; Fernig, D. G.
Biochem. J. 2002, 366, 235-244.
(16) Guzman-Casado, M.; Cardenete, A.; Gimenez-Gallego, G.; Parody-Morreale,
A. Int. J. Biol. Macromol. 2001, 28, 305-313.
(17) McPherson, J. M.; Sawamura,S. J.; Condell, R. A.; Rhee, W.; Wallace, D. G.
Coll. Relat. Res. 1988, 8, 65-82.
(18) Gettins, P.; Wooten, E. W. Biochemistry 1987, 26, 4403-4408.
(19) Svensson, G.; Linse, S.; Mani, K. Biochemistry 2009, 48, 9994-10004.
(20) Zakrzewska, M.; Wiedlocha, A.; Szlachcic, A.; Krowarsch, D.; Otlewski, J.;
Olsnes, S. J. Biol. Chem. 2009, 284, 25388-25403.
(21) Powell, A. K.; Zhi, Z. L.; Turnbull, J. E. Methods Mol. Biol. 2009, 534, 313-
329.
7,
10.1021/ac100188x © 2010 American Chemical Society
Published on Web 03/30/2010
Since the interaction of HS with its protein partners can alter
their activity and often serves as a means of assembling functional
complexes, it has been suggested that this may occur by
stabilization of the protein structure, illustrated, for example, by
antithrombin III?? and also by the FGFs.?°?~*7 Consequently,
we have employed a recently described technique, which mea-
suresprotein stability,** to develop a new method for determining
the specificity of protein—polysaccharide interactions.
The method usesa sensitive dye (Sypro Orange), which when
bound to exposed core residues of denatured proteins exhibits
high fluorescence. Small volumes (10 wL) and protein concentra-
tions (low micromolar range) are used, and the assay can be
adapted to a multiwell format, taking less than 1 h, making it
suitable for high-throughput screening. Theassay utilizes heparin
as an internal control, allowing the comparison of the tested
compoundswith heparin andcalculation oftheir relative stabilizing
effects. In this study, we determined the minimal length of
oligosaccharide and the sulfation pattern required for the interac-
tion of the threeillustrative proteins: FGF-1, FGF-2 (prototypical
HSbinding proteins), and FGF-18, with a range of homogenously
modified polysaccharides employed widely as probes of struc-
ture—function relationships in HS. The methodcanalso be applied
to the measurement of melting temperatures of protein—GAG
complexes. The results with FGF-1 and FGF-2 are in good
agreement with published data demonstrating that this method
can be used to establish the specificity of the interactions between
GAGsandproteins.
EXPERIMENTAL SECTION
Protein and Polysaccharide Preparation. Recombinant
FGF-1 (aFGF) (UniProt Accession, P05230; residues, 16-155) and
FGF-2 (bFGF) (UniProt Accession, P09038-2; residues, 1-155)
were expressed in C41 Escherichia coli cells using a pET-14b
system (Novagen, Merck Chemical Ltd., Nottingham, Notts,
U.K.).2° FGF-2 was purified as described previously,*” and the
same procedure was employedto purify FGF-1. FGF-18 (zFGF5)
(UniProt Accession, 076093; residues, 28-207) (Figure S-1 in the
Supporting Information) was cloned in a modified pET-24b vector
(pETM-11, kind gift of Dr. Paul Elliott, University of Liverpool)
and expressed in C41 E. coli cells. Bacteria were grown under
standard conditions and, following induction (1 mM IPTG, 16 h
at 16 °C), cells were collected by centrifugation at 3000g for 7
min, washed with 50 mM Tris pH 7.5, 0.15 M NaCl, and sonicated
in buffer A (50 mM Tris pH 7.5, 0.5 M NaCl, 50 mM imidazole)
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on ice. Whena clear solution had been obtained, the lysate was
applied to a 3 mL ProBondnickel-chelating resin (Invitrogen,
Paisley, Scotland, U.K.) column equilibrated with buffer A.
Following extensive washing with buffer A, protein was eluted
using 50 mM Tris pH 7.5, 0.5 M NaCl, 500 mM imidazole. The
histidine tag of the eluted protein was cleaved with a histidine-
tagged TEVprotease (also a kind gift from Dr. Paul Elliot) at 4
°C. Following overnight digestion, the sample was reapplied to
the ProBondnickel-chelating resin columnto separate the cleaved
tag, TEV protease, and impurities from the FGF-18. The cleaved
protein (unbound fraction) was further purified using a HiTrap
Heparin HP 1 mL column (GE Healthcare, Amersham, Bucks,
U.K.). All proteins were prepared as 10 times concentrated stocks
in 50 mM Tris pH 7.5, 2 M NaCl.
The sameheparin (17 kDa average molecular weight) (Celsus
Lab, Cincinnati, OH) was used in the assay and asa starting
material for the production of modified derivatives*"' (Figure S-2
in the Supporting Information) and oligosaccharides,”all of which
were used as 10 times concentrated stock solutions (1.75 mg/
mL) in HPLC grade water.
Differential Scanning Fluorimetry (DSF). The experiment
was performed using a 7500 Fast Real Time PCR System (software
version 1.4.0) (Applied Biosystems, Warrington, Cheshire, U.K.),
and the samples were subjected to the heating cycle as described
previously.”* Briefly, heparin derivatives (10% v/v), protein stock
solutions (10% v/v), and Dulbecco’s phosphate-buffered saline
without CaCl./MgCl, (Gibco-Europe, Paisley, Scotland, U.K.)
(70% v/v) were added to a Fast Optical 96 Well Reaction Plate
(Applied Biosystems) maintained on ice. Freshly prepared 100x
water based dilution of Sypro Orange 5000x (Invitrogen,
Paisley, Scotland, U.K.) was added as 10% v/v. The final volume
of the reaction mixture waseither 10 or 25 wL. Final concentra-
tions of the proteins were 10 «M (FGF-1 and FGF-2in screens
of oligosaccharides and chemically modified heparin derivatives
and all FGF-18 assays) or 5 uM (FGF-2 and gradient of heparin
concentrations). For experiments with ranges of heparin
concentrations, the final concentrations of heparin were cal-
culated according to the molar ratio of the heparin versus the
protein within a range 0.5—500 uM.In oligosaccharide and
chemically modified heparin derivative assays, the species
under examination comprised pools of defined oligosaccha-
rides, which made molarity difficult to define. In addition, as
the mechanism of binding of the saccharidesto the protein is
unclear, the concentration range expressed in micrograms per
milliliter was selected to compare the bestowedstabilization
effects. Thus, the effective concentration of heparin was chosen
(for instance, 175 wg/mL corresponding to ~10 «M), andall
other heparin-derived compoundswere used at the same w/v
ratio (175 ug/mL). In the case of FGF-18, the same massratio
was maintained for the screen of oligosaccharides. For chemi-
cally modified heparin derivatives, their concentration was
doubled (to 350 ug/mL, analogous to 20 uM concentration of
heparin) as 175 ug/mL wasinsufficient to bestow anystabiliz-
ing effect by any of the compounds and compared with 350
ug/mL of heparin. After sealing with Optical Adhesive Film
(Applied Biosystems), the plate was gently vortexed and
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Figure 1. Concentration dependenteffect of heparin on thermalstabilization of FGF-2. (A) Melting curveprofile of 5 wM FGF-2 in the presence
of various concentrations of heparin ligand (0, 0.5—100 uM). (B) The first derivatives of each melting curve where each maximum ofthefirst
derivative indicates the Tm (melting temperature). (C) Mean Tm valuesplotted from the maximaof the derivatives calculated from three repeats
of at least two experiments performedintriplicate (+SD). (D) Ratios of assayed concentrations of FGF-2 and heparin juxtaposed with their
corresponding mean Tm values (SD) from at least two independent experiments performedintriplicate.
directly analyzed in the real-time polymerase chain reaction
(RT-PCR) instrument. The heating cycle comprised a 120 s
prewarming step at 31 °C and a subsequent gradient between
32 and 81 °C in 99 steps of 20 s, each of 0.5 °C ramp. Data
were collected using the calibration setting for TAMRA dye
detection (/, 560 nm; A,,,, 582 nm) installed on the instrument.
Data Analysis. The data were analyzed using thePlot v. 0.997
software for Mac OS X (plot.micw.eu) by application of an
exponential correlation function approximationof the first deriva-
tive for each melting curve. For each heparin derivative, three
distinct melting curves were analyzed. However, the figures
include only one melting curve/derivative per polysaccharide
variant tested for clarity. The maximaofdistinct derivatives were
used to calculate the mean Tm (melting temperature) and the
standard deviation (SD) of each Tm wasbased on three repeats.
Subsequently, data were normalized to allow comparison between
the stabilization effects of assayed heparin derivatives with that
of heparin. To perform normalization, each compound was
characterized by the difference between the Tm oftheprotein in
PBS (Tm PBS) and the Tm ofthe protein in the presence of the
heparin derivative (Tm x) according to eq 1
Tm x — Tm PBS (1)
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Next, the comparison ofstabilization potency versus heparin
was obtained from eq 2
Tm x — Tm PBS (2)
Tm hep — Tm PBS
where Tm hep is the mean Tm ofthe protein in the presence of
heparin. Thus, therelative stability of protein in PBS wasset to
0, while the relative stabilizing effect of heparin wasset to 1. To
calculate absolute Tm of FGF-1 and FGF-2,at least two indepen-
dent experimentsin triplicate were analyzed and the final Tm is
the mean of all obtained values.
RESULTS AND DISCUSSION
Suitability of DSF for Detecting Heparin Dependent
Thermostabilizing Effects on FGF-2. Theinteraction of FGF-2
with heparin has been studied extensively and thestabilizing effect
of the interaction is well documented.?**4 To establish whether
DSFhasthe potential to measure protein—sugar interactions, a
screen was performed,in which a range of heparin concentrations
(0.5-100 uM) wastested against a constant amount of FGF-2 (5
uM). The denaturation curves show that stabilizing effect is
apparent from 1.25 uM heparin (heparin—FGF-2 molarratio 1:4)
with concentrations of heparin of 25 uM or more sufficient to
prevent full denaturation in the temperature range used (Figure
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1A). Thefirst derivatives of the denaturation curves wereplotted,
where the maxima defined the Tm (Figure 1B). This experiment
clearly showed that heparin had a concentration dependenteffect
on FGF-2 stability (Figure 1B—D). Importantly, there was no
background signal arising from heparin—Sypro Orange interac-
tions (inset of Figure 1A); therefore, the methodis suitable for
measuring the interactions of proteins with polysaccharides
throughthestabilization effect, since all the signal derives from
the denatured protein.
Application of DSF to Probe the Structural Requirements
of Heparin-Derived Compoundsfor Protein Stabilization.
Having shown that DSF could identify the interaction between
heparin and FGF-2, the ability of DSF to discriminate between
the bindingspecificity of structurally different heparinswastested.
To verify DSF against published data, the interactions of FGF-1
and FGF-2 with heparin, oligosaccharides of various lengths and
full-length homogenously modified heparin derivatives bearing a
range of different sulfation patterns were tested (Figure S-2 in
the Supporting Information). The data were collected at a 1:1
molar ratio of protein to heparin, because at this ratio the
stabilization effect was in the medium to high range, so providing
a good dynamic range. For other saccharide ligands, the same
concentration (175 ug/mL) was employed, under the assumption
that the differences between the potency of the compoundsshould
be detectable at this ratio. Data were then analyzed as before and
normalized to reveal the ability of each compoundtostabilize the
protein relative to heparin, whose potency was defined as 1
(referred to as 0, with no ligand present). The minimal length of
oligosaccharide requiredto stabilize FGF-1 or FGF-2 at the same
level as heparin was established using a library of various
oligosaccharides of varying lengths defined as degree of poly-
merization, dp, where dp 2 is a basic repeating disaccharide unit.
The data clearily showed that even dp 2 had a small effect on
FGF-1 thermostability, which thereafter increased as the length
of the oligosaccharides increased to reach a maximum around
dp 8—dp 10 (Figure 2A,C). In contrast, there was a detectable
effect of dp 4 but not dp 2 on FGF-2 thermostability in accord
with published data that indicated a tetrasaccharide as the minimal
binding unit.!°°* This experiment confirmed the published data,
that binding sites of FGF-1 and FGF-2 can accommodate oligosac-
chardesof up to dp 10.°*°°
The experimentin which various desulfated heparins were
tested employed chemically modified heparin derivatives in
which sulfate groups had been systematically removed to
homogeneity, to give eight variants.*! In addition, a persulfated
heparin derivative bearing two additional sulfate groups (3-O-
sulfate at uronic acid and 3-O-sulfate at glucosamine) was also
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assayed, as a control for processes driven essentially by high
charge density. The results again confirmed the published data,
showing that sulfation is important for the interaction of the
polysaccharide with both FGF-1 and FGF-2 (Figure 2B,D).
Nevertheless, the potency of the persulfated heparin derivative
did not exceed that of heparin, supporting the notion that
although the interaction of these proteins with the sugars
require sulfate groups,it is the disposition of the sulfates and
their overall conformational consequencesthatare critical for
the interactions. As shown using other approaches,the singley
desulfated species had contrasting effects on FGF-1 and FGF-
2, revealing distinct specificity profiles. Thus, it was shown that
for FGF-1 all three sulfate groups, N-sulfate, 6-O-sulfate and
2-O-sulfate are required for interaction, while in the case of
FGF-2, only N-sulfate and 2-O-sulfate play important roles?°°3*°*
in these homogeneousderivatives. These findings were con-
firmed by the DSF method,as the presence of the 6-O-sulfate
group contributed muchless to the heparin-dependentstability
of FGF-2 than of FGF-1 (Figure 2B,D). It was, therefore,
possible to differentiate between two specific binding require-
ments of FGF-1 and FGF-2 and to show that this method could
be applied to an assay of protein binding specificity.
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Characterization of the Thermostabilizing Effect of Hep-
arin, Heparin Oligosaccharides and Modified Heparin De-
rivatives on FGF-18. FGF-18 was chosenas test protein to be
characterized using this method becauselimited data are available
concerning its interaction with heparin and HS.In contrast to
FGF-1 and FGF-2, which both belong to the same FGF-1 subfam-
ily, FGF-18 belongs to the FGF-8 subfamily, together with FGF-8
and FGF-17."* The published data describe FGF-18 as a heparin-
binding growth factor that binds octasaccharides (dp 8) and
requires both 2-O-sulfate and 6-O-sulfates, with an apparent
preference for 2-O-sulfate groups.*°First, the effect of heparin on
FGF-18 stability was characterized. Interestingly, the protein alone
had a very shallow denaturing curve, suggesting aggregation
rather than unfolding following temperature elevation (Figure 3A).
Nevertheless, addition of only 0.125 mol equiv of heparin was
sufficient to sharpen the denaturation curve while, at the same
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Figure 4. Relative thermostabilizing effect of heparin, heparin-derived oligosaccharides, and chemically modified heparins on FGF-18,calculated
according to eq 2. (A, C) Thefirst derivatives of each melting curve andrelative thermostabilizing effect of heparin-derived oligosaccharides,
respectively. (B, D) Thefirst derivatives of each melting curve andrelative thermostability effect of chemically modified heparins, respectively.
(C, D) Results are the mean + SDof three repeats after normalization.
time,affecting the Tm value only subtly (Figure 3A,B). Subsequent
heparin concentrations modified the thermostability of the com-
plex gradually, resulting in a thermostability shift from 57 to
71 °C at 1:50 molar ratio of FGF-18 to heparin.It is important to
note that this difference was broadly comparable with, albeit
somewhat lower than, that observed with FGF-2 and heparin
(Figure 1), in which a 1:1 (protein—heparin) molar ratio was the
final condition covered by the temperature range of the experi-
ment. To conclude, the interaction between FGF-18 and heparin
resulted in a less pronouncedstabilization effect than with FGF-1
and FGF-2 but, nonetheless, even low heparin concentrations
affected the protein behavior, as indicated by the visibly steeper
denaturation curves (Figure 3A,B; compare PBS and 1.25 uM
curves).
The potency of oligosaccharide derivatives in mediating the
stability effect on FGF-18 were then examined. The shorter
oligosaccharides dp 2—dp 6 wereineffective at altering the Tm
of FGF-18 and neither did they affect the denaturation curve of
the putatively aggregating FGF-18. In contrast, dp 8 oligosaccha-
rides not only managedto sharpen the denaturation curve of FGF-
18 but also significantly influencedits stability (Figure 4A,C). This
size requirement correlated with the published data, where an
octasaccharide library was used to characterize FGF-18 sulfate
group binding specificity.“° The sulfation requirements of sac-
charide binding were examined using the same set of heparin
derivatives. However, in order to obtain reproducible denaturation
curves, FGF-18 had to be incubated with increased amounts of
the heparin derivatives, otherwise the stabilization effect was not
detectable (data not shown). This modification highlights the
importanceforall three sulfate groups in mediating the structure
affecting/stabilizing property of heparin. Under the new condi-
tions, FGF-18, in contrast to FGF-1 and FGF-2, was equally
stabilized by three singly desulfated heparin derivatives though
to a lesser extent than with heparin (Figure 4B,D). These data
suggest that FGF-18 interactionsare altered by loss of any of the
three sulfate groups of heparin at comparablelevels, which results
in a reduction of the stabilizing effect.
DSFCharacterization of FGF-1 and FGF-2 Stability. The
method described permits the comparison betweenthe effects of
various carbohydrate ligands on protein—polysaccharide complex
stability to be made by conducting an experiment under defined
conditions and including appropriate controls. Although such an
approachallowsvirtual independencefrom external data, because
the Tm values so obtained are normalized against the Tm of
internal controls, it was decided to check whether the DSF Sypro
method wasconsistent with other published data concerning the
stability of FGF-1 and of FGF-2. It should be noted that the final
Tm obtained in various experiments was dependent on many
variables, including the protein, buffer conditions, protein con-
centration, intervals between data collection, and the method of
Analytical Chemistry, Vol. 82, No. 9, May 1, 2010 3801
 Table 1. Comparison of Experimentally Obtained Melting Temperatures of FGF-1 and FGF-2 Using Various Methods,
Buffer Types, and Protein Constructs with Appropriate References”
method T [°C] buffer type ref residues additional ref
CD 40.3 0.7 M guanidine-Cl 20 21-154
Trp fluorescence 39.8 0.7 M guanidine-Cl 20 21-154
CD 40.7 1.5 M urea 20 21-154
Trp fluorescence 35 Naphosphate pH 7.4 25 1-155 41
FGFA CD 42 Na phosphate pH 7.4 25 1155
DSC 42 Na phosphate pH 7.4 25 1-155
ANSfluorescence 52 Na phosphate Nacitrate 0.15 M NaCl 26 2-155 Human Phage Biotechnology
Corporation patent info
DSC 39.45 0.7 M guanidine-Cl 27 16-155 42
DSF Sypro 48.5 Na phosphate pH 7.4 0.35 M NaCl 16-155
FGF-2 DSC 59 K phosphate pH 6.5 23 10-155 43
FT-IR 57 Tris-Cl pH 8.5 24 10-155
DSF Sypro 55.4 Na phosphate pH 7.4 0.35 M NaCl 1-155
“ The values obtained using the DSF Sypro method are the mean value ofat least two independent experiments performedintriplicate.
 
calculation. Table 1 shows juxtaposed melting temperatures of
FGF-1 and FGF-2 obtained by different methods and employing
distinct protein constructs in various buffer systems. For FGF-1,
the Tm values covered a wide range of temperatures from 35 to
52 °C, while for FGF-2, the temperature range was limited to
between 55 and 59 °C. Our experimental approach provided Tm
values comparable with those obtained in the previous studies,
also in the case of heparin-induced stability showing an ap-
proximately 20 °C rise in the melting temperatures (data not
shown for FGF-1).2°?3~°6
However, it is emphasized that experimental variability can
result in diverse Tm measurements and,while relative values are
informative, the absolute values should beinterpreted with caution.
CONCLUSIONS
A new method for the elucidation of the specificity of the
interactions between proteins and GAGsis presented. The method
enables calculation of protein melting temperatures in complexes
with various heparin-derived molecules and can provide important
structure—function information. The assay comprises a multicom-
pound array consisting of internal controls (protein with and
without heparin) and tested ligands, which permits normalization
within a defined set of ligands. The assay requires a hydrophobic
dye, Sypro Orange, whichinteracts with the protein core residues
exposed upon denaturation, altering its emission spectrum and
permits denaturation curves to be recorded as a function of
temperature. It was confirmed that heparin derivatives do not
interact with Sypro Orange, which excluded the possibility of
nonspecific backgroundsignals. The assay requires low volumes
(10 L per well) and low concentrations of protein and ligand, 5
 
(41) Linemeyer, D. L.; Menke, J. G.; Kelly, L. J.; DiSalvo, J.; Soderman, D.;
Schaeffer, M. T.; Ortega, S.; Gimenez-Gallego, G.; Thomas, K. A. Growth
Factors 1990, 3, 287-298.
(42) Gimenez-Gallego, G.; Conn, G.; Hatcher, V. B.; Thomas, K. A. Biochem.
Biophys. Res. Commun. 1986, 138, 611-617.
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K. A; Gospodarowicz, D.; Fiddes, J. C. Science 1986, 233, 545-548.
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uM in the case of FGF-2 (17 kDa). It is convenient because the
denaturation cycle takes only ~30 min andis entirely compatible
with multiwell plates and automation. The screen requires a
standard RT-PCR machine compatible with multiwell plates and
can be used withoutspecific calibration by employing the common
TAMRA dyesetting generally available. The method can be
standarized easily and produces valuable data concerning the
biophysical properties of protein interactions. This approach will
shed new light on the role of GAGsin signaling complexes,or as
extracellular buffers regulating transportation and theavailability
of the proteins. It could be applied to other polysaccharides and
a range of hydrophilic ligands, or small molecules as a means of
characterizing their interactions.
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Supplemental data 3
Supplemental data 3 contains the spectra of the peptides analysed by MALDI-Q-TOFfor the
P&L experiment of the Fc rNRP-1 binding to heparin (Table 4.2, Section 4.4).
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Supplemental data 3
2: TOF MSMS 1800.96LD+
 
2.60e3100 1800.96 le
%
310.16
227.08 706.43383.19 468.27 842.42 1078.51 1293-72 1669.95
° 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800.
1800.96 2.60E+03 VRIK(Biotin)PASWETGISM
lon fragment mass (m/z) Intensity Assignment(error - ppm)
84:07 1.11E+02 K(-128)
227.08 2.23E+02 Biotin(0)
239.15 9.89E+01 bo-NH3(-1.1)
256.17 8.07E+01 be(-27) / PAS(159) / SW-H20(242)
310.16 8.10E+02 K(Biotin)(0)
383.19 1.13E+02 ETGI-H2O(-6.6)
452.24 7.84E+01 K(Biotin)P(16)
468.27 1.11E+02 IK(Biotin)(13)
523.28 8.38E+01 K(Biotin)PA(20)
571.26 8.44E+01 PASWE(16)
635.36 8.28E+01
706.43 2.51E+02 —b4-NH3(33) / IK(Biotin)PAS-NH3(100)
723.48 1.28E+02 b4 (64) / IK(Biotin)PAS(130)
842.42 9.22E+01 PASWETGI(19)
1078.51 8.40E+01 Y¥10(21)
1293.72 1.78E+02 bg (33)
1669.95 9.57E+01 b13+H20(46)
1783.01 7.92E+01 MH-H20(60)
1799.83 7.92E+01
1800.96 2.60E+03 MH(26)
 
 Doctoral thesis Study of Neuropilin-1 interactions by Katarzyna Adela Uniewicz 149
Supplemental data 3
KU2
4571_054 18 (0.934) 2: TOF MSMS 1494.76LD+
1.35e3400 275.12 394.18 35e:
%
110.06 325.19
258.10 |
462.26172.10 571.32 599.32 791.41
736.39 900.49 928.48
0 mass100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950
 
1494.76. 1.35E+03 AGAFR(Acetyl)SDK(Biotin)C(Carbamidomethyl)GGT
lon fragment mass (m/z) Intensity Assignment(error - ppm)
110.06 5.10E+02
126.08 1.29E+02 K(-90)
172. 2.25E+02 a3 (-47)
202.1 2.24E+02
214.1 1.69E+02
227.09 9.94E+01 Biotin(44)
247.13 3.49E+02 C(Carbamidomethyl)GG-28(178)
257.11 2.52E+02
258.1 4.06E+02
275.12 1.35E+03 C(Carbamidomethyl)GG(142)
285.11 1.21E+02
293.14 9.84E+01
303.12 1.18E+02
310.16 1.84E+02 K(Biotin) (0)
325.19 5.77E+02
366.18 1.08E+02
377.16 1.13E+02
394.18 1.32E+03 y4(104)
412.22 1.41E+02
434.26 2.40E+02
440.19 1.20E+02
462.26 2.63E+02
549.26 1.43E+02
567.27 1.01E+02
571.32 1.91E+02
599.32 2.29E+02
736.39 1.04E+02
791.41 2.33E+02
900.49 1.08E+02
928.48 1.12E+02
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Supplemental data 3
2: TOF MSMS1926.02LD+
 
1926.02 15123
1881.93
1881.03 |
1864.05
546.32 766.34 988.66 1142.67 1527-69446876 1769.91 |
400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
1926.02 1.51E+03 DK(Biotin)NISRKPGNVLKTL(Ammonium)
lon fragment mass (m/z) Intensity Assignment(error - ppm)
227.08 4.68E+01 Biotin(0)
294.15 1.68E+01
310.16 8.42E+01 K(Biotin)(0)
546.32 1.99E+01
766.34 1.62E+01 bs-H2O0(-20)
988.66 1.64E+01
1125.65 1.56E+01 Y10-NH3(-54)
1142.67 2.53E+01 Y10(-58)
1225.68 2.08E+01
1276.69 1.62E+01
1319.63 2.09E+01 bi9-NH3(-17)
1337.74 2.35E+01
1363.73 3.65E+01
1381.71 2.62E+01
1468.76 2.67E+01
1750.95 1.60E+01
1769.91 2.24E+01
1789.98 7.06E+01
1812.03 1.58E+01
1832.87 1.88E+01
1862.96 4.89E+01
1877.99 1.71E+01
1905.84 1.91E+01
1923 3.95E+01
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KU24571_054 39 (1.591) 2: TOF MSMS2024.10LD+
400 767.42 224
%
670.41 896.46
652.40 1981.06
310.16 438.25 1910.98 |
1110.62 1250.64 1579.86 1892.99
0 | + 4 | | | | mass200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000
2024.10 224 TLPPSRDELTK(Biotin)NQVSL
lon fragment mass (m/z) Intensity Assignment(error - ppm)
227.08 1.60E+01 Biotin(0)
310.16 3.86E+01 K(Biotin)(0)
396.23 2.09E+01
421.22 9.04E+00 PPSR-NH3(1.4)
438.25 2.52E+01 PPSR(9.3) / TK(Biotin)-H20(75) / PSRD-H20(92)
493.25 1.08E+01
536.27 2.05E+01 PPSRD-NH3(44)
652.4 4.72E+01 b¢(34)
665.29 9.50E+00 PPSRDE-NHs3(1.6) / LTK(Biotin)N-H2O(-81)
669.43 1.80E+01
695.44 1.72E+01
723.38 1.11E+01
750.37 1.34E+01 b7-NH3(-11)
767.42 2.24E+02 PPSRDEL-28(20) / b7(20) / LPPSRDE-28(20)
778.42 1.10E+01 LPPSRDE-NH3(60) / PPSRDEL-NH3(60)
785.41 1.25E+01 DELTK(Biotin)-28(30)
896.46 6.77E+01 ye-H2O(-6.5) / PPSRDELT(14) / bg (14)
1110.62 9.71E+00 yg-H2O(20)/ b19(37)
1250.64 1.34E+01 §PPSRDELTK(Biotin)(16) / PSRDELTK(Biotin)N-NH3(45)
1464.77 1.01E+01 b14(13) / PPSRDELTK(Biotin)NQ-28(30)
1578.81 1.62E+01 by2(9.8)
1749.9 9.31E+00
1778.93 1.13E+01
1791.97 1.37E+01 LPPSRDELTK(Biotin)NQVS(36)/ y14-H2O0(36)
1810 1.27E+01 y14(46)
1892.99 1.65E+01 b45(19)
1910.06 1.21E+01
1963.1 1.37E+01
1968.98 1.15E+01
1979.15 2.99E+01
1989 9.74E+00
1995.08 9.66E+00
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2: TOF MSMS 2125.14LD+
88.3
1680.841579.85 1896.021297.68
mass
KU2
4571_054 68 (2.498)+00 767.42
868.47
%
896.47a10.48 670.41
652.40 997.55396.22
°300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000
 
2125.14 88.30 VVVDVSHEDPEVK(Biotin)FNW
lon fragment mass (m/z) Intensity Assignment(error - ppm)
310.16 2.10E+01 K(Biotin)(0)
396.22 7.65E+00
438.25 7.50E+00
652.4 1.19E+01 PEVK(Biotin)-28(79)
665.29 7.35E+00 VSHEDP(1.6) / DVSHED-H20(56)
670.41 2.53E+01
753.44 8.94E+00
767.42 8.83E+01 DPEVK(Biotin)-28(58)
771.49 7.40E+00
868.47 5.37E+01
896.47 2.79E+01 EDPEVK(Biotin)-28(58)
996.48 7.55E+00
1297.68 6.86E+00
1476.73 6.81E+00
1565.76 8.62E+00
1579.85 1.13E+01
1619.84 7.36E+00
1638.8 7.27E+00
1679.94 7.36E+00 §VVDVSHEDPEVK(Biotin)F-28(78)
1708.02 7.71E+00 VVDVSHEDPEVK(Biotin) F(126)
1723.92 6.52E+00
1768.98 7.58E+00
1798.82 6.59E+00
1842.84 7.47E+00
1876.88 7.62E+00
1881.84 7.78E+00
1896.02 1.04E+01
1911.03 8.83E+00
1978.9 7.34E+00
1991.94 6.89E+00
1996.97 8.44E+00
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ian 275.12 994
394.18
%
110.06
258.10 325.19
ine a6226 599.32
— TARA 858.47
0 mass100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850
1452.74 994 AGAFRSDK(Biotin)C(Carbamidomethyl)GGT
lon fragment mass (m/z) Intensity Assignment(error - ppm)
84.07 6.80E+01 K(-128)
110.06 3.90E+02
126.08 1.56E+02 K(-90)
172.1 1.02E+02 a3(-47)
202.1 1.52E+02
214.1 8.64E+01
247.13 2.22E+02 C(Carbamidomethyl)GG-28(178)
257.11 1.63E+02
275.12 9.94E+02 C(Carbamidomethyl)GG(142)
285.11 6.76E+01
303.12 8.27E+01
308.17 6.77E+01
310.16 1.16E+02 K(Biotin)(0)
325.19 2.86E+02
342.21 7.69E+01 RSD-NH3(202)
349.15 6.73E+01
366.18 6.80E+01
377.15 7.16E+01
394.18 9.24E+02 y4(104)
412.21 1.17E+02
430.2 6.30E+01
434.26 1.05E+02 AFRS-28(21)
440.19 6.48E+01
462.25 1.71E+02 AFRS(8.8)
479.29 7.63E+01
531.27 9.69E+01
549.29 7.51E+01 AFRSD-28(22)
571.32 1.05E+02
599.32 1.46E+02
736.39 6.08E+01
749.41 8.32E+01
858.47 6.56E+01
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100
310.16
227.08 470.22
468.27 615.34670.33 913.46
0 100 200 300 400 500 600 700 800 900 §=©1000
2: TOF MSMS 1790.91LD+
1790.92
1475.76
||
1476.68 1790.07
| ih
1100 1200 1300 1400 1500 1600 1700 1800
 
1790.92 1.03E+03 TVDK(Biotin)SRWQQGNVF
lon fragment mass (m/z) Intensity Assignment(error - ppm)
84.07 6.36E+01 K(-128) Q(-128)
227.08 1.19E+02 Biotin(0)
310.16 5.17E+02 K(Biotin)(0)
383.17 3.11E+01
468.27 3.36E+01
510.23 3.86E+01 QQGNV-NH3(-1.3)
557.26 3.54E+01 DK(Biotin)S(38)
598.33 3.69E+01 K(Biotin)SR(28)
615.34 4.90E+01
670.33 4.64E+01 b4(11)
896.43 3.45E+01 bg-NH3(0.60)
913.46 5.76E+01 bg (4.4)
1475.76 3.30E+02 Y10(26)
1746.86 7.88E+01
1773.88 4.91E+01 MH-NH3(24)
1788.84 5.40E+01
 
1.03e3
1791.82
|
mass
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4571_054 99 (3.468) 2: TOF MSMS1381.71LD+310.16 979100
” 227.08
84.07 294.15
311.18110.06 455.98472.19 766-16 379.25 410-23 456.25 56433581.36 a
: mass100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 550 575 600 625 650 675 700
 
1381.71 979 NGK(Biotin)EYKCKVS
lon fragment mass (m/z) Intensity Assignment(error - ppm)
84.07 1.63E+02 K(-128)
110.06 6.61E+01
115.08 4.71E+01
155.08 4.28E+01 bo-NH3(225)
172.1 4.09E+01 b2(165)
227.08 4.78E+02 Biotin(0)
266.16 7.58E+01
269.16 4.50E+01
294.15 1.71E+02
310.16 9.80E+02 K(Biotin)(0)
379.25 6.82E+01
394.23 4.65E+01
407.25 5.35E+01
438.22 5.87E+01
456.25 4.39E+01 K(Biotin)E-28(49)
521.33 4.06E+01
564.33 4.34E+01 y5(22)
581.36 5.02E+01
683.28 8.24E+01
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KU24571_054 101 (3.530) 2: TOF MSMS 1516.72LD+
400 10.16 311
227.08
%
110.06
408.16
589.26 5. 25785.41 1242.59 1379.66
452.19 . 922.46 1105.52
0 + : mass100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400
1516.72 311 QVIFEGEIGK(Biotin)GN
lon fragment mass (m/z) Intensity Assignment(error - ppm)
84.07 6.59E+01 Q(-128) / K(-128)
110.06 1.24E+02
227.08 1.86E+02 Biotin(0)
249.09 4.07E+01 FE-28(-134)
266.12 4.16E+01
310.16 3.11E+02 K(Biotin)(0)
346.12 4.94E+01
363.14 5.14E+01
381.15 5.12E+01
406.18 4.23E+01
436.15 4.36E+01
452.19 5.58E+01 GK(Biotin)G-NH3(-14)
567.26 4.28E+01
589.26 8.03E+01 as (-126)
600.26 5.91E+01 bs-NH3(-71)
633.24 4.85E+01 FEGEIG(-76)
693.25 6.56E+01 EIGK(Biotin)G-H2O(-128) / GEIGK(Biotin)-H2O(-128)
726.32 5.89E+01
785.41 7.28E+01 b7-H20(35)
922.46 5.72E+01
1059.5 4.59E+01
1105.52 5.66E+01
1196.57 4.29E+01
1224.61 4.29E+01
1242.59 7.62E+01
1379.66 8.61E+01
 
Doctoral thesis Study of Neuropilin-1 interactions by Katarzyna Adela Uniewicz 157
Supplemental data 3
 
KU2
4571_054 122 (4.187) 2: TOF MSMS 1811.92LD+‘oo 1811.93 45
310.16
1813.02
%
181 0.841813.85227.08 1752.931410.82451.2657934 638.27 1087.43 4498.44 1751.82 |1818.06
0 7 ' | lL mass100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800
 
1811.92 435 SQADENQK(Biotin)Gk(Acetyl) VARL
lon fragment mass (m/z) Intensity Assignment(error - ppm)
110.06 5.30E+01
227.08 1.03E+02 Biotin(0)
310.16 3.24E+02 K(Biotin)(0)
412.21 3.14E+01 K(Biotin)G(21) / ADEN-H20(155)
451.26 4.48E+01
456.15 2.92E+01
579.34 3.41E+01
638.27 3.20E+01
642.24 2.81E+01
694.37 2.75E+01
1057.43 4.88E+01
1128.44 3.21E+01
1410.82 5.93E+01 y10(48)
1751.82 2.70E+01
1792.99 2.64E+01
1808.83 3.02E+01
1813.02 2.53E+02
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lon fragment mass (m/z) Intensity Assignment(error - ppm)
110.06 8.21E+00 H(-102)
310.16 1.45E+01 K(Biotin)(0)
444.28 1.26E+01 y4(-29)
1113.68 8.41E+00 y7(83)
1233.62 8.10E+00 yg-NH3(0.22)
1249.59 1.41E+01
1348.77 9.12E+00 Yg-NH3(91)
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1828.9 9.11E+00
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1957.94 1.03E+01
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310.16
%
84.07 239.15
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lon fragment mass (m/z) Intensity Assignment(error - ppm)
84.07 2.06E+02 K(-128)
110.06 7.22E+01
169.12 3.38E+01 PA(135)
180.09 2.26E+01
188.06 4.23E+01
197.12 5.23E+01
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210.15 3.43E+01
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505.27 2.89E+01
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460 596.21 382
281.07 467.16
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227.08 1054.38
1270.47 1626.81
0 | mass100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700
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lon fragment mass (m/z) Intensity Assignment(error - ppm)
110.06 1.80E+02 H(-102)
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568.23 9.65E+01
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675.3 6.73E+01
705.27 8.34E+01
733.28 1.45E+02
774.31 4.73E+01 y4-NH3(19)
848.31 2.19E+02
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1887.92 3.99E+00
1945.04 4.74E+00
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KU24571_054 321 (10.410) 2: TOF MSMS1364.69LD+20100 310.16
227.08
84.07
110.06
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lon fragment mass (m/z) Intensity Assignment(error - ppm)
84.07 5.77E+01 K(-128)
110.06 3.35E+01
126.08 1.55E+01 K(-90)
154.08 1.50E+01
197.12 3.27E+01
210.16 1.90E+01
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438.23 1.74E+01
466.22 1.51E+01 K(Biotin)E-H20(17)
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